
<html lang="en"     class="pb-page"  data-request-id="bf767248-06fa-4024-a311-67dacd0a684f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm200884j;website:website:acspubs;issue:issue:10.1021/jmcmar.2011.54.issue-19;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Inhalation by Design: Novel Tertiary Amine Muscarinic M3 Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease" /></meta><meta name="dc.Creator" content="Paul A.  Glossop" /></meta><meta name="dc.Creator" content="Christine A. L.  Watson" /></meta><meta name="dc.Creator" content="David A.  Price" /></meta><meta name="dc.Creator" content="Mark E.  Bunnage" /></meta><meta name="dc.Creator" content="Donald S.  Middleton" /></meta><meta name="dc.Creator" content="Anthony  Wood" /></meta><meta name="dc.Creator" content="Kim  James" /></meta><meta name="dc.Creator" content="Dannielle  Roberts" /></meta><meta name="dc.Creator" content="Ross S.  Strang" /></meta><meta name="dc.Creator" content="Michael  Yeadon" /></meta><meta name="dc.Creator" content="Christelle  Perros-Huguet" /></meta><meta name="dc.Creator" content="Nicholas P.  Clarke" /></meta><meta name="dc.Creator" content="Michael A.  Trevethick" /></meta><meta name="dc.Creator" content="Ian  Machin" /></meta><meta name="dc.Creator" content="Emilio F.  Stuart" /></meta><meta name="dc.Creator" content="Steven M.  Evans" /></meta><meta name="dc.Creator" content="Anthony C.  Harrison" /></meta><meta name="dc.Creator" content="David A.  Fairman" /></meta><meta name="dc.Creator" content="Balaji  Agoram" /></meta><meta name="dc.Creator" content="Jane L.  Burrows" /></meta><meta name="dc.Creator" content="Neil  Feeder" /></meta><meta name="dc.Creator" content="Craig K.  Fulton" /></meta><meta name="dc.Creator" content="Barry R.  Dillon" /></meta><meta name="dc.Creator" content="David A.  Entwistle" /></meta><meta name="dc.Creator" content="Fiona J.  Spence" /></meta><meta name="dc.Description" content="A novel tertiary amine series of potent muscarinic M3 receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmo..." /></meta><meta name="Description" content="A novel tertiary amine series of potent muscarinic M3 receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 20, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm200884j" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm200884j" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm200884j" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm200884j" /></link>
        
    
    

<title>Inhalation by Design: Novel Tertiary Amine Muscarinic M3 Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm200884j" /></meta><meta property="og:title" content="Inhalation by Design: Novel Tertiary Amine Muscarinic M3 Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0013.jpeg" /></meta><meta property="og:description" content="A novel tertiary amine series of potent muscarinic M3 receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease. Geminal dimethyl functionality present in this series of compounds confers very long dissociative half-life (slow off-rate) from the M3 receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips. Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation. Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug–drug interactions, and reduce systemically mediated adverse events. Compound 47 (PF-3635659) is identified as a Phase II clinical candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm200884j"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm200884j">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm200884j&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm200884j&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm200884j&amp;href=/doi/10.1021/jm200884j" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 6888-6904</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm2008562" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm200892s" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Inhalation by Design: Novel Tertiary Amine Muscarinic M<sub>3</sub> Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+A.++Glossop">Paul A. Glossop</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine+A.+L.++Watson">Christine A. L. Watson</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+A.++Price">David A. Price</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+E.++Bunnage">Mark E. Bunnage</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donald+S.++Middleton">Donald S. Middleton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony++Wood">Anthony Wood</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kim++James">Kim James</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dannielle++Roberts">Dannielle Roberts</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ross+S.++Strang">Ross S. Strang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Yeadon">Michael Yeadon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christelle++Perros-Huguet">Christelle Perros-Huguet</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+P.++Clarke">Nicholas P. Clarke</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>▽̂</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Trevethick">Michael A. Trevethick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ian++Machin">Ian Machin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emilio+F.++Stuart">Emilio F. Stuart</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven+M.++Evans">Steven M. Evans</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+C.++Harrison">Anthony C. Harrison</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+A.++Fairman">David A. Fairman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Balaji++Agoram">Balaji Agoram</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jane+L.++Burrows">Jane L. Burrows</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neil++Feeder">Neil Feeder</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Craig+K.++Fulton">Craig K. Fulton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Barry+R.++Dillon">Barry R. Dillon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+A.++Entwistle">David A. Entwistle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fiona+J.++Spence">Fiona J. Spence</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▽̂</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Department of Worldwide Medicinal Chemistry, <sup>‡</sup>Allergy and Respiratory Research Unit, <sup>§</sup>Department of Pharmacokinetics, Dynamics and Metabolism, <sup>⊥</sup>Department of Pharmaceutical Sciences, and <sup>▽̂</sup>Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div><div class="corresp-info">(P.G.) Phone: +441304812980; e-mail: <a href="/cdn-cgi/l/email-protection#8cfcedebe0e3ffffe3fcccebe1ede5e0a2efe3e1"><span class="__cf_email__" data-cfemail="502031373c3f23233f2010373d31393c7e333f3d">[email protected]</span></a>. (C.W.) Phone: +441223847005; e-mail: <a href="/cdn-cgi/l/email-protection#a6c5ced4cfd5d2cfc8c388d1c7d2d5c9c8979696e6c1cbc7cfca88c5c9cb"><span class="__cf_email__" data-cfemail="583b302a312b2c31363d762f392c2b3736696868183f35393134763b3735">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm200884j&amp;href=/doi/10.1021%2Fjm200884j" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 6888–6904</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 29, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 July 2011</li><li><span class="item_label"><b>Published</b> online</span>20 September 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 October 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm200884j" title="DOI URL">https://doi.org/10.1021/jm200884j</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6888%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPaul%2BA.%2BGlossop%252C%2BChristine%2BA.%2BL.%2BWatson%252C%2BDavid%2BA.%2BPrice%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D19%26contentID%3Djm200884j%26title%3DInhalation%2Bby%2BDesign%253A%2BNovel%2BTertiary%2BAmine%2BMuscarinic%2BM3%2BReceptor%2BAntagonists%2Bwith%2BSlow%2BOff-Rate%2BBinding%2BKinetics%2Bfor%2BInhaled%2BOnce-Daily%2BTreatment%2Bof%2BChronic%2BObstructive%2BPulmonary%2BDisease%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6904%26publicationDate%3DOctober%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm200884j"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2732</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">24</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm200884j" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Inhalation by Design: Novel Tertiary Amine Muscarinic M3 Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;A. Glossop&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;A. L. Watson&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;A. Price&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;E. Bunnage&quot;},{&quot;first_name&quot;:&quot;Donald&quot;,&quot;last_name&quot;:&quot;S. Middleton&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;Wood&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;James&quot;},{&quot;first_name&quot;:&quot;Dannielle&quot;,&quot;last_name&quot;:&quot;Roberts&quot;},{&quot;first_name&quot;:&quot;Ross&quot;,&quot;last_name&quot;:&quot;S. Strang&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Yeadon&quot;},{&quot;first_name&quot;:&quot;Christelle&quot;,&quot;last_name&quot;:&quot;Perros-Huguet&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;P. Clarke&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Trevethick&quot;},{&quot;first_name&quot;:&quot;Ian&quot;,&quot;last_name&quot;:&quot;Machin&quot;},{&quot;first_name&quot;:&quot;Emilio&quot;,&quot;last_name&quot;:&quot;F. Stuart&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;M. Evans&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;C. Harrison&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;A. Fairman&quot;},{&quot;first_name&quot;:&quot;Balaji&quot;,&quot;last_name&quot;:&quot;Agoram&quot;},{&quot;first_name&quot;:&quot;Jane&quot;,&quot;last_name&quot;:&quot;L. Burrows&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Feeder&quot;},{&quot;first_name&quot;:&quot;Craig&quot;,&quot;last_name&quot;:&quot;K. Fulton&quot;},{&quot;first_name&quot;:&quot;Barry&quot;,&quot;last_name&quot;:&quot;R. Dillon&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;A. Entwistle&quot;},{&quot;first_name&quot;:&quot;Fiona&quot;,&quot;last_name&quot;:&quot;J. Spence&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;6888-6904&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm200884j&quot;},&quot;abstract&quot;:&quot;A novel tertiary amine series of potent muscarinic M3 receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease. Geminal dimethyl functionality present in this series of compounds confers very long dissociative half-life (slow off-rate) from the M3 receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips. Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation. Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug–drug interactions, and reduce systemically mediated adverse events. Compound 47 (PF-3635659) is identified as a Phase II clinical candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200884j&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200884j" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200884j&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200884j" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200884j&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200884j" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm200884j&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200884j&amp;href=/doi/10.1021/jm200884j" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm200884j" /></input><a href="/doi/pdf/10.1021/jm200884j" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm200884j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm200884j%26sid%3Dliteratum%253Aachs%26pmid%3D21870878%26genre%3Darticle%26aulast%3DGlossop%26date%3D2011%26atitle%3DInhalation%2Bby%2BDesign%253A%2BNovel%2BTertiary%2BAmine%2BMuscarinic%2BM3%2BReceptor%2BAntagonists%2Bwith%2BSlow%2BOff-Rate%2BBinding%2BKinetics%2Bfor%2BInhaled%2BOnce-Daily%2BTreatment%2Bof%2BChronic%2BObstructive%2BPulmonary%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D19%26spage%3D6888%26epage%3D6904%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290851" title="Half-life">Half-life</a>,</li><li><a href="/action/doSearch?ConceptID=291683" title="Dissociation">Dissociation</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jmcmar.2011.54.issue-19/production/jmcmar.2011.54.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel tertiary amine series of potent muscarinic M<sub>3</sub> receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease. Geminal dimethyl functionality present in this series of compounds confers very long dissociative half-life (slow off-rate) from the M<sub>3</sub> receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips. Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation. Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug–drug interactions, and reduce systemically mediated adverse events. Compound <b>47</b> (PF-3635659) is identified as a Phase II clinical candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span>#</span> Author Present Address</h4><p class="last">Pfizer Global Research and Development, Eastern Point Rd., Groton, CT 06340.</p></div><div class="extra-info-sec articleNote"><h4><span>¥</span> Author Present Address</h4><p class="last">Pfizer, 2002 Executive Suite, 200 Cambridge Park Dr., Cambridge, MA 02140.</p></div><div class="extra-info-sec articleNote"><h4><span>Δ</span> Author Present Address</h4><p class="last">Peakdale Chemistry Services, Ramsgate Rd, Sandwich, Kent CT13 9NJ, U.K.</p></div><div class="extra-info-sec articleNote"><h4><span>∥</span> Author Present Address</h4><p class="last">MedImmune, Milstein Building, Granta Park, Cambridge, CB21 6GH, U.K.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66553" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66553" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is both progressive and not fully reversible, resulting in deterioration of lung function and chronic dyspnea.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The airflow limitation is associated with an abnormal inflammatory response to noxious particles, often developing in smokers. COPD is currently the fourth largest cause of death in the U.S. and is projected to become the third leading cause of death worldwide by 2020.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Bronchodilator drugs are commonly used to manage the symptoms of COPD, maximize lung function, and reduce exacerbation rates. Inhaled muscarinic receptor antagonists such as ipratropium bromide and tiotropium bromide<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>) are examples of one class of bronchodilators prescribed for symptom control. Ipratropium bromide is a short-acting agent administered four times per day, whereas tiotropium bromide (Spiriva) is administered once-daily, for example, from the HandiHaler capsule-based dry powder inhaler (DPI). Tiotropium is classed as a long-acting muscarinic antagonist (LAMA) or long-acting anticholinergic (LAAC).</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0015.jpeg" id="gr13" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">By definition, anticholinergic agents are particularly effective because they prevent acetylcholine-induced airway smooth muscle contraction, an overall effect manifested in the lungs as bronchodilation. Cholinergic tone is therefore highly relevant and acknowledged as the major reversible component of airflow obstruction in COPD.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Five distinct muscarinic acetylcholine receptors (M<sub>1</sub>–M<sub>5</sub>) are known in humans, three of which are present in human lung (M<sub>1</sub>–M<sub>3</sub>). The M<sub>3</sub> receptor is located on airway smooth-muscle cells where it mediates the contractile response.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">A major area of current effort in the respiratory field is identification of novel long-acting muscarinic antagonists that provide inhaled once-daily bronchodilatory efficacy with potential for improved therapeutic index (TI) versus systemically driven adverse events such as tachycardia and dry mouth.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> An agent of this type would have value as either a stand-alone therapy or for use in combination products with other once-daily bronchodilator and/or anti-inflammatory agents.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Reports in the literature have described numerous chemical series that offer promise against these objectives, although to date, none of these compounds have received regulatory approval as new once-daily inhaled agents.<a onclick="showRef(event, 'ref6 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref8">(6, 8)</a> Novel quaternary ammonium agents from these efforts include darotropium bromide (GSK233705B)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and aclidinium bromide (LAS-34273).<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> Marketed quaternary ammonium oral agents reformulated for inhaled delivery include glycopyrronium bromide (NVA-237)<a onclick="showRef(event, 'ref6 ref7 ref12'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref12">(6, 7, 12)</a> and trospium chloride (ALKS-27).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> These four clinical agents have progressed to phase II or phase III trials in COPD (Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>).</div><figure id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0016.jpeg" id="gr14" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this paper we describe the application of an “inhalation by design” philosophy to the discovery of a novel tertiary amine series of muscarinic receptor antagonists that combine the pharmacology required for once-daily inhaled administration, with pharmacokinetics designed to minimize systemic exposure and provide potential for improved therapeutic index versus systemically driven adverse events.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68345" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68345" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our carboxamide target compounds were prepared across three chemical series: pyrrolidines, piperidines, and azetidines. The pyrrolidine lead <b>4</b> was prepared by initial nucleophilic addition of diphenylacetonitrile to <i>tert</i>-butyl acrylate (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Subsequent ester deprotection gave acid <b>2</b>, a key intermediate in the synthesis of all our target compounds. Aldehyde formation (<b>3</b>), followed by reductive amination and nitrile hydrolysis, delivered amide <b>4</b> in good overall yield.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrrolidine <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <sup><i>t</i></sup>Butyl acrylate, KOH, MeOH, <sup><i>t</i></sup>BuOH, 50 °C, 5 h, 90%; (b) 4 M HCl in 1,4-dioxane, RT, 18 h, 77%; (c) (i) CDI, THF, RT, 18 h; (ii) NaBH<sub>4</sub>, RT, 18 h, 40%; (d) Dess–Martin periodinane, CH<sub>2</sub>Cl<sub>2</sub>, RT, 3 h, 90%; (e) (<i>S</i>)-3-phenoxypyrrolidine, Na(OAc)<sub>3</sub>BH, AcOH, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, RT, 5 h, 47%; (f) KOH, 3-methyl-3-pentanol, reflux, 18 h, 62%.</p></p></figure><div class="NLM_p">One approach to the synthesis of <i>gem</i>-dimethyl pyrrolidines is shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. In this case, commercially available homochiral phenoxy-substituted pyrrolidines were coupled to an activated ester of <b>2</b>, to give amides (<i>R</i>)- and (<i>S</i>)-<b>5</b> and (<i>S</i>)-<b>6</b>. The dimethyl moiety was subsequently introduced with a modified Bouveault reaction.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Amides (<i>R</i>)- and (<i>S</i>)-<b>5</b> and (<i>S</i>)-<b>6</b> were treated with excess zirconium tetrachloride or titanium tetrachloride, followed by Grignard reagent, to deliver compounds (<i>R</i>)- and (<i>S</i>)-<b>7</b> and (<i>S</i>)-<b>8</b> in good yield. Hydrolysis of these nitriles with potassium hydroxide delivered amides (<i>R</i>)- and (<i>S</i>)-<b>9</b> and (<i>S</i>)-<b>10</b>. Demethylation of (<i>S</i>)-<b>10</b> with boron tribromide delivered phenol (<i>S</i>)-<b>11</b> in good yield.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrrolidines (<i>R</i>)- and (<i>S</i>)-<b>9</b> and (<i>S</i>)-<b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (<i>S</i>)-3-phenoxypyrrolidine or (<i>R</i>)-3-phenoxypyrrolidine or (<i>S</i>)-3-(3-methoxyphenoxy)pyrrolidine, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, RT, 18 h, 41–100%; (b) TiCl<sub>4</sub>, THF, −10 °C, 0.5 h; MeMgBr, −5 °C–RT, 18 h, 54%, or ZrCl<sub>4</sub>, THF, −20 °C, 1 h; MeMgCl, −10 °C, 2 h, 59–78%; (c) KOH, 3-methyl-3-pentanol, reflux, 18 h, 62–96%; (d) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 0.5 h, 60%.</p></p></figure><div class="NLM_p">An alternative strategy toward the synthesis of the pyrrolidine derivatives is shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. In this approach, a late stage pyrrolidine alcohol intermediate was prepared to allow rapid analogue generation. Both (<i>R</i>)- and (<i>S</i>)-enantiomers of amide <b>12</b> could be prepared by coupling (<i>R</i>)- or (<i>S</i>)-3-benzyloxypyrrolidine to acid <b>2</b> under standard conditions. Modified Bouveault reaction followed by nitrile hydrolysis gave amides (<i>R</i>)- and (<i>S</i>)-<b>13</b> in good yield. Subsequent benzyl ether deprotection proceeded in good yield to give alcohols (<i>R</i>)- and (<i>S</i>)-<b>14</b> as key intermediates. Mitsunobu reaction was then performed with inversion of configuration to give a broad range of phenyl ether derivatives. In some cases, a biphenol was used in this reaction to provide phenol test compounds directly ((<i>S</i>)-<b>15</b>, (<i>S</i>)-<b>16</b>). In other cases, where a methyl ether protecting group was employed, test compounds were prepared by Mitsunobu reaction to give ethers ((<i>R</i>)-<b>10</b>, (<i>S</i>)-<b>17</b>, (<i>R</i>)-<b>18</b>) followed by boron tribromide deprotection to give phenols ((<i>R</i>)-<b>11</b>, (<i>S</i>)-<b>19</b>, (<i>R</i>)-<b>20</b>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Pyrrolidines (<i>R</i>)-<b>11</b>, (<i>S</i>)-<b>15</b>, (<i>S</i>)-<b>16</b>, (<i>S</i>)-<b>19</b>, and (<i>R</i>)-<b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (<i>R</i>)-3-benzyloxypyrrolidine, CDI, THF, RT, 18 h, 83%, or (<i>S</i>)-3-benzyloxypyrrolidine, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, RT, 18 h, 70%; (b) (i) ZrCl<sub>4</sub>, THF, −20 °C, 1 h; MeMgCl, −10 °C, 2 h, 76% (ii) KOH, 3-methyl-3-pentanol, reflux, 24 h, 78–89%; (c) FeCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, RT, 3 h, 60%, or 20% Pd(OH)<sub>2</sub>/C, 1 M HCl, EtOH, H<sub>2</sub>, 50 psi, 50 °C, 28 h, 90%; (d) ArOH, PPh<sub>3</sub>, DIAD, THF, 0 °C–RT, 2–22 h, 75–7%; (e) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, RT, 18 h, 46–68%.</p></p></figure><div class="NLM_p">Azetidine <b>25</b> and piperidine <b>26</b> were prepared using a similar approach to that described in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Thus, commercially available phenoxy-substituted azetidine <b>21</b> and piperidine <b>22</b> were coupled to acid <b>2</b> to give amides <b>23</b> and <b>24</b> in good yield (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). Subsequent Bouveault reaction and nitrile hydrolysis yielded compounds <b>25</b> and <b>26</b>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Azetidine <b>25</b> and Piperidine <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>2</b>, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, Et<sub>3</sub>N, DMF, RT, 18 h, 75–95%; (b) (i) ZrCl<sub>4</sub>, THF, −20 °C, 1 h; (ii) MeMgCl, −10 °C, 2 h, 38–41%; (c) KOH, 3-methyl-3-pentanol, reflux, 18 h, 88–93%.</p></p></figure><div class="NLM_p">Phenol-substituted piperidine <b>32</b> was prepared according to the route shown in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Boc-protected piperidine alcohol <b>27</b> was alkylated with 3-bromobenzyl bromide to give <b>28</b>, which was deprotected under acidic conditions to give amine <b>29</b> in good overall yield. Derivatization to <i>gem</i>-dimethyl intermediate <b>30</b> was accomplished under the amide coupling, Bouveault, and nitrile hydrolysis conditions already described. The benzyl ether of <b>30</b> was removed via hydrogenation to give alcohol <b>31</b>, followed by Mitsunobu reaction with resorcinol to give phenol <b>32</b>.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Piperidine <b>32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaH, 3-bromobenzyl bromide, THF, 0 °C–RT, 18 h, 61%; (b) 4 M HCl in 1,4-dioxane, RT, 2.5 h, 98%; (c) <b>2</b>, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, Et<sub>3</sub>N, DMF, RT, 18 h, 95%; (d) (i) ZrCl<sub>4</sub>, THF, −20 °C, 1 h; (ii) MeMgCl, −10 °C, 2 h, 33%; (e) KOH, 3-methyl-3-pentanol, reflux, 18 h, 99%; (f) 20% Pd(OH)<sub>2</sub>/C, 1 M HCl, EtOH, H<sub>2</sub>, 50 psi, 50 °C, 18 h, 95%; (g) resorcinol, PPh<sub>3</sub>, DIAD, THF, 0 °C–RT, 12 h, 14%.</p></p></figure><div class="NLM_p">The ortho-substituted azetidine <b>35</b> was prepared from acid <b>2</b> and 3-(methanesulfonyl)azetidine as shown in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. Initial coupling via the acid chloride gave mesylate <b>33</b> that was used to alkylate 2-(benzyloxy)phenol. Subsequent Bouveault reaction proceeded in poor yield in this case, but still afforded <i>gem</i>-dimethyl azetidine <b>34</b>. Nitrile hydrolysis and hydrogenation of the benzyl protecting group afforded phenol <b>35</b>.</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Azetidine <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) oxalyl chloride, DMF, CH<sub>2</sub>Cl<sub>2</sub>, 2 h; (ii) 3-(methanesulfonyl)azetidine, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C, 1 h, 97%; (b) (i) 2-(benzyloxy)phenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 18 h, 77%; (ii) ZrCl<sub>4</sub>, THF, −35 °C, 1 h; (iii) MeMgCl, −20 °C, 1 h, 10%; (c) (i) KOH, 3-methyl-3-pentanol, reflux, 20 h, 55%; (ii) NH<sub>4</sub>HCO<sub>2</sub>, 20% Pd(OH)<sub>2</sub>/C, EtOH, reflux, 4 h, 100%.</p></p></figure><div class="NLM_p">The low yield of the modified Bouveault reaction led us to seek an alternative method for the introduction of the <i>gem</i>-dimethyl group in the azetidine series. Synthesis began with Boc-protected oxathiazinane dioxide <b>36</b> (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Ring-opening of protected sulfamate esters similar to <b>36</b> has been reported using a broad range of nucleophiles including amines, acetates, azides,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and carbon nucleophiles such as malonate derivates and aryl-substituted enolates.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Gratifyingly, deprotonation of diphenylacetonitrile under basic conditions, followed by nucleophilic attack on sulfamate <b>36</b>, gave ring-opened intermediate <b>37</b>, after deprotection of the Boc group. Reaction of amine <b>37</b> with racemic epichlorohydrin delivered azetidine <b>38</b> in moderate yield, which could be converted to mesylate <b>39</b> under standard conditions. Mesylate <b>39</b> was a key intermediate that furnished a broad range of azetidine derivatives. Thus, reaction of <b>39</b> with a panel of phenols, suitably protected where appropriate, gave compounds <b>40</b>–<b>46</b> in high yield. Hydrolysis of the nitrile and removal of any protecting groups gave carboxamide derivatives <b>47</b>–<b>53</b>. Alternatively, alkylation of alcohol <b>38</b> with 1-allyloxy-3-bromomethylbenzene under basic conditions led to a benzylated intermediate that gave amide <b>54</b> after treatment with potassium hydroxide. Interestingly, potassium hydroxide led to isomerization of the allyl protecting group to give an enol ether that could be cleaved readily under acid conditions to give phenol <b>55</b>. In general, the protected phenol derivatives employed in Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a> were commercially available; however, when synthesis was required, they could be prepared by monoprotection of the corresponding biphenol under standard conditions.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Azetidines <b>47</b>–<b>53</b> and <b>55</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) diphenylacetonitrile, KO<sup>t</sup>Bu, THF, RT, 4 h; (ii) 4 M HCl in dioxane, 50 °C, 2 h, 87%; (b) epichlorohydrin, EtOH, 70 °C, 18 h, 79%; (c) MsCl, pyridine, −15–5 °C, 3 h, 100%; (d) ArOH, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 18 h, 68–90%; (e) KOH, 3-methyl-3-pentanol, reflux, 18 h, 72–96%; (f) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 2 h, 25–100%, or 4 M HCl in dioxane, 60 °C, 0.5 h, 61%; (g) 1-allyloxy-3-bromomethylbenzene, NaH, DMF, 0 °C, 1 h, 54%; (h) 4 M HCl in dioxane, 85 °C, 0.5 h, 70%.</p></p></figure><div class="NLM_p">The route to cyclopentyl derivative <b>64</b> is shown in Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>. The synthesis began with conversion of 2-cyclopentyl ethanol to sulfamate ester <b>56</b> using chlorosulfonyl isocyanate and formic acid. Treatment of <b>56</b> with rhodium acetate in the presence of magnesium oxide and an oxidant resulted in C–H insertion to produce oxathiazine dioxide <b>57</b>.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Boc protection proceeded under standard conditions to deliver compound <b>58</b> that was subsequently converted to phenol <b>64</b> via intermediates <b>59</b>–<b>63</b>, using similar conditions to those described for the corresponding <i>gem</i>-dimethyl derivative <b>47</b> (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>).</div><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Azetidine <b>64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) HCOOH, 0 °C, 0.5 h; (ii) 2-cyclopentyl ethanol, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, < 7 °C, 2 h, 95%; (b) rhodium acetate dimer, magnesium oxide, iodobenzene diacetate, CH<sub>2</sub>Cl<sub>2</sub>, 18 h, 75%; (c) di-<i>tert</i>-butyl dicarbonate, Et<sub>3</sub>N, 4-dimethylaminopyridine, CH<sub>2</sub>Cl<sub>2</sub>, 3 h, 46%; (d) (i) diphenylacetonitrile, KO<sup>t</sup>Bu, DMF, 18 h; (ii) 4 M HCl in dioxane, 40 °C, 2 h, 67%; (e) epichlorohydrin, MeOH, 60 °C, 48 h, 52%; (f) MsCl, pyridine, −15 °C, 2 h, 59%; (g) 3-methoxyphenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 18 h, 73%; (h) KOH, 3-methyl-3-pentanol, reflux, 20 h, 48%; (i) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 2 h, 53%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27133" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27133" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The objective of our research was to identify a long-acting muscarinic M<sub>3</sub> receptor antagonist with suitability for once-daily inhaled administration and pharmacokinetics consistent with minimal systemic exposure. We were confident that we would be able to apply our “inhalation by design” experience to maximize TI versus systemic muscarinic effects through careful optimization of the pharmacokinetic properties, specifically, by incorporation of a metabolically labile functional group. In contrast, strategies to incorporate long duration of action (DoA) are far less well understood. One approach reported in the field of antimuscarinics is quaternization of the tertiary amino functional group, for example, as applied in the design of aclidinium bromide.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, this approach does not guarantee long DoA, as evidenced by the short-acting nature of the quaternary agent ipratropium bromide. Both aclidinium and tiotropium are known to exhibit an off-rate from the muscarinic M<sub>3</sub> receptor slower than that of ipratropium, and this is thought to be important in driving their long-acting effects in vivo.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Consequently, we decided to use targeted screening to identify a compound with a long dissociation half-life from the M<sub>3</sub> receptor as a strategy to secure intrinsic, sustained DoA in the lung.</div><div class="NLM_p">Previous efforts in our laboratories had focused on the delivery of an oral muscarinic antagonist for the treatment of urinary urge incontinence and overactive bladder. This culminated in the identification of the carboxamide clinical candidate darifenacin.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> At the start of our program to identify an inhaled candidate, we rescreened a subset of legacy muscarinic antagonists from our compound file, this time looking specifically for slow dissociation from the M<sub>3</sub> receptor, measured in a dilution filtration binding assay.</div><div class="NLM_p">Under our assay conditions, both tiotropium and ipratropium had high affinity for the M<sub>3</sub> receptor (binding <i>K</i><sub>i</sub> = 0.075 and 0.29 nM, respectively, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The dissociation half-life of tiotropium was >1440 min, whereas ipratropium dissociated rapidly (17 min), in agreement with literature data.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Legacy carboxamide <b>4</b> had good binding affinity (<i>K</i><sub>i</sub> = 1.9 nM) but a relatively rapid dissociation half-life (38 min). However, <i>gem</i>-dimethyl substitution adjacent to the basic amine moiety had a profound effect on the rate of dissociation. Compound (<i>S</i>)-<b>9</b> had a similar binding affinity (<i>K</i><sub>i</sub> = 1.8 nM) to <b>4</b> but greatly extended dissociation half-life (>1440 min), similar to tiotropium. We speculate that dimethyl substitution may restrict conformational freedom in close proximity to the amine functional group (a key binding motif), requiring significant reordering of the ligand and receptor for binding to occur, resulting in reduced rates of association and dissociation. The enantiomer of (<i>S</i>)-<b>9</b> had a similar, exciting profile ((<i>R</i>)-<b>9</b>), albeit slightly less potent. The achiral azetidine (<b>25</b>) and piperidine (<b>26</b>) analogues also looked interesting; it appeared that the <i>gem</i>-dimethyl effect on dissociation half-life translated across different ring systems. Azetidine <b>25</b> had excellent, tiotropium-like binding affinity (<i>K</i><sub>i</sub> = 0.11 nM) and retained an encouraging dissociation half-life (481 min), while the piperidine had a profile similar to that of the pyrrolidines (<i>S</i>)- and (<i>R</i>)-<b>9</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. M<sub>3</sub> Functional Potency, M<sub>3</sub> and M<sub>2</sub> Binding Affinity, M<sub>3</sub> Dissociation Half-Life, clogP and log <i>D</i>, and HLM Clearance Data for Compounds <b>4</b>, (<i>S</i>)- and (<i>R</i>)-<b>9</b>, <b>25</b>, and <b>26</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0022.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0023.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Cell-based functional potency in CHO cells expressing recombinant human M<sub>3</sub> receptors. Carbamoyl choline (CCh) and test compounds were coadministered and allowed to equilibrate for 4 h. Compound inhibition of CCh stimulated calcium currents was measured. All compounds appeared to be full antagonists in this assay. Determinations were the mean of at least two replicates.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Binding affinity determined in human recombinant M<sub>3</sub> receptors expressed in CHO cells following incubation with [<sup>3</sup>H]-NMS and test compounds for 2 h. Determinations were the mean of at least two replicates.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Binding affinity determined in human recombinant M<sub>2</sub> receptors expressed in CHO cells following incubation with [<sup>3</sup>H]-NMS and test compounds for 2 h. Determinations were the mean of at least two replicates.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Test compound was incubated with CHO cells expressing the recombinant human M<sub>3</sub> receptor for 2 h at 100-fold its hM<sub>3</sub> binding <i>K</i><sub>i</sub>. 90-fold dilution with buffer containing excess [<sup>3</sup>H]-NMS followed. The dissociation half-life of the compound was measured by monitoring the association rate of [<sup>3</sup>H]-NMS. Determinations were the mean of at least four replicates.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Intrinsic clearance in human liver microsomes.</p></div><div class="footnote" id="t1fn6"><sup>Table f</sup><p class="last">ND: not determined.</p></div></div><div></div></div><div class="NLM_p">Both tiotropium and ipratropium are nonselective muscarinic antagonists, binding to the M<sub>1</sub>–M<sub>5</sub> receptors with approximately equal affinity.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Compounds representing our novel carboxamide series were also shown to be nonselective muscarinic antagonists when tested against the M<sub>2</sub> receptor (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), which we deemed to be the most relevant initial counter-screen due to the potential for M<sub>2</sub>-mediated tachycardia. Data against the M<sub>1</sub>, M<sub>4</sub>, and M<sub>5</sub> receptors were not gathered at this stage. All compounds tested were full M<sub>3</sub> antagonists in a functional cell-based assay where inhibition of carbamyl choline-stimulated calcium currents was measured. The potency of the carboxamide series in this functional assay was found to be broadly equivalent to affinity in the filtration binding experiment (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div><div class="NLM_p">Compounds (<i>S</i>)- and (<i>R</i>)-<b>9</b>, <b>25</b>, and <b>26</b> gave us confidence that slow dissociation from the M<sub>3</sub> receptor and potential for long DoA was achievable in our <i>gem</i>-dimethyl-substituted carboxamides. Attention then turned to optimization of the pharmacokinetic properties to maximize TI. Inhaled anticholinergics are associated with a range of side effects related to systemic exposure including dry mouth, constipation, glaucoma, urinary retention, and cardiovascular effects. Consequently, we aimed to minimize such systemic effects through reduced oral bioavailability (of the swallowed fraction of the dose) and high clearance of the inhaled dose.</div><div class="NLM_p">Quaternary muscarinic antagonists have low oral bioavailability, largely as a consequence of reduced absorption due to their polarity.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Both tiotropium and ipratropium have log <i>D</i> < 1 (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), resulting in reduced membrane permeability and low oral absorption that drives low systemic exposure of the swallowed fraction of the dose. In contrast, our carboxamides leads (<i>S</i>)- and (<i>R</i>)-<b>9</b>, <b>25</b>, and <b>26</b> possessed high clogP and moderate log <i>D</i> and would therefore be expected to have good membrane permeability and be well absorbed. Compound (<i>S</i>)-<b>9</b> was typical, with a moderate cell permeability and no evidence of transporter-mediated efflux (<i>P</i><sub>app</sub>(A–B) = 16 × 10<sup>–6</sup> cm/s, <i>P</i><sub>app</sub>(B–A) = 13 × 10<sup>–6</sup> cm/s), measured by apical to basal flux rate in Caco-2 cells. It is widely understood that absorption is only one component of oral bioavailability; first pass metabolism is also important. We therefore aimed to achieve a good TI by designing in high hepatic clearance in addition to reduced permeability. Encouragingly, (<i>S</i>)-<b>9</b> and <b>25</b> were turned over rapidly in HLM (Cl<sub>int</sub> > 440 (μL/min)/mg); as expected, tiotropium and ipratropium showed high levels of microsomal stability due to their polarity, but are subject to rapid renal clearance in humans.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Both the rate and route of clearance are important in determining TI across a patient population. For example, are the metabolites pharmacologically active? Which enzymes are responsible for drug clearance? A compound metabolized by only cytochrome P450 (CYP) 3A4 could be particularly vulnerable to drug–drug interactions, where a patient exposed to a CYP3A4 inhibitor (e.g., ketoconazole) would suffer from increased systemic exposure and increased muscarinic receptor-driven side effects. Interpatient variability can also be caused by genetic polymorphism, for example, CYP2D6 substrates are cleared at a significantly lower rate in certain subsets of the population (6–8% of Caucasians do not express CYP2D6).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> We therefore sought to maximize clearance by targeting multiple clearance routes with high capacity and the lowest risk of saturation or inhibition.</div><div class="NLM_p">Early on, we decided to target glucuronidation as a significant route of clearance for our compounds. There is little evidence of clinically relevant drug-related inhibition of glucuronidation so the risk of drug–drug interactions is low.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This is due to the low affinity of any inhibitors to the uridine-5′-diphosphoglucuronosyl transferase (UGT) enzymes responsible for glucuronidation and the potential for multiple UGTs to effect the glucuronidation process. Glucuronidation results in the conjugation of glucuronic acid from UDPGA (uridine-5′-diphosphoglucuronic acid) to a reactive functional group in the substrate. In this way, a lipophilic drug molecule is derivatized to a polar, water-soluble glucuronide which can be cleared by biliary or renal elimination. The chance of a pharmacologically active metabolite is therefore low. Phenols and carboxylic acids are the main substrates for UGTs, but our experience in the design of β<sub>2</sub>-adrenoreceptor agonists led us to favor glucuronidation of phenols as our phase II clearance route.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">Phenolic substitution appeared to be well tolerated in some of our initial examples (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). For example phenol (<i>S</i>)-<b>11</b> displayed similar, excellent M<sub>3</sub> functional potency (<i>K</i><sub>i</sub> = 0.21 nM) to its nonphenolic counterpart (<i>S</i>)-<b>9</b> (<i>K</i><sub>i</sub> = 0.25 nM). Importantly, the dissociation half-life of (<i>S</i>)-<b>11</b> (>1440 min) also appeared to be unaffected and the phase I clearance rate remained high (HLM Cl<sub>int</sub> > 440 (μL/min)/mg), despite the lower log <i>D</i> (2.4 vs 2.9). The enantiomer (<i>R</i>)-<b>11</b> had a very similar profile in terms of both pharmacology and oxidative clearance. Interestingly, the location of the phenol substituent (ortho-, meta-, or para-position) had little impact on M<sub>3</sub> functional potency in the pyrrolidine series ((<i>S</i>)-<b>15</b>, (<i>S</i>)-<b>11</b>, (<i>S</i>)-<b>19</b>, respectively). However, ortho- and para-substitution ((<i>S</i>)-<b>15</b>, (<i>S</i>)-<b>19</b>) resulted in a drop in the dissociation half-life (387 and 229 min, respectively).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. M<sub>3</sub> Functional Potency, M<sub>3</sub> Dissociation Half-Life, clogP and log <i>D</i>, and in Vitro Clearance Data for Phenolic Compounds (<i>R</i>)- and (<i>S</i>)-<b>11</b>, (<i>S</i>)-<b>15</b>, (<i>S</i>)-<b>19</b>, <b>32</b>, <b>35</b>, <b>47</b>, <b>55</b>, and <b>64</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0001.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0002.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Cell based functional potency in CHO cells expressing recombinant human M<sub>3</sub> receptors. Carbamoyl choline (CCh) and test compounds were coadministered and allowed to equilibrate for 4 h. Compound inhibition of CCh stimulated calcium currents was measured. All compounds appeared to be full antagonists in this assay. Determinations were the mean of at least two replicates.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Test compound was incubated with CHO cells expressing the recombinant human M<sub>3</sub> receptor for 2 h at 100-fold its hM<sub>3</sub> binding <i>K</i><sub>i</sub>. 90-fold dilution with buffer containing excess [<sup>3</sup>H]-NMS followed. The dissociation half-life of the compound was measured by monitoring the association rate of [<sup>3</sup>H]-NMS. Determinations were the mean of at least four replicates.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Intrinsic clearance in human liver microsomes activated with NADPH.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Intrinsic clearance in human hepatocytes.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Intrinsic clearance in human liver microsomes treated with Brij-58 and UDPGA.</p></div><div class="footnote" id="t2fn6"><sup>Table f</sup><p class="last">ND: not determined.</p></div></div><div></div></div><div class="NLM_p">We were encouraged that our phenols were still cleared rapidly by oxidative metabolism but wanted to establish whether they were also glucuronidation substrates. One method frequently used to assess clearance via glucuronidation is the measurement of turnover of a compound in human hepatocytes. However, hepatocytes support both phase I and phase II metabolism, making it more difficult to determine the degree of non-P450-mediated clearance for compounds with rapid turnover in the standard HLM assay. Therefore, we also employed a detergent-treated (Brij-58) HLM preparation where UDPGA was added as a glucuronic acid donor to assess specific UGT metabolic activity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In contrast to our standard HLM assay, no NADPH was provided in the preparation, so phase I metabolism was not supported. Brij-58 was added to allow access to the active site of the UGTs, as the metabolizing enzymes lie on the luminal side of the endoplasmic reticulum. The SAR for clearance via glucuronidation (Gluc Cl<sub>int</sub>) is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Once again, the enantiomeric pair (<i>R</i>)- and (<i>S</i>)-<b>11</b> had similar profiles, both demonstrating moderate clearance (52 and 82 (μL/min)/mg, respectively). In contrast, <i>o</i>- and <i>p</i>-phenols (<i>S</i>)-<b>15</b> and (<i>S</i>)-<b>19</b> did not undergo significant turnover in this assay (13 and <4 (μL/min)/mg, respectively), indicating that glucuronidation would be a minor clearance process for these compounds. The clearance in human hepatocytes revealed the same trend, with (<i>S</i>)-<b>15</b> showing a turnover (30 (μL/min)/million) lower than that for (<i>R</i>)- and (<i>S</i>)-<b>11</b> (67 and 65 (μL/min)/million, respectively).</div><div class="NLM_p">The <i>m</i>-phenol-substituted piperidine <b>32</b> exhibited significantly reduced M<sub>3</sub> potency (<i>K</i><sub>i</sub> = 2.3 nM). In contrast, the azetidine core showed excellent potency and dissociation half-life with the meta-substituted phenol <b>47</b> and the benzyl analogue <b>55</b> having subnanomolar potency (<i>K</i><sub>i</sub> = 0.20 and 0.18 nM, respectively). Phenol substitution was not always tolerated by the receptor; for example, ortho-substituted azetidine <b>35</b> lost significant (55-fold) activity relative to its meta-substituted analogue (<b>47</b>). Interestingly, cyclization of the <i>gem</i>-dimethyl moiety into a cyclopentyl ring gave another potent derivative <b>64</b> (<i>K</i><sub>i</sub> = 0.73 nM) that also retained a long dissociation half-life (>1440 min). While all of the azetidine derivatives showed high levels of oxidative clearance, it was the meta-substituted phenyl ethers (<b>47</b>, <b>64</b>) that again showed the most encouraging turnover in the glucuronidation assay. Compound <b>47</b> had an excellent profile in all the in vitro assays. It possessed high affinity for the M<sub>3</sub> receptor (<i>K</i><sub>i</sub> = 0.20 nM), a long dissociation half-life (>1440 min), similar to tiotropium, rapid clearance in human liver microsomes (Cl<sub>int</sub> > 282 (μL/min)/mg) and human hepatocytes (Cl<sub>int</sub> = 96 (μL/min)/million), and very high turnover in our glucuronidation assay (Cl<sub>int</sub> = 221 μL/min/mg).</div><div class="NLM_p">The human hepatocyte assay could be used to rank compounds for phase II clearance to some degree, but the glucuronidation HLM assay clearly showed that SAR existed for glucuronidation. It was found that certain phenol derivatives were not significantly turned over by the UGTs. In some cases this might be explained by steric hindrance, for example, as with the low clearance of <i>o</i>-phenol (<i>S</i>)-<b>15</b>. In other cases, it appeared to be related to structure more broadly. For example, there was a general trend for the azetidine series to exhibit higher clearance via glucuronidation than the pyrrolidine series (e.g., <b>47</b> vs (<i>R</i>)-<b>11</b>). The low clearance of benzyl derivative <b>55</b> versus phenyl analogue <b>47</b> seemed to indicate that even relatively lipophilic and sterically accessible phenols could be quite stable with respect to glucuronidation. UGTs are reported to turn over a wide array of chemical structures as a result of their important role in detoxification of endogenous compounds and xenobiotics.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Our data showed that structural features could be used to tune the rate of clearance up or down. Such information could also be illuminating in drug discovery programs where low clearance compounds are desired.</div><div class="NLM_p">We were keen to investigate further structural features that could affect the rate of turnover by UGTs. Structural studies have indicated that the transfer of glucuronic acid to the phenol functional group is a base-catalyzed process where conserved carboxylate and histidine residues facilitate the deprotonation of the phenol, enabling nucleophilic attack on UDPGA.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> We were therefore keen to investigate whether the p<i>K</i><sub>a</sub> of the phenol could be a factor in determining the rate of clearance. As meta-substituted phenols had shown the best balance of potency, dissociation half-life, and clearance (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), the properties of halogen-substituted <i>m</i>-phenols were therefore explored (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). In the azetidine core, the M<sub>3</sub> potency of chlorophenol <b>48</b> was reduced 10-fold relative to <b>47</b>, although there was little change in dissociation half-life. The additional chlorine atom resulted in increased clogP, and HLM and hepatocyte clearance remained high. In addition, the clearance by glucuronidation increased to 430 (μL/min)/mg, possibly as a result of increased clogP, but reduced p<i>K</i><sub>a</sub> could also be a factor. The calculated p<i>K</i><sub>a</sub> of the phenol of <b>48</b> was significantly lower than that of <b>47</b> (7.9 vs 9.5). The addition of a <i>m</i>-chloro substituent (<b>49</b>) also resulted in the retention of M<sub>3</sub> potency (<i>K</i><sub>i</sub> = 0.22 nM), high oxidative clearance (HLM Cl<sub>int</sub> = 361 (μL/min)/mg), and rapid glucuronidation (Gluc Cl<sub>int</sub> = 223 (μL/min)/mg). The corresponding fluorophenol <b>50</b> had a similar profile, again demonstrating very rapid glucuronidation (Cl<sub>int</sub> = 403 (μL/min)/mg). Addition of a second halogen substituent (<b>51</b>) resulted in retention of the high clearance properties of the lead azetidine (<b>47</b>) but significant loss of potency (37-fold) and dissociation half-life (165 min). Fluoro substitution ortho to the phenol (<b>52</b>) resulted in a slightly reduced rate of phase II clearance (Gluc Cl<sub>int</sub> = 52 (μL/min)/mg), but excellent potency (<i>K</i><sub>i</sub> = 0.26 nM) was retained. Fluorophenol isomer <b>53</b> had a similar profile to its parent azetidine (<b>47</b>), with good potency against the M<sub>3</sub> receptor, long dissociation half-life, and rapid phase I and phase II clearance.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. The Effect of Halogen Substitution on M<sub>3</sub> Functional Potency, M<sub>3</sub> Dissociation Half-Life, clogP and log <i>D</i>, in Vitro Clearance, and Calculated Acidic p<i>K</i><sub>a</sub> of Phenolic Compounds (<i>S</i>)-<b>16</b>, (<i>R</i>)-<b>20</b>, and <b>48</b>–<b>53</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0003.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0004.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Cell-based functional potency in CHO cells expressing recombinant human M<sub>3</sub> receptors. Carbamoyl choline (CCh) and test compounds were coadministered and allowed to equilibrate for 4 h. Compound inhibition of CCh-stimulated calcium currents was measured. All compounds appeared to be full antagonists in this assay. Determinations were the mean of at least two replicates.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Test compound was incubated with CHO cells expressing the recombinant human M<sub>3</sub> receptor for 2 h at 100-fold its hM<sub>3</sub> binding <i>K</i><sub>i</sub>. 90-fold dilution with buffer containing excess [<sup>3</sup>H]-NMS followed. The dissociation half-life of the compound was measured by monitoring the association rate of [<sup>3</sup>H]-NMS. Determinations were the mean of at least four replicates.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Intrinsic clearance in human liver microsomes activated with NADPH.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Intrinsic clearance in human hepatocytes.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">Intrinsic clearance in human liver microsomes treated with Brij-58 and UDPGA.</p></div><div class="footnote" id="t3fn6"><sup>Table f</sup><p class="last">Most acidic p<i>K</i><sub>a</sub> value calculated at 25 °C and zero ionic strength in aqueous solutions, using ACD/Physchem Batch 9.03 software from Advanced Chemistry Development, Inc.</p></div><div class="footnote" id="t3fn7"><sup>Table g</sup><p class="last">ND: not determined.</p></div></div><div></div></div><div class="NLM_p">In the pyrrolidine core, addition of a chloro substituent ((<i>S</i>)-<b>16</b>) resulted in reduced potency (10-fold) relative to phenol (<i>S</i>)-<b>11</b> but did provide an approximately 3-fold increase in the rate of glucuronidation (Cl<sub>int</sub> = 146 (μL/min)/mg). This effect may also be due to a combination of increased clogP and reduced p<i>K</i><sub>a</sub>. The <i>m</i>-fluoro derivative (<i>R</i>)-<b>20</b> possessed good potency (<i>K</i><sub>i</sub> = 0.56 nM), a very long dissociation half-life (>1440 min), rapid clearance in HLM, and high hepatocyte clearance that indicated a high level of turnover by glucuronidation. To conclude, we were able to affect the rate of clearance of compounds in our glucuronidation assay by modification of the substituents on the phenol ring.</div><div class="NLM_p">A selection of promising compounds ((<i>R</i>)- and (<i>S</i>)-<b>11</b>, <b>47</b>, <b>52</b>), based on a combination of pharmacology and material properties, was advanced to more comprehensive evaluation and comparison against tiotropium and ipratropium (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Following observations that these agents dissociated very slowly from the M<sub>3</sub> receptor (slow off-rate, small <i>k</i><sub>off</sub>), there was an accompanying possibility that they would demonstrate slow association (slow on-rate, small <i>k</i><sub>on</sub>), a rate that is a function of both ligand concentration (dose) and time.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> This property has the potential to extend incubation times and concentrations required for an assay to reach ligand–receptor equilibrium and accurately define the equilibrium dissociation constant (<i>K</i><sub>d</sub>). In response to these observations, M<sub>3</sub> binding affinity (<i>K</i><sub>i</sub>) was determined for the selected compounds in revised assay conditions requiring incubation with test compound for 24 h. Slightly increased potency (up to 12-fold) was observed for (<i>R</i>)- and (<i>S</i>)-<b>11</b>, <b>47</b>, <b>52</b>, and tiotropium, illustrating the importance of incubation time when screening compounds that possess slow kinetics of binding. As expected, ipratropium potency under these conditions was unaffected due to its rapid binding kinetics. M<sub>3</sub> dissociation half-lives (<i>t</i><sub>1/2</sub>) determined under this revised incubation time (24 h) confirmed that all these agents (except ipratropium) exhibited very long residence time and potential for extended pharmacological effect.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The rapid dissociation half-life observed for ipratropium is in agreement with literature data.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The effect of these agents on airway smooth muscle was investigated in vitro using appropriate compound incubation times in isolated guinea pig tracheal (GPT) strips<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and human bronchial rings. Potency within 10-fold of tiotropium was observed for (<i>R</i>)- and (<i>S</i>)-<b>11</b>, <b>47</b>, and <b>52</b> in GPT, along with very long-lasting DoA (<i>T</i><sub>25</sub> >16 h); remarkably, the time taken for the contractile response to recover by 25% following inhibition with compounds (<i>R</i>)- and (<i>S</i>)-<b>11</b>, <b>47</b>, and <b>52</b> was in excess of 16 h, indicating DoA that was at least tiotropium-like (<i>T</i><sub>25</sub> >12.9 h). Ipratropium was confirmed to be short-acting (<i>T</i><sub>25</sub> = 1.47 h). Human bronchus data indicated that <b>47</b> (p<i>K</i><sub>b</sub> = 9.6) was the most potent of these analogues and more importantly was also within 10-fold of tiotropium (p<i>K</i><sub>b</sub> = 10.2). This trend was also observed in vivo following lung resistance studies in anaesthetized guinea pigs (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Overall, <b>47</b> was consistently the most attractive agent from these studies, possessing tiotropium-like DoA and potency within approximately 10-fold.</div><figure id="fig1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0018.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Lung resistance data in anaesthetized guinea pigs for (<i>R</i>)- and (<i>S</i>)-<b>11</b>, <b>47</b>, <b>52</b>, and tiotropium bromide, following cumulative intratracheal administration at hourly intervals, as solutions in micelle vehicle. ACh (iv) challenge was administered hourly (prior to the next escalating dose of compound) and the maximum increase in lung resistance recorded over a 5 min period. Data are expressed as a percentage of the pretreatment ACh (iv) control response (100%).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Additional in Vitro and in Vivo Characterization of Selected Compounds (<i>R</i>)- and (<i>S</i>)-<b>11</b>, <b>47</b>, and <b>52</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">guinea pig trachea</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">M<sub>3</sub> binding <i>K</i><sub>i</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center">M<sub>3</sub> dissociation <i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (min)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> (nM)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>25</sub><a class="ref internalNav" href="#t4fn4" aria-label="d">d</a> (h)</th><th class="colsep0 rowsep0" align="center">human bronchus p<i>K</i><sub>b</sub><a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">guinea pig in vivo IC<sub>50</sub><a class="ref internalNav" href="#t4fn6" aria-label="f">f</a> (μg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">0.201</td><td class="colsep0 rowsep0" align="left">>1440</td><td class="colsep0 rowsep0" align="left">3.87 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">>16 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">8.0 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">20 (<i>n</i> = 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">0.180</td><td class="colsep0 rowsep0" align="left">>1440</td><td class="colsep0 rowsep0" align="left">4.30 (<i>n</i> = 4)</td><td class="colsep0 rowsep0" align="left">>16 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">9.3 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">10 (<i>n</i> = 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char=".">0.128</td><td class="colsep0 rowsep0" align="left">>1440</td><td class="colsep0 rowsep0" align="left">1.53 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">>16 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">9.6 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">3 (<i>n</i> = 6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="char" char=".">0.163</td><td class="colsep0 rowsep0" align="left">>1440</td><td class="colsep0 rowsep0" align="left">3.48 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">>16 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">8.8 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">4 (<i>n</i> = 4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tiotropium</td><td class="colsep0 rowsep0" align="char" char=".">0.0098</td><td class="colsep0 rowsep0" align="left">>1370</td><td class="colsep0 rowsep0" align="left">0.41 (<i>n</i> = 16)</td><td class="colsep0 rowsep0" align="left">>12.9 (<i>n</i> = 4)</td><td class="colsep0 rowsep0" align="left">10.2 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">0.4 (<i>n</i> = 10)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ipratropium</td><td class="colsep0 rowsep0" align="char" char=".">0.213</td><td class="colsep0 rowsep0" align="left">11.8</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">1.47 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Binding affinity at human recombinant M<sub>3</sub> receptors expressed in CHO cells following incubation with [<sup>3</sup>H]-NMS and test compound for 24 h. Determinations were the mean of at least six replicates.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Test compound was incubated with CHO cells expressing the recombinant human M<sub>3</sub> receptor for 24 h at 100-fold its hM<sub>3</sub> binding <i>K</i><sub>i</sub>. 90-fold dilution with buffer containing excess [<sup>3</sup>H]-NMS followed. The dissociation half-life of the compound was measured by monitoring the association rate of [<sup>3</sup>H]-NMS. Determinations were the mean of at least six replicates.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Potency in guinea pig trachea following incubation with test compound for 8 h.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Time taken for the EFS contractile response to recover by 25% of the inhibition induced by an <i>E</i><sub>max</sub> concentration of the test compound incubated for 2 h.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Potency in isolated human bronchial ring following incubation with test compound for 4 h.</p></div><div class="footnote" id="t4fn6"><sup>f</sup><p class="last">Potency in an anaesthetized guinea pig model of ACh (iv)-induced bronchoconstriction, following cumulative intratracheal administration of test compound at hourly intervals, as a solution in micelle. ACh (iv) challenge was administered hourly (prior to the next escalating dose of compound), and the maximum increase in lung resistance recorded over a 5 min period, in order to produce a five-point dose–response curve.</p></div><div class="footnote" id="t4fn7"><sup>g</sup><p class="last">ND: not determined.</p></div></div></div><div class="NLM_p">Compound <b>47</b> was subsequently profiled across human M<sub>1</sub>–M<sub>5</sub> receptors to build a comprehensive picture of muscarinic pharmacology (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Binding affinity (<i>K</i><sub>i</sub>) determined with 24 h compound incubation demonstrated that <b>47</b> had balanced, potent activity across all M<sub>1</sub>–M<sub>5</sub> receptors, similar to ipratropium and tiotropium. Dissociation half-life determined with 24 h compound incubation indicated that <b>47</b> possessed tiotropium-like kinetic selectivity for M<sub>3</sub> vs M<sub>2</sub> receptors.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> This kinetic selectivity could be receptor rather than compound driven, as ipratropium has also been reported to show this kinetic behavior, albeit over a much shorter, less clinically relevant time frame.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Furthermore, with the exception of M<sub>3</sub> receptor dissociation half-life previously discussed, it appeared that <b>47</b> had a dissociation half-life shorter than that for tiotropium across M<sub>1</sub>–M<sub>5</sub> receptors. Finally, the binding kinetics of <b>47</b> were investigated according the method of Motulsky and Mahan.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Interestingly, the off-rate (<i>k</i><sub>off</sub>) for <b>47</b> in this experiment was approximately 1 order of magnitude slower than that for tiotropium, confirming a very slow dissociation half-life (<i>t</i><sub>1/2</sub> = 4998 min). The on-rate (<i>k</i><sub>on</sub>) for <b>47</b> was also slower than that for tiotropium and appeared consistent with previous in vitro observations. The resulting binding affinity for <b>47</b> (<i>K</i><sub>i</sub> = 0.0132 nM) was within 3-fold of that for tiotropium (<i>K</i><sub>i</sub> = 0.0057 nM), both of which were very potent in this assay and more potent than ipratropium, which was confirmed to have fast on-rate and off-rate.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacological Effect of Compound <b>47</b> at Human Muscarinic M<sub>1</sub>–M<sub>5</sub> Receptors in Vitro</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">binding <i>K</i><sub>i</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (nM)</th><th class="rowsep1 colsep0" colspan="5" align="center">dissociation <i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a> (min)</th><th class="rowsep1 colsep0" colspan="4" align="center">M<sub>3</sub> binding kinetics<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">M<sub>1</sub></th><th class="colsep0 rowsep0" align="center">M<sub>2</sub></th><th class="colsep0 rowsep0" align="center">M<sub>3</sub></th><th class="colsep0 rowsep0" align="center">M<sub>4</sub></th><th class="colsep0 rowsep0" align="center">M<sub>5</sub></th><th class="colsep0 rowsep0" align="center">M<sub>1</sub></th><th class="colsep0 rowsep0" align="center">M<sub>2</sub></th><th class="colsep0 rowsep0" align="center">M<sub>3</sub></th><th class="colsep0 rowsep0" align="center">M<sub>4</sub></th><th class="colsep0 rowsep0" align="center">M<sub>5</sub></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>on</sub> (M<sup>–1</sup>s<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>off</sub> (s<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">dissociation <i>t</i><sub>1/2</sub> (min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="center">0.115 (<i>n</i> = 10)</td><td class="colsep0 rowsep0" align="center">0.137 (<i>n</i> = 6)</td><td class="colsep0 rowsep0" align="center">0.128 (<i>n</i> = 23)</td><td class="colsep0 rowsep0" align="center">0.115 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="center">0.169 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="center">838 (<i>n</i> = 7)</td><td class="colsep0 rowsep0" align="center">263 (<i>n</i> = 8)</td><td class="colsep0 rowsep0" align="center">>1440 (<i>n</i> = 8)</td><td class="colsep0 rowsep0" align="center">587 (<i>n</i> = 7)</td><td class="colsep0 rowsep0" align="center">>1000 (<i>n</i> = 8)</td><td class="colsep0 rowsep0" align="center">0.0132 (<i>n</i> = 5)</td><td class="colsep0 rowsep0" align="center">1.05 × 10<sup>7</sup></td><td class="colsep0 rowsep0" align="center">1.39 × 10<sup>–4</sup></td><td class="colsep0 rowsep0" align="center">4998</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tiotropium</td><td class="colsep0 rowsep0" align="center">0.0130 (<i>n</i> = 57)</td><td class="colsep0 rowsep0" align="center">0.0215 (<i>n</i> = 55)</td><td class="colsep0 rowsep0" align="center">0.0098 (<i>n</i> = 340)</td><td class="colsep0 rowsep0" align="center">0.0078 (<i>n</i> = 32)</td><td class="colsep0 rowsep0" align="center">0.0266 (<i>n</i> = 29)</td><td class="colsep0 rowsep0" align="center">>1430 (<i>n</i> = 50)</td><td class="colsep0 rowsep0" align="center">>781 (<i>n</i> = 45)</td><td class="colsep0 rowsep0" align="center">>1350 (<i>n</i> = 78)</td><td class="colsep0 rowsep0" align="center">>1440 (<i>n</i> ≥ 6)</td><td class="colsep0 rowsep0" align="center">>1440 (<i>n</i> = 60)</td><td class="colsep0 rowsep0" align="center">0.0057 (<i>n</i> = 7)</td><td class="colsep0 rowsep0" align="center">2.12 × 10<sup>8</sup></td><td class="colsep0 rowsep0" align="center">1.22 × 10<sup>–3</sup></td><td class="colsep0 rowsep0" align="center">567.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ipratropium</td><td class="colsep0 rowsep0" align="center">0.433 (<i>n</i> = 62)</td><td class="colsep0 rowsep0" align="center">0.413 (<i>n</i> = 58)</td><td class="colsep0 rowsep0" align="center">0.213 (<i>n</i> = 348)</td><td class="colsep0 rowsep0" align="center">0.382 (<i>n</i> = 25)</td><td class="colsep0 rowsep0" align="center">1.04 (<i>n</i> = 25)</td><td class="colsep0 rowsep0" align="center"><15 (<i>n</i> = 50)</td><td class="colsep0 rowsep0" align="center"><15 (<i>n</i> = 44)</td><td class="colsep0 rowsep0" align="center"><15 (<i>n</i> = 58)</td><td class="colsep0 rowsep0" align="center"><15 (<i>n</i> = 47)</td><td class="colsep0 rowsep0" align="center"><39 (<i>n</i> = 58)</td><td class="colsep0 rowsep0" align="center">0.157 (<i>n</i> = 7)</td><td class="colsep0 rowsep0" align="center">1.00 × 10<sup>9</sup></td><td class="colsep0 rowsep0" align="center">1.60 × 10<sup>–1</sup></td><td class="colsep0 rowsep0" align="center">4.40</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Binding affinity at human recombinant muscarinic M<sub>1</sub>–M<sub>5</sub> receptors expressed in CHO cells following incubation with [<sup>3</sup>H-NMS] and test compound for 24 h.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Test compound was incubated with CHO cells independently expressing the recombinant human M<sub>1</sub>–M<sub>5</sub> receptors for 24 h at 100-fold the respective binding <i>K</i><sub>i</sub>. 90-fold dilution with buffer containing excess [<sup>3</sup>H]-NMS followed. The dissociation half-life of the compound was measured by monitoring the association rate of [<sup>3</sup>H]-NMS.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Binding affinity and kinetics determined by the method of Motulsky and Mahan.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></p></div></div></div><div class="NLM_p">With encouraging pharmacology in hand, we profiled <b>47</b> in a conscious dog model of bronchoconstriction to assess in vivo efficacy, DoA, and cardiovascular (CV) side effects (e.g., heart rate).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Dogs were treated with intratracheal (it.) solution administration of either M<sub>3</sub> antagonist or vehicle (micelle). Methacholine (MCh) challenge was administered it. to induce an increase in lung resistance (R<sub>L</sub>). R<sub>L</sub> and CV parameters with antagonist treatment were compared to the control MCh response. In this model, <b>47</b> was found to be approximately 3-fold more potent (ID<sub>50</sub> = 3.0 μg) than that for ipratropium (ID<sub>50</sub> = 10.0 μg) but slightly less potent than that for tiotropium (ID<sub>50</sub> < 3.0 μg) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). At the ID<sub>50</sub> dose (3.0 μg), <b>47</b> displayed long-lasting intrinsic DoA (>24 h) that was significantly superior to ipratropium (10.0 μg). Furthermore, a 3-fold higher dose of <b>47</b> (10 μg) afforded greater efficacy and DoA that was comparable to that for tiotropium (3.0 μg); both compounds were still efficacious 32 h postdose. Slower onset of action was observed for both doses of <b>47</b>, when compared to that for ipratropium and tiotropium. In vivo onset/DoA data for <b>47</b> appeared consistent with binding on-rate/off-rate kinetics observed in vitro (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Hemodynamic data from these studies confirmed that, relative to the control response measured in each animal at the start of the study, <b>47</b> (10 μg), ipratropium (10 μg), and tiotropium (3.0 μg) had no detectable CV effects up to 32 h postdose (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). These comparative data to clinical agents in a well validated in vivo model provided strong evidence that <b>47</b> would be able to deliver long-lasting (≥24 h) bronchodilation in humans from a projected once-daily inhaled dose of approximately 200 μg.</div><figure id="fig2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0019.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Lung resistance data in conscious dogs for <b>47</b>, ipratropium bromide, and tiotropium bromide, following intratracheal administration of a single dose, as a solution in micelle vehicle. MCh (it.) challenge was administered at 0.5 h, 1 h, and subsequently 2 h intervals, for up to 32 h, to measure the maximum increase in lung resistance, expressed as a percentage of the pretreatment MCh (it.) control response (100%).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0020.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Heart rate data in conscious dogs for <b>47</b>, ipratropium bromide and tiotropium bromide following intratracheal administration of a single dose, as a solution in micelle vehicle. MCh (it.) challenge was administered at 0.5 h, 1 h and subsequently 2 h intervals, for up to 32 h, to measure CV parameters relative to the pretreatment MCh (it.) control response measured in that animal at the start of the study. Data are presented as heart rate, in beats-per-minute (bpm).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In vitro observations illustrated that <b>47</b> met our criteria of rapid CYP-mediated oxidative metabolism (Cl<sub>int</sub> > 440 (μL/min)/mg) and phenolic glucuronidation (Cl<sub>int</sub> > 221 (μL/min)/mg) (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Furthermore, in vitro permeability data in MDCK-MDR1 cells revealed that while <b>47</b> displayed high intrinsic permeability, it was also subject to very high transporter-mediated efflux (<i>P</i><sub>app</sub>(A–B) = 7 × 10<sup>–6</sup> cm/s, <i>P</i><sub>app</sub>(B–A) = 64 × 10<sup>–6</sup> cm/s), most likely as a substrate for P-glycoprotein (P-gp) (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Interestingly, the phenolic moiety appeared to be responsible for two of these observations: first, it introduced a site for extensive glucuronidation, and second, it induced significant P-gp efflux that was not observed for nonphenolic analogues (e.g., <b>25</b>; <i>P</i><sub>app</sub>(A–B) = 27 × 10<sup>–6</sup> cm/s, <i>P</i><sub>app</sub>(B–A) = 28 × 10<sup>–6</sup> cm/s). With desirable in vitro data predictive of low oral bioavailability (due to transporter limited absorption through the gut lumen and high first pass metabolism), <b>47</b> was advanced to rat in vivo pharmacokinetic (PK) studies (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Following iv administration, <b>47</b> exhibited rapid and extensive distribution (<i>V</i><sub>dss</sub> = 8.4 L/kg), very high unbound and total clearance (Cl<sub>u</sub> = 2065 (mL/min)/kg, Cl<sub>T</sub> = 134 (mL/min)/kg) that exceeded liver blood flow, and a short terminal half-life (<i>t</i><sub>1/2</sub> = 0.9 h). Oral administration to rats resulted in no detectable systemic exposure, consistent with predictions from in vitro data.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vitro Permeability and in Vivo Pharmacokinetic Data for Compound <b>47</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">in vitro permeability, MDCK-MDR1 <i>P</i><sub>app</sub> x 10<sup>–6</sup> (cm/s)</th><th class="rowsep1 colsep0" colspan="4" align="center">rat in vivo PK, iv</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">A–B</th><th class="colsep0 rowsep0" align="center">B–A</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>d</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center">Cl<sub>T</sub> ((mL/min)/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">ppb (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>47</b></td><td class="colsep0 rowsep0" align="center">7</td><td class="colsep0 rowsep0" align="center">64</td><td class="colsep0 rowsep0" align="center">8.4</td><td class="colsep0 rowsep0" align="center">134</td><td class="colsep0 rowsep0" align="center">0.9</td><td class="colsep0 rowsep0" align="center">93.5</td></tr></tbody></table></div></div><div class="NLM_p">The metabolites of <b>47</b> were found to be similar across a range of in vitro incubations in rat, dog, and human hepatocytes and liver microsomes. The major phase I metabolite from microsomal preparations was the azetidinol, resulting from O-dearylation. This metabolite was found to possess >10-fold weaker M<sub>3</sub> binding affinity (<i>K</i><sub>i</sub> = 1.64 nM) and much shorter M<sub>3</sub> dissociation half-life (<i>t</i><sub>1/2</sub> = 69 min) than that for <b>47</b>, when assessed using these assays in their 24 h incubation format. In contrast, the major metabolite in hepatocytes was a phase II glucuronide, most likely the O-glucuronide from conjugation of the phenol group. Analysis of rat PK plasma samples showed that neither of these metabolites circulated in vivo to any meaningful extent. The primary enzyme-mediating phase I oxidative metabolism of <b>47</b> was found to be CYP3A4. Coincubation of human hepatocytes with the CYP3A4 inhibitor ketoconazole led to only a minor reduction (30%) in metabolism of <b>47</b>, again confirming extensive clearance of <b>47</b> by glucuronidation.</div><div class="NLM_p">Overall, <b>47</b> exhibited an ideal pharmacokinetic profile for an inhaled agent by virtue of incomplete oral absorption (of the swallowed fraction) and high unbound clearance predicted in humans via oxidative metabolism and glucuronidation. Systemic exposure and associated adverse events in humans were therefore predicted to be minimal.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Furthermore, clinically relevant drug–drug interactions (DDI) were predicted to be minimal as a consequence of multiple routes of metabolism.</div><div class="NLM_p">Subsequently, the hydrochloride salt form of <b>47</b> was isolated from ethanol and found to possess material properties that were consistent with our solid form requirements.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Analysis using well-known techniques such as PXRD, DSC, TGA, and DVS found <b>47</b> to be highly crystalline, anhydrous and nonhygroscopic (0.1% water uptake at 90% relative humidity) with high melting point (223 °C). The solid-state stability of <b>47</b> with lactose monohydrate (the most common carrier excipient used in commercial DPI) was demonstrated following storage of material blended at a 1:100 ratio for 28 days at 40 °C and 75% relative humidity. These material properties confirmed that <b>47</b> was compatible with inhaled administration from a DPI.</div><div class="NLM_p last">From a drug safety perspective, <b>47</b> demonstrated a safety margin in excess of 100-fold when evaluated for broader pharmacological activity against a wide ranging panel of in vitro assays representing receptors, enzymes, and ion channels. In vitro genetic toxicity testing and in vivo rat toleration studies were also completed without observing any meaningful adverse effects. Furthermore, <b>47</b> was inactive in a validated rabbit lung cough model following it. solution administration of doses up to 2000 μg.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> These data provided preclinical confidence that <b>47</b> was unlikely to elicit cough in humans, thus addressing a key attrition risk for inhaled compound development and endorsing compound progression. Overall, <b>47</b> had a preclinical safety profile that suggested it should be well tolerated in humans at all clinically relevant inhaled doses.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In conclusion, we have described our “inhalation by design” strategy to deliver a novel muscarinic M<sub>3</sub> receptor antagonist (<b>47</b>) that has potential for once-daily inhaled administration in humans for the treatment of COPD. Geminal dimethyl functionality confers very long dissociative half-life (slow off-rate) from the M<sub>3</sub> receptor that mediates very long-lasting bronchodilation in vivo (≥24 h). Incorporation of the phenol moiety delivers extensive glucuronidation “by design” and negligible oral absorption, features that are complemented by rapid oxidative metabolism to provide <b>47</b> with an optimal preclinical PK profile for an inhaled agent. Material properties and projected once-daily inhaled dose size (∼200 μg) are fully compatible with administration from a DPI delivery device. Furthermore, the preclinical safety profile of <b>47</b> suggests that it will be well tolerated in humans at all clinically relevant doses.</div><div class="NLM_p">Successful delivery of this compelling profile ultimately identified <b>47</b> (PF-3635659) as a phase II clinical candidate (Chart <a class="ref internalNav" href="#cht3" aria-label="3">3</a>). Spirometry data from healthy volunteers in phase I clinical studies illustrate that <b>47</b> provides efficacious 24 h bronchodilation (FEV<sub>1</sub> > 100 mL) from a single inhaled dose, thus confirming the suitability of <b>47</b> as a novel once-daily inhaled muscarinic M<sub>3</sub> receptor antagonist for the treatment of COPD (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Human pharmacokinetic data from multidose phase I studies demonstrate very low levels of unbound systemic exposure at all doses (e.g., day 7, 200 μg dose, <i>C</i><sub>maxu</sub> = 0.008 nM), with no accumulation on repeat dosing, findings that are consistent with preclinical predictions. Safety (tachycardia) and toleration (dry mouth) data from multidose phase I studies indicate an adverse event profile that is at least noninferior to tiotropium bromide.</div><figure id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0021.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Phase I spirometry data in healthy human volunteers for <b>47</b>, following inhalation of dry-powder formulations. Data are expressed as the mean change in FEV<sub>1</sub> from baseline, by treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="cht3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0017.jpeg" id="gr15" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Biology. In Vitro Potency at Recombinant Human M<sub>3</sub> Receptors Expressed in CHO Cells</h3><div class="NLM_p last">M<sub>3</sub> potency was determined in CHO-K1 cells transfected with the NFAT-Betalactamase gene. The cells were resuspended at 2 × 10<sup>5</sup> cells/mL in growth medium, and 20 μL of this cell suspension was added to each well of a 384-well, black, clear-bottomed plate. The assay buffer used was PBS, supplemented with 0.05% Pluronic F-127 and 2.5% DMSO. Muscarinic M<sub>3</sub> receptor signaling was stimulated, in the presence and absence M<sub>3</sub> receptor antagonists, using 80 nM carbamyl choline incubated with the cells for 4 h at 37 °C/5% CO<sub>2</sub> and monitored at the end of the incubation period using a Tecan SpectraFluor+ plate reader (λ, excitation 405 nm, emission 450 and 503 nm). Inhibition curves were plotted and IC<sub>50</sub> values generated using a four-parameter sigmoid fit and converted to <i>K</i><sub>i</sub> values using the Cheng–Prusoff correction and the <i>K</i><sub>D</sub> value for carbamyl choline in the assay.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> In Vitro Binding Affinity at Recombinant Human M<sub>1</sub>–M<sub>5</sub> Receptors Expressed in CHO Cells</h3><div class="NLM_p last">Affinity and selectivity at human recombinant M<sub>1</sub>–M<sub>5</sub> receptors, separately expressed in Chinese hamster ovary (CHO) cell membranes, were assessed using an <i>N</i>-methyl [<sup>3</sup>H] scopolamine ([<sup>3</sup>H]-NMS) filter binding assay similar to that previously described.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Briefly, CHO cell membranes were incubated in the presence or absence of test compounds and <sup>3</sup>H-NMS at room temperature for 2 or 24 h with shaking. The assay was terminated by rapidly filtering through GF/B Unifilter plates which were read on an NXT Topcount. Percent specific binding versus test compound concentration was plotted to determine an IC<sub>50</sub> from a sigmoid curve using an in-house data analysis program. IC<sub>50</sub> values were corrected to <i>K</i><sub>i</sub> values by applying the Cheng–Prussoff equation.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> In Vitro Assessment of Dissociation Half-Life at Recombinant Human M<sub>1</sub>–M<sub>5</sub> Receptors</h3><div class="NLM_p last">Duration of action at M<sub>1</sub>–M<sub>5</sub> receptors was assessed using a dilution–offset filter binding assay.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Briefly, the receptor was maximally occupied with the compound of interest, by incubating the membrane for 2 or 24 h with test compound at 100 × <i>K</i><sub>i</sub>. At various time points thereafter (between 15–1440 min) the mixture was diluted (90-fold), reducing the test compound concentration to 1 × <i>K</i><sub>i</sub>. This dilution was performed with assay buffer containing [<sup>3</sup>H]-NMS, to give a final assay concentration of 12.5 × <i>K</i><sub>D</sub>. Therefore, the test compound was encouraged to dissociate from the receptor by both dilution and competition with [<sup>3</sup>H]-NMS. Nonspecific binding was defined by 1 μM atropine, and total binding by equivalent DMSO (0.01%). Following 1440 min incubation, the assay was terminated by rapid filtration and the bound radioactivity quantified as described above. The association of [<sup>3</sup>H]-NMS to the receptor was fitted to a generalized hyperbola, fixing the maximum to the maximum specific binding for the assay plate. The offset of the test compound was inferred from the association of [<sup>3</sup>H]-NMS, expressed as the time taken to reach 50% of total [<sup>3</sup>H]-NMS binding, for solvent-treated membranes. Offset values (<i>t</i><sub>1/2</sub>) were expressed as arithmetic means with 95% confidence intervals (CI). When the time to 50% recovery was estimated outside of the time points measured, results were quoted as >1440 or <15 min.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> In Vitro Potency and Duration of Action in Guinea Pig Isolated Trachea</h3><div class="NLM_p">Tracheal strips (removed from male Dunkin–Hartley guinea pigs) were suspended in 5 mL of tissue baths under an initial tension of 1 g and bathed in warmed (37 °C), aerated (95% O<sub>2</sub>/5% CO<sub>2</sub>) Krebs solution containing 3 μM indomethacin and 10 μM guanethidine. At the end of the equilibration (1 h), tissues were electrically field stimulated (EFS) using the following parameters: 10 V, 10 Hz 0.1 ms pulse width with 10 s trains every 2 min. In each tissue a voltage response curve was constructed over the range 10–30 V (keeping all other stimulation parameters constant) to determine a just maximal stimulation. Using these stimulation parameters EFS responses were 100% nerve mediated and 100% cholinergic as confirmed by blockade by 1 μM tetrodotoxin or 1 μM atropine. Tissues were then repeatedly stimulated at 2 min intervals until the responses were reproducible.</div><ul class="NLM_list-list_type-label"><li><p class="inline">To assess potency (IC<sub>50</sub>), the study compound was added to the tissue baths, with each tissue receiving a single concentration of compound and allowed to equilibrate for 8 h. At 8 h postaddition, the inhibition of the EFS response was recorded and IC<sub>50</sub> curves were generated using a range of compound concentrations over tracheal strips from the same animal.</p></li><li><p class="inline">To assess duration of action, the study compound was added for 2 h, the tissues were then rapidly washed, and the 1 mL/min perfusion with Krebs solution was re-established. Tissues were stimulated for a further 16 h, and recovery of the EFS response was recorded. At the end of the 16 h, 10 μM histamine was added to the baths to confirm tissue viability. The just maximal concentration (tested concentration giving a response >70% inhibition but less than 100%) of antagonist was identified from the IC<sub>50</sub> curve, and the time to 25% recovery of the induced inhibition (<i>T</i><sub>25</sub>) was calculated in tissues receiving this concentration. Compounds are typically tested at <i>n</i> = 2–5 to estimate duration of action.</p></li></ul></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> In Vivo Potency and Duration of Action in the Conscious Dog</h3><div class="NLM_p">Conscious male and female beagle dogs (10–15 kg) which had previously undergone a tracheostomy and esophagotomy were implanted with telemetry to continuously monitor arterial blood pressure (ABP), heart rate, myocardial contactility (change in left ventricular pressure (LVP) with time), and ECG. Flow was measured via a Fleisch tube and validyne attached to a trach tube placed in the tracheostomy. Pleural pressure was measured using a balloon catheter placed in the esophagotomy, linked to a pressure transducer. Total lung resistance and dynamic lung compliance (derived from flow and pulmonary pressure (PP)) were measured after each intratracheal methacholine (MCh) challenge. Following instrumentation and a 30 min stabilization period, nebulized MCh (1.0 mg/mL) was given to provide cardiovascular (CV) and respiratory parameters as a control response.</div><ul class="NLM_list-list_type-label"><li><p class="inline">For the dose–response study, doses of test compound or vehicle were given via intratracheal (it.) administration at cumulative 1 h intervals using a Penn-Century insufflator. Intratracheal MCh challenge was repeated 1 h posttest compound administration to compare airway resistance and CV parameters to the control MCh response.</p></li><li><p class="inline">For the duration of action studies, one dose of test compound or vehicle was administered intratracheally and MCh challenge (it.) repeated at 0.5 h, 1 h, and subsequently 2 h intervals for up to 32 h to compare airway resistance and CV parameters to the control MCh response.</p></li></ul></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Chemistry</h3><div class="NLM_p last">Unless otherwise indicated, all reactions were carried out under a nitrogen atmosphere, using commercially available anhydrous solvents. Thin-layer chromatography was performed on glass-backed precoated Merck silica gel (60 F254) plates, and compounds were visualized using UV light, 5% aqueous potassium permanganate, or chloroplatinic acid/potassium iodide solution. Silica gel column chromatography was carried out using 40–63 μm silica gel (Merck silica gel 60). Ion exchange chromatography was performed using Isolute strong cation exchange resin (SCX-2) cartridges which had been prewashed with methanol. Proton NMR spectra were measured on a Varian Inova 400 or Varian Mercury 400 spectrometer in the solvents specified. In these NMR spectra, exchangeable protons that appeared distinct from solvent peaks are also reported. Low resolution mass spectra were recorded using the following system: PAL CAT sample injector; Agilent 1100 stack comprising of solvent degasser, pump and UV detector; Micromass ZQ 2000 MS detector with a scanning range of <i>m</i>/<i>z</i> 150–900. Test compound purity ≥95% was determined using combustion analysis conducted by Exeter Analytical U.K. Ltd., Uxbridge, Middlesex, U.K. Tiotropium bromide was synthesized according to literature procedures.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Ipratropium bromide was purchased from Sigma.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 5-Amino-5-methyl-2,2-diphenylhexanenitrile Hydrochloride Salt (<b>37</b>)</h3><div class="NLM_p last">A solution of diphenylacetonitrile (25.6 g, 132.3 mmol) in tetrahydrofuran (200 mL) was treated with potassium <i>tert</i>-butoxide (14.8 g, 132.3 mmol) and the resulting solution stirred for 10 min. A solution of <i>tert</i>-butyl 4,4-dimethyl-1,2,3-oxathiazinane-3-carboxylate 2,2-dioxide (<b>36</b>)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (35.1 g, 132.3 mmol) in tetrahydrofuran (300 mL) was then added over 15 min. The resulting solution was stirred for 4 h and then concentrated in vacuo. The residue was treated with 4 M hydrochloric acid in dioxane (165 mL, 661.5 mmol) and heated at 50 °C for 2 h. The solution was concentrated in vacuo to low volume, basified with saturated aqueous sodium carbonate solution, and extracted with dichloromethane (150 mL). The organic layer was dried (sodium sulfate) and concentrated in vacuo. The residue was treated with 4 M hydrochloric acid in dioxane (50 mL), concentrated in vacuo, and triturated with diethyl ether to give <b>37</b> as a solid, 36.2 g, 87% yield. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.35 (s, 6H), 1.70–1.74 (m, 2H), 2.56–2.61 (m, 2H), 7.32–7.47 (m, 10H) ppm. LRMS: <i>m</i>/<i>z</i> 279 [M + H]<sup>+</sup>.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 5-(3-Hydroxyazetidin-1-yl)-5-methyl-2,2-diphenylhexanenitrile (<b>38</b>)</h3><div class="NLM_p last">A solution of amine hydrochloride salt <b>37</b> (22.1 g, 70.2 mmol) in dichloromethane (250 mL) was washed with saturated aqueous sodium carbonate solution (100 mL). The organic layer was dried (sodium sulfate) and concentrated in vacuo. The residue was dissolved in ethanol (250 mL) and treated with 2-chloromethyloxirane (7.8 g, 84.2 mmol), and the resulting solution was heated at 70 °C for 18 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was crystallized from toluene/pentane to give <b>38</b> as a solid, 18.1 g, 79% yield. <sup>1</sup>H NMR (400 MHz CDCl<sub>3</sub>) δ: 0.92 (s, 6H), 1.31–1.36 (m, 2H), 2.42–2.46 (m, 2H), 2.88–2.97 (m, 2H), 3.29–3.37 (m, 2H), 4.31–4.38 (m, 1H), 7.27–7.43 (m, 10H) ppm. LRMS: <i>m</i>/<i>z</i> 335 [M + H]<sup>+</sup>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Methanesulfonic Acid 1-(4-Cyano-1,1-dimethyl-4,4-diphenylbutyl)azetidin-3-yl Ester (<b>39</b>)</h3><div class="NLM_p last">A solution of hydroxyazetidine <b>38</b> (15.0 g, 44.9 mmol) in pyridine (150 mL) at −15 °C was treated dropwise with methanesulfonyl chloride (10.4 mL, 134.6 mmol) over 15 min. The resulting solution was stirred at 0–5 °C for 3 h. The mixture was quenched with saturated aqueous sodium hydrogen carbonate solution (150 mL) and extracted with ethyl acetate (2 × 150 mL). The combined organic layers were dried (sodium sulfate) and concentrated in vacuo. The residue was redissolved in toluene (100 mL) and the solvent removed in vacuo to give <b>39</b> as a gum, 18.6 g, 100% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 0.92 (s, 6H), 1.29–1.33 (m, 2H), 2.41–2.45 (m, 2H), 2.98 (s, 3H), 3.21–3.24 (m, 2H), 3.37–3.41 (m, 2H), 4.96–5.01 (m, 1H), 7.26–7.40 (m, 10H) ppm. LRMS: <i>m</i>/<i>z</i> 413 [M + H]<sup>+</sup>.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 5-[3-(3-Methoxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanenitrile (<b>40</b>)</h3><div class="NLM_p last">A solution of mesylate <b>39</b> (12.3 g, 29.8 mmol) in acetonitrile (150 mL) was treated with 3-methoxyphenol (3.9 mL, 35.8 mmol) and potassium carbonate (10.3 g, 74.5 mmol). The resulting mixture was stirred at 80 °C for 3.5 h. The mixture was cooled to room temperature and concentrated in vacuo, and the residue was partitioned between ethyl acetate (250 mL) and saturated aqueous sodium hydrogen carbonate solution (150 mL). The aqueous layer was separated and extracted with ethyl acetate (2 × 200 mL). The combined organic layers were washed with brine (300 mL), dried (sodium sulfate), and concentrated in vacuo to give <b>40</b> as a brown oil, 16.2 g, 69% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 0.95 (s, 6H), 1.31–1.44 (m, 2H), 2.41–2.56 (m, 2H), 3.07–3.24 (m, 2H), 3.42–3.54 (m, 2H), 3.77 (s, 3H), 4.63–4.74 (m, 1H), 6.28–6.38 (m, 2H), 6.48–6.55 (m, 1H), 7.26–7.49 (m, 11H) ppm. LRMS: <i>m</i>/<i>z</i> 441 [M + H]<sup>+</sup>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide (<b>47</b>, PF-3635659)</h3><div class="NLM_p">A solution of nitrile <b>40</b> (13.4 g, 30.4 mmol) in 3-methylpentan-3-ol (150 mL) was treated with potassium hydroxide (34.1 g, 608 mmol), and the resulting solution was stirred at 120 °C for 18 h. The mixture was cooled to room temperature and concentrated in vacuo, and the residue was partitioned between ethyl acetate (200 mL) and water (200 mL). The organic layer was separated, washed with water (200 mL), dried (sodium sulfate), and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate/methanol/0.88 specific gravity ammonia (90:10:1, by volume) to give 5-[3-(3-methoxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide as a white foam, 10.7 g, 77% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 0.92 (s, 6H), 1.12–1.23 (m, 2H), 2.40–2.50 (m, 2H), 3.10–3.25 (m, 2H), 3.44–3.58 (m, 2H), 3.78 (s, 3H), 4.62–4.72 (m, 1H), 6.30–6.38 (m, 2H), 6.47–6.54 (m, 1H), 7.10–7.18 (m, 1H), 7.22–7.45 (m, 10H) ppm. LRMS: <i>m</i>/<i>z</i> 459 [M + H]<sup>+</sup>.</div><div class="NLM_p last">A solution of 5-[3-(3-methoxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide (9.0 g, 19.6 mmol) in dichloromethane (1.25 L) at 0 °C was treated dropwise with 1 M boron tribromide in dichloromethane (58.9 mL, 58.9 mmol). The resulting mixture was warmed to room temperature with stirring over 2 h. The mixture was recooled to 0 °C, quenched with addition of 1 M aqueous sodium hydroxide solution (200 mL), and allowed to warm to room temperature over 1 h. The aqueous layer was separated and extracted with ethyl acetate (2 × 200 mL). The combined organic layers were dried (sodium sulfate) and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with (dichloromethane/methanol/0.88 specific gravity ammonia (90:10:1, by volume))/pentane (50:50, by volume) to give <b>47</b> as a white foam, 3.40 g, 39% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.10 (s, 6H), 1.22–1.34 (m, 2H), 2.42–2.55 (m, 2H), 3.28–3.40 (m, 2H), 3.65–3.88 (m, 2H), 4.70–4.80 (m, 1H), 5.55–5.70 (bs, 2H), 6.23–6.36 (m, 2H), 6.45–6.53 (m, 1H), 7.03–7.12 (m, 1H), 7.19–7.39 (m, 10H) ppm. LRMS: <i>m</i>/<i>z</i> 443 [M – H]<sup>−</sup>, 445 [M + H]<sup>+</sup>. Anal. (C<sub>28</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub>·1.0H<sub>2</sub>O) C, H, N. HPLC analysis: ≥98.5% purity.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-5"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38"><a href="/doi/suppl/10.1021/jm200884j">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52074" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52074" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Biology experimental section for the in vitro human bronchus assay, in vivo anaesthetized guinea pig model, and in vivo rabbit lung Aδ-fiber cough model; chemistry experimental details and analytical data for intermediates <b>1</b>–<b>3</b>, (<i>R</i>)- and (<i>S</i>)-<b>5</b>, (<i>S</i>)-<b>6</b>, (<i>R</i>)- and (<i>S</i>)-<b>7</b>, (<i>S</i>)-<b>8</b>, (<i>R</i>)- and (<i>S</i>)-<b>10</b>, (<i>R</i>)- and (<i>S</i>)-<b>12</b>–<b>14</b>, (<i>S</i>)-<b>17</b>, (<i>R</i>)-<b>18</b>, <b>23</b>, <b>24</b>, <b>28</b>–<b>31</b>, <b>33</b>, <b>34</b>, <b>41</b>–<b>46</b>, <b>54</b>, <b>56</b>–<b>63</b>, and test compounds <b>4</b>, (<i>R</i>)- and (<i>S</i>)-<b>9</b>, (<i>R</i>)- and (<i>S</i>)-<b>11</b>, (<i>S</i>)-<b>15</b>, (<i>S</i>)-<b>16</b>, (<i>S</i>)-<b>19</b>, (<i>R</i>)-<b>20</b>, <b>25</b>, <b>26</b>, <b>32</b>, <b>35</b>, <b>48</b>–<b>53</b>, <b>55</b>, <b>64</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm200884j/suppl_file/jm200884j_si_001.pdf">jm200884j_si_001.pdf (327.78 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm200884j" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78351" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78351" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul A. Glossop</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#95e5f4f2f9fae6e6fae5d5f2f8f4fcf9bbf6faf8b5f6fde7fce6e1fcfbf0bbe2f4e1e6fafba4a5a5d5f2f8f4fcf9bbf6faf8"><span class="__cf_email__" data-cfemail="91e1f0f6fdfee2e2fee1d1f6fcf0f8fdbff2fefc">[email protected]</span> <span class="__cf_email__" data-cfemail="5b38332932282f32353e752c3a2f2834356a6b6b1b3c363a323775383436">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine A. L. Watson</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d8a8b9bfb4b7ababb7a898bfb5b9b1b4f6bbb7b5f8bbb0aab1abacb1b6bdf6afb9acabb7b6e9e8e898bfb5b9b1b4f6bbb7b5"><span class="__cf_email__" data-cfemail="b3c3d2d4dfdcc0c0dcc3f3d4ded2dadf9dd0dcde">[email protected]</span> <span class="__cf_email__" data-cfemail="5e3d362c372d2a37303b70293f2a2d31306f6e6e1e39333f3732703d3133">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David A. Price</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark E. Bunnage</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donald S. Middleton</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony Wood</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim James</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dannielle Roberts</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ross S. Strang</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Yeadon</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christelle Perros-Huguet</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas P. Clarke</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Trevethick</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ian Machin</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emilio F. Stuart</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven M. Evans</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony C. Harrison</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David A. Fairman</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Balaji Agoram</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jane L. Burrows</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Feeder</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Craig K. Fulton</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barry R. Dillon</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David A. Entwistle</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fiona J. Spence</span> - <span class="hlFld-Affiliation affiliation">†Department of Worldwide Medicinal Chemistry, ‡Allergy and Respiratory Research Unit, §Department of Pharmacokinetics, Dynamics and Metabolism, ⊥Department of Pharmaceutical Sciences, and ▽̂Department of Drug Safety, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, U.K.</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82480" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82480" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Michele Coghlan, Stuart Marshall, Sheena Patel, Jo Ann Rhodes, and Jessica Watson for their contributions to in vitro biology studies, and John Adcock, Tim Davies, James Philip, Louise Sladen, and Karen Wright for in vivo biology studies. We also thank Katie Bainbridge, Trish Costello, David Cox, Steve Denton, David Fengas, Ben Greener, Tim Hobson, Simon Mantell, Louise Marples, and Keith Reeves for assistance with the chemistry program. Dzelal Serdarevic is also thanked for the provision of clinical data.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i36" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i36"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i37" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i37"> Abbreviations Used</h2><tr><td class="NLM_term">ACh</td><td class="NLM_def"><p class="first last">acetyl choline</p></td></tr><tr><td class="NLM_term">CCh</td><td class="NLM_def"><p class="first last">carbamyl choline</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">DoA</td><td class="NLM_def"><p class="first last">duration of action</p></td></tr><tr><td class="NLM_term">DPI</td><td class="NLM_def"><p class="first last">dry powder inhaler</p></td></tr><tr><td class="NLM_term">DSC</td><td class="NLM_def"><p class="first last">differential scanning calorimetry</p></td></tr><tr><td class="NLM_term">DVS</td><td class="NLM_def"><p class="first last">dynamic vapor sorption</p></td></tr><tr><td class="NLM_term">EFS</td><td class="NLM_def"><p class="first last">electrical field stimulation</p></td></tr><tr><td class="NLM_term">FEV<sub>1</sub></td><td class="NLM_def"><p class="first last">forced expiratory volume in 1 s</p></td></tr><tr><td class="NLM_term">GPT</td><td class="NLM_def"><p class="first last">guinea pig trachea</p></td></tr><tr><td class="NLM_term">IT</td><td class="NLM_def"><p class="first last">intratracheal</p></td></tr><tr><td class="NLM_term">LAAC</td><td class="NLM_def"><p class="first last">long-acting anticholinergic</p></td></tr><tr><td class="NLM_term">LAMA</td><td class="NLM_def"><p class="first last">long-acting muscarinic antagonist</p></td></tr><tr><td class="NLM_term">MCh</td><td class="NLM_def"><p class="first last">methacholine</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">reduced form of nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">NMS</td><td class="NLM_def"><p class="first last"><i>N</i>-methylscopolamine</p></td></tr><tr><td class="NLM_term">PXRD</td><td class="NLM_def"><p class="first last">powder X-ray diffraction</p></td></tr><tr><td class="NLM_term"><i>R</i><sub>L</sub></td><td class="NLM_def"><p class="first last">lung resistance</p></td></tr><tr><td class="NLM_term">TGA</td><td class="NLM_def"><p class="first last">thermogravimetric analysis</p></td></tr><tr><td class="NLM_term">TI</td><td class="NLM_def"><p class="first last">therapeutic index</p></td></tr><tr><td class="NLM_term">UDPGA</td><td class="NLM_def"><p class="first last">uridine-5′-diphosphoglucuronic acid</p></td></tr><tr><td class="NLM_term">UGT</td><td class="NLM_def"><p class="first last">uridine-5′-diphosphoglucuronosyl transferase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Rabe, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurd, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzueto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Roisin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Weel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zielinski, J.</span><span> </span><span class="NLM_article-title">Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">176</span><span class="NLM_x">, </span> <span class="NLM_fpage">532</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1164%2Frccm.200703-456SO" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=17507545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A280%3ADC%252BD2sritlGhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2007&pages=532-555&author=K.+F.+Rabeauthor=S.+Hurdauthor=A.+Anzuetoauthor=P.+J.+Barnesauthor=S.+A.+Buistauthor=P.+Calverleyauthor=Y.+Fukuchiauthor=C.+Jenkinsauthor=R.+Rodriguez-Roisinauthor=C.+van+Weelauthor=J.+Zielinski&title=Global+Strategy+for+the+Diagnosis%2C+Management%2C+and+Prevention+of+Chronic+Obstructive+Pulmonary+Disease%3A+GOLD+Executive+Summary"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</span></div><div class="casAuthors">Rabe Klaus F; Hurd Suzanne; Anzueto Antonio; Barnes Peter J; Buist Sonia A; Calverley Peter; Fukuchi Yoshinosuke; Jenkins Christine; Rodriguez-Roisin Roberto; van Weel Chris; Zielinski Jan</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">532-55</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) remains a major public health problem.  It is the fourth leading cause of chronic morbidity and mortality in the United States, and is projected to rank fifth in 2020 in burden of disease worldwide, according to a study published by the World Bank/World Health Organization.  Yet, COPD remains relatively unknown or ignored by the public as well as public health and government officials.  In 1998, in an effort to bring more attention to COPD, its management, and its prevention, a committed group of scientists encouraged the U.S.  National Heart, Lung, and Blood Institute and the World Health Organization to form the Global Initiative for Chronic Obstructive Lung Disease (GOLD).  Among the important objectives of GOLD are to increase awareness of COPD and to help the millions of people who suffer from this disease and die prematurely of it or its complications.  The first step in the GOLD program was to prepare a consensus report, Global Strategy for the Diagnosis, Management, and Prevention of COPD, published in 2001.  The present, newly revised document follows the same format as the original consensus report, but has been updated to reflect the many publications on COPD that have appeared.  GOLD national leaders, a network of international experts, have initiated investigations of the causes and prevalence of COPD in their countries, and developed innovative approaches for the dissemination and implementation of COPD management guidelines.  We appreciate the enormous amount of work the GOLD national leaders have done on behalf of their patients with COPD.  Despite the achievements in the 5 years since the GOLD report was originally published, considerable additional work is ahead of us if we are to control this major public health problem.  The GOLD initiative will continue to bring COPD to the attention of governments, public health officials, health care workers, and the general public, but a concerted effort by all involved in health care will be necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQt87qJVGIYXLYtC3U5jeOifW6udTcc2eY0w44UQGScvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sritlGhsA%253D%253D&md5=19028a83e5ad7543912586212f1f8693</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1164%2Frccm.200703-456SO&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200703-456SO%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26aulast%3DHurd%26aufirst%3DS.%26aulast%3DAnzueto%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DBuist%26aufirst%3DS.%2BA.%26aulast%3DCalverley%26aufirst%3DP.%26aulast%3DFukuchi%26aufirst%3DY.%26aulast%3DJenkins%26aufirst%3DC.%26aulast%3DRodriguez-Roisin%26aufirst%3DR.%26aulast%3Dvan%2BWeel%26aufirst%3DC.%26aulast%3DZielinski%26aufirst%3DJ.%26atitle%3DGlobal%2520Strategy%2520for%2520the%2520Diagnosis%252C%2520Management%252C%2520and%2520Prevention%2520of%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%253A%2520GOLD%2520Executive%2520Summary%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2007%26volume%3D176%26spage%3D532%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hansel, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Tiotropium bromide: A novel once-daily anticholinergic bronchodilator for the treatment of COPD</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">585</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1358%2Fdot.2002.38.9.696535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD38XosFKhtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2002&pages=585-600&author=T.+T.+Hanselauthor=P.+J.+Barnes&title=Tiotropium+bromide%3A+A+novel+once-daily+anticholinergic+bronchodilator+for+the+treatment+of+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD</span></div><div class="casAuthors">Hansel, Trevor T.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">585-600</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">0025-7656</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">Tiotropium bromide (Spiriva, BA679BR, Boehringer Ingelheim) is a novel inhaled, long-acting anti-cholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).  Like ipratropium bromide, tiotropium bromide is a quaternary ammonium deriv. that binds to muscarinic receptors.  However, although tiotropium binds with high affinity to muscarinic receptors of M1-, M2- and M3-subtypes, it dissocs. very slowly from M1- and M3-receptors but more rapidly from M2-receptors, thereby giving it a unique kinetic selectivity.  To date, the short-acting anticholinergic agents ipratropium and oxitropium bromide have been extensively employed as bronchodilator therapy for patients with COPD.  Indeed, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy emphasizes the role of bronchodilators in symptomatic management of all stages of COPD.  It is encouraging that tiotropium given once daily from a dry powder inhaler at 18 μg has been shown to cause greater improvement in lung function and redn. in symptoms than ipratropium bromide given four times daily.  Furthermore, clin. studies over a 1-yr period have demonstrated that tiotropium has impressive and maintained effects on lung function, symptoms and health-related quality of life, and may also reduce exacerbations.  In a recent large scale comparative study over 6 mo, tiotropium has been shown to cause superior bronchodilation and symptomatic improvement when compared to twice daily salmeterol in COPD.  The only significant reported adverse event is dry mouth, which is found in approx. 10%-15% of subjects, but this is reversible and rarely causes discontinuation of therapy.  Based on these promising features, it is likely that tiotropium used alone or in combination with other bronchodilators will emerge as first-line maintenance treatment for patients with airway obstruction due to COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp36GmvIgkIbVg90H21EOLACvtfcHk0ljg1R27NQFBhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XosFKhtbc%253D&md5=e5fead30196f449a4f2cb714b8b24a35</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1358%2Fdot.2002.38.9.696535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2002.38.9.696535%26sid%3Dliteratum%253Aachs%26aulast%3DHansel%26aufirst%3DT.%2BT.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DTiotropium%2520bromide%253A%2520A%2520novel%2520once-daily%2520anticholinergic%2520bronchodilator%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DDrugs%2520Today%26date%3D2002%26volume%3D38%26spage%3D585%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Gross, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skorodin, M. S.</span><span> </span><span class="NLM_article-title">Role of the Parasympathetic System in Airway Obstruction Due to Emphysema</span> <span class="citation_source-journal">N. Eng. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1056%2FNEJM198408163110701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=6749189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A280%3ADyaL2c3ntVGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=1984&pages=421-425&author=N.+J.+Grossauthor=M.+S.+Skorodin&title=Role+of+the+Parasympathetic+System+in+Airway+Obstruction+Due+to+Emphysema"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the parasympathetic system in airway obstruction due to emphysema</span></div><div class="casAuthors">Gross N J; Skorodin M S</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">421-5</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">To study the relative contributions of parasympathetic and sympathetic mechanisms in airway obstruction in patients with emphysema, we gave supramaximal doses of anticholinergic and adrenergic agents in sequence and in combination.  Serial doses of one agent were administered to achieve a plateau of bronchodilatation; after that the other agent was administered.  The plateau achieved with the anticholinergic agent (atropine methonitrate) was significantly higher than that achieved with the adrenergic agent (salbutamol).  When the adrenergic agent was given first, additional bronchodilatation was achieved with subsequent use of the anticholinergic agent.  When the anticholinergic agent was given first, no additional bronchodilatation was achieved with subsequent administration of the adrenergic agent.  When both agents were given simultaneously, the degree of bronchodilatation was virtually identical to that obtained with the anticholinergic agent alone.  Tests sensitive to small-airway and large-airway function and lung volumes gave essentially the same results.  Thus, all achievable bronchodilatation was obtained with the anticholinergic agent alone.  These results suggest that the two classes of agents produce bronchodilatation through a common cholinergic pathway in emphysema, and support the concept that parasympathetic activity is the dominant reversible component of airway obstruction in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbD4U-qyRieu3MPKNEWB5RfW6udTcc2eaGuq2RHGB_U7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c3ntVGgtQ%253D%253D&md5=8db96527324d9d91a101a7a639e69804</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJM198408163110701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198408163110701%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DN.%2BJ.%26aulast%3DSkorodin%26aufirst%3DM.%2BS.%26atitle%3DRole%2520of%2520the%2520Parasympathetic%2520System%2520in%2520Airway%2520Obstruction%2520Due%2520to%2520Emphysema%26jtitle%3DN.%2520Eng.%2520J.%2520Med.%26date%3D1984%26volume%3D311%26spage%3D421%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Coulson, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fryer, A. D.</span><span> </span><span class="NLM_article-title">Muscarinic acetylcholine receptors and airway diseases</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1016%2FS0163-7258%2803%2900004-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=12667888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12nsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2003&pages=59-69&author=F.+R.+Coulsonauthor=A.+D.+Fryer&title=Muscarinic+acetylcholine+receptors+and+airway+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Muscarinic acetylcholine receptors and airway diseases</span></div><div class="casAuthors">Coulson, Fiona R.; Fryer, Allison D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-69</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  Parasympathetic nerves provide the dominant autonomic innervation of the airways.  Release of acetylcholine from parasympathetic nerves activates postjunctional muscarinic receptors present on airway smooth muscle, submucosal glands, and blood vessels to cause bronchoconstriction, mucus secretion, and vasodilatation, resp.  Acetylcholine also feeds back onto prejunctional muscarinic receptors to enhance or inhibit further acetylcholine release.  In asthma and chronic obstructive pulmonary disease, bronchoconstriction and mucus secretion is increased and the airways are hyperresponsive to contractile agents.  These changes are due to increased parasympathetic nerve activity.  The no. and function of postjunctional muscarinic receptors in the airways are unchanged in animal models of asthma.  Rather, it is the supply of acetylcholine to the postjunctional cells (smooth muscle and submucosal gland) that is increased.  The increase in acetylcholine release occurs because prejunctional, inhibitory M2 muscarinic receptors on the parasympathetic nerves are dysfunctional.  M2 muscarinic receptor dysfunction and subsequent airway hyperreactivity were demonstrated to occur in animals in response to a variety of triggers, including antigen challenge, virus infection, ozone exposure, and vitamin A deficiency.  In humans, there is evidence that loss of M2 muscarinic receptor function is related to asthma.  The mechanisms by which neuronal M2 muscarinic receptor function is lost and its relevance to human airway disease are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK8xZ3prJjm7Vg90H21EOLACvtfcHk0lgOu1Lf3Y1E0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12nsbc%253D&md5=c63bed82af7061b6d8d095314660e691</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900004-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900004-4%26sid%3Dliteratum%253Aachs%26aulast%3DCoulson%26aufirst%3DF.%2BR.%26aulast%3DFryer%26aufirst%3DA.%2BD.%26atitle%3DMuscarinic%2520acetylcholine%2520receptors%2520and%2520airway%2520diseases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D98%26spage%3D59%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Joos, G. F.</span><span> </span><span class="NLM_article-title">Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Expert. Opin. Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">264</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=257-264&author=G.+F.+Joos&title=Potential+for+long-acting+muscarinic+antagonists+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJoos%26aufirst%3DG.%2BF.%26atitle%3DPotential%2520for%2520long-acting%2520muscarinic%2520antagonists%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DExpert.%2520Opin.%2520Investig.%2520Drugs%26date%3D2010%26volume%3D19%26spage%3D257%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Lainé, D. I.</span><span> </span><span class="NLM_article-title">Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1586%2Fecp.09.48" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=22111532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyiur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=43-53&author=D.+I.+Lain%C3%A9&title=Long-acting+muscarinic+antagonists+for+the+treatment+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Laine, Dramane I.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Muscarinic acetylcholine receptor antagonists, particularly of the M3 subtype, are useful therapeutics as bronchodilators in chronic obstructive pulmonary disease (COPD).  The first long-acting muscarinic antagonist, tiotropium bromide (Spiriva), was launched in 2002 and has since become established as the gold-std. muscarinic antagonist for the treatment of COPD.  This review will survey the preclin. profiles of tiotropium and nine inhaled development candidates as well as literature reports of other preclin. compds. specifically designed as inhaled antimuscarinic agents for the treatment of COPD.  The design strategies employed lay behind three common principles: high potency and slow reversibility at the M3 receptor and low systemic exposure.  In addn. to their effectiveness as bronchodilators, the differentiation of these agents in the clinic may be linked to their potential to be utilized in combination with other therapeutics.  In the long term, the emerging knowledge around the role of muscarinic antagonists in the inflammation and remodeling of the airways may also help in discriminating them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKrhaXj61Tm7Vg90H21EOLACvtfcHk0liNxgM__Nir-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyiur7O&md5=690cd53b03e85b28a97edeff1941abca</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1586%2Fecp.09.48&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.09.48%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26atitle%3DLong-acting%2520muscarinic%2520antagonists%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2010%26volume%3D3%26spage%3D43%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Cazzola, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matera, M. G.</span><span> </span><span class="NLM_article-title">Emerging inhaled bronchodilators: an update</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">757</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1183%2F09031936.00013109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=19720811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Whsb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=757-769&author=M.+Cazzolaauthor=M.+G.+Matera&title=Emerging+inhaled+bronchodilators%3A+an+update"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging inhaled bronchodilators an update</span></div><div class="casAuthors">Cazzola, M.; Matera, M. G.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">757-769</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Bronchodilators remain central to the symptomatic management of chronic obstructive pulmonary disease and asthma, and, for this reason and also because the patent protection of many bronchodilators has expired, several companies have reinitiated research into the field.  The only limits set for the development of a long-lasting bronchodilator with a new product profile are medical needs and marketing opportunities.  The incorporation of once-daily dose administration is an important strategy for improving adherence and is a regimen preferred by most patients.  A variety of β2-agonists and antimuscarinic agents with longer half-lives and inhalers contg. a combination of several classes of long-acting bronchodilator are currently under development.  The present article reviews all of the most important compds. under development, describing what has been done and discussing their genuine advantage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Ttk1mXA947Vg90H21EOLACvtfcHk0li1ZoyHCWDkeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Whsb7L&md5=0f5ddd276c714d15974318b51a8a5be5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1183%2F09031936.00013109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00013109%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26atitle%3DEmerging%2520inhaled%2520bronchodilators%253A%2520an%2520update%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D34%26spage%3D757%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolzoni, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battipaglia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenacchi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cacciani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaniboni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scudellaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razzetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span> </span><span class="NLM_article-title">Bronchodilator Activity of (3<i>R</i>)-3-[[[(3-Fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane Bromide (CHF5407), a Potent, Long-Acting, and Selective Muscarinic M<sub>3</sub> Receptor Antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">–</span> <span class="NLM_lpage">635</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1124%2Fjpet.110.170035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=20805306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=622-635&author=G.+Villettiauthor=F.+Pastoreauthor=M.+Bergamaschiauthor=F.+Bassaniauthor=P.+T.+Bolzoniauthor=L.+Battipagliaauthor=G.+Amariauthor=A.+Rizziauthor=M.+Delcanaleauthor=R.+Voltaauthor=V.+Cenacchiauthor=F.+Caccianiauthor=M.+Zaniboniauthor=F.+Bertiauthor=G.+Rossoniauthor=S.+Harrisonauthor=P.+Petrilloauthor=E.+Santoroauthor=R.+Scudellaroauthor=F.+Manniniauthor=P.+A.+Geppettiauthor=R.+Razzettiauthor=R.+Patacchiniauthor=M.+Civelli&title=Bronchodilator+Activity+of+%283R%29-3-%5B%5B%5B%283-Fluorophenyl%29%5B%283%2C4%2C5-trifluorophenyl%29methyl%5Damino%5Dcarbonyl%5Doxy%5D-1-%5B2-oxo-2-%282-thienyl%29ethyl%5D-1-azoniabicyclo%5B2.2.2%5Doctane+Bromide+%28CHF5407%29%2C+a+Potent%2C+Long-Acting%2C+and+Selective+Muscarinic+M3+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist</span></div><div class="casAuthors">Villetti, G.; Pastore, F.; Bergamaschi, M.; Bassani, F.; Bolzoni, P. T.; Battipaglia, L.; Amari, G.; Rizzi, A.; Delcanale, M.; Volta, R.; Cenacchi, V.; Cacciani, F.; Zaniboni, M.; Berti, F.; Rossoni, G.; Harrison, S.; Petrillo, P.; Santoro, E.; Scudellaro, R.; Mannini, F.; Geppetti, P. A.; Razzetti, R.; Patacchini, R.; Civelli, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">622-635</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The novel quaternary ammonium salt (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407) showed subnanomolar affinities for human muscarinic M1 (hM1), M2 (hM2), and M3 (hM3) receptors and dissocd. very slowly from hM3 receptors (t1/2 = 166 min) with a large part of the receptorial complex (54%) remaining undissociated at 32 h from radioligand washout.  In contrast, [3H]CHF5407 dissocd. quickly from hM2 receptors (t1/2 = 31 min), whereas [3H]tiotropium dissocd. slowly from both hM3 (t1/2 = 163 min) and hM2 receptor (t1/2 = 297 min).  In the guinea pig isolated trachea and human isolated bronchus, CHF5407 produced a potent (pIC50 = 9.0-9.6) and long-lasting (up to 24 h) inhibition of M3 receptor-mediated contractile responses to carbachol.  In the guinea pig elec. driven left atrium, the M2 receptor-mediated inhibitory response to carbachol was recovered more quickly in CHF5407-pretreated than in tiotropium-pretreated prepns.  CHF5407, administered intratracheally to anesthetized guinea pigs, potently inhibited acetylcholine (Ach)-induced bronchoconstriction with an ED50 value of 0.15 nmol/kg.  The effect was sustained over a period of 24 h, with a residual 57% inhibition 48 h after antagonist administration at 1 nmol/kg.  In conscious guinea pigs, inhaled CHF5407 inhibited Ach-induced bronchoconstriction for at least 24 h as did tiotropium at similar dosages.  Cardiovascular parameters in anesthetized guinea pigs were not significantly changed by CHF5407, up to 100 nmol/kg i.v. and up to 1000 nmol/kg i.t.  In conclusion, CHF5407 shows a prolonged antibronchospastic activity both in vitro and in vivo, caused by a very slow dissocn. from M3 receptors.  In contrast, CHF5407 is markedly short-acting at M2 receptors, a behavior not shared by tiotropium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnCU6YfyC1MLVg90H21EOLACvtfcHk0lhvG0DxNxbgVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrnJ&md5=54ae71e74a98081c6c574a5f7dd0faad</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.170035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.170035%26sid%3Dliteratum%253Aachs%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DBattipaglia%26aufirst%3DL.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DCacciani%26aufirst%3DF.%26aulast%3DZaniboni%26aufirst%3DM.%26aulast%3DBerti%26aufirst%3DF.%26aulast%3DRossoni%26aufirst%3DG.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DPetrillo%26aufirst%3DP.%26aulast%3DSantoro%26aufirst%3DE.%26aulast%3DScudellaro%26aufirst%3DR.%26aulast%3DMannini%26aufirst%3DF.%26aulast%3DGeppetti%26aufirst%3DP.%2BA.%26aulast%3DRazzetti%26aufirst%3DR.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DCivelli%26aufirst%3DM.%26atitle%3DBronchodilator%2520Activity%2520of%2520%25283R%2529-3-%255B%255B%255B%25283-Fluorophenyl%2529%255B%25283%252C4%252C5-trifluorophenyl%2529methyl%255Damino%255Dcarbonyl%255Doxy%255D-1-%255B2-oxo-2-%25282-thienyl%2529ethyl%255D-1-azoniabicyclo%255B2.2.2%255Doctane%2520Bromide%2520%2528CHF5407%2529%252C%2520a%2520Potent%252C%2520Long-Acting%252C%2520and%2520Selective%2520Muscarinic%2520M3%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D622%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_contrib-group">Wan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmonte, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M.</span><span> </span><span class="NLM_article-title">Discovery of (3-<i>endo</i>)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4560</span><span class="NLM_x">–</span> <span class="NLM_lpage">4562</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4560-4562&author=Z.+Wanauthor=D.+I.+Laineauthor=H.+Yanauthor=C.+Zhuauthor=K.+L.+Widdowsonauthor=P.+T.+Buckleyauthor=M.+Burmanauthor=J.+J.+Foleyauthor=H.+M.+Sarauauthor=D.+B.+Schmidtauthor=E.+F.+Webbauthor=K.+E.+Belmonteauthor=M.+Palovich&title=Discovery+of+%283-endo%29-3-%282-cyano-2%2C2-diphenylethyl%29-8%2C8-dimethyl-8-azoniabicyclo%5B3.2.1%5Doctane+bromide+as+an+efficacious+inhaled+muscarinic+acetylcholine+receptor+antagonist+for+the+treatment+of+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DZ.%26aulast%3DLaine%26aufirst%3DD.%2BI.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DBuckley%26aufirst%3DP.%2BT.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DSchmidt%26aufirst%3DD.%2BB.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DBelmonte%26aufirst%3DK.%2BE.%26aulast%3DPalovich%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520%25283-endo%2529-3-%25282-cyano-2%252C2-diphenylethyl%2529-8%252C8-dimethyl-8-azoniabicyclo%255B3.2.1%255Doctane%2520bromide%2520as%2520an%2520efficacious%2520inhaled%2520muscarinic%2520acetylcholine%2520receptor%2520antagonist%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4560%26epage%3D4562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_contrib-group">Lainé, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neipp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmonte, K.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Structure–Activity Relationship of Tropane Muscarinic Acetylcholine Receptor Antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5241</span><span class="NLM_x">–</span> <span class="NLM_lpage">5252</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900736e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5241-5252&author=D.+I.+Lain%C3%A9author=Z.+Wanauthor=H.+Yanauthor=C.+Zhuauthor=H.+Xieauthor=W.+Fuauthor=J.+Busch-Petersenauthor=C.+Neippauthor=R.+Davisauthor=K.+L.+Widdowsonauthor=F.+E.+Blaneyauthor=J.+Foleyauthor=A.+M.+Baconauthor=E.+F.+Webbauthor=M.+A.+Luttmannauthor=M.+Burmanauthor=H.+M.+Sarauauthor=M.+Salmonauthor=M.+R.+Palovichauthor=K.+Belmonte&title=Design%2C+Synthesis%2C+and+Structure%E2%80%93Activity+Relationship+of+Tropane+Muscarinic+Acetylcholine+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm900736e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900736e%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26aulast%3DWan%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26aulast%3DNeipp%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26aulast%3DFoley%26aufirst%3DJ.%26aulast%3DBacon%26aufirst%3DA.%2BM.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DBelmonte%26aufirst%3DK.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Structure%25E2%2580%2593Activity%2520Relationship%2520of%2520Tropane%2520Muscarinic%2520Acetylcholine%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5241%26epage%3D5252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Prat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buil, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crepso, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casals, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tort, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monleón, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doménech, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antón, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huerta, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sentellas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">González, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertí, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segarra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cárdenas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, H.</span><span> </span><span class="NLM_article-title">Discovery of Novel Quaternary Ammonium Derivatives of (3<i>R</i>)-Quinuclidinol Esters as Potent and Long-Acting Muscarinic Antagonists with Potential for Minimal Systemic Exposure after Inhaled Administration: Identification of (3<i>R</i>)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane Bromide (Aclidinium Bromide)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5076</span><span class="NLM_x">–</span> <span class="NLM_lpage">5092</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900132z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5076-5092&author=M.+Pratauthor=D.+Fern%C3%A1ndezauthor=M.+A.+Builauthor=M.+I.+Crepsoauthor=G.+Casalsauthor=M.+Ferrerauthor=L.+Tortauthor=J.+Castroauthor=J.+M.+Monle%C3%B3nauthor=A.+Gavald%C3%A0author=M.+Miralpeixauthor=I.+Ramosauthor=T.+Dom%C3%A9nechauthor=D.+Vilellaauthor=F.+Ant%C3%B3nauthor=J.+M.+Huertaauthor=S.+Espinosaauthor=M.+L%C3%B3pezauthor=S.+Sentellasauthor=M.+Gonz%C3%A1lezauthor=J.+Albert%C3%ADauthor=V.+Segarraauthor=A.+C%C3%A1rdenasauthor=J.+Beletaauthor=H.+Ryder&title=Discovery+of+Novel+Quaternary+Ammonium+Derivatives+of+%283R%29-Quinuclidinol+Esters+as+Potent+and+Long-Acting+Muscarinic+Antagonists+with+Potential+for+Minimal+Systemic+Exposure+after+Inhaled+Administration%3A+Identification+of+%283R%29-3-%7B%5BHydroxy%28di-2-thienyl%29acetyl%5Doxy%7D-1-%283-phenoxypropyl%29-1-azoniabicyclo%5B2.2.2%5Doctane+Bromide+%28Aclidinium+Bromide%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm900132z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900132z%26sid%3Dliteratum%253Aachs%26aulast%3DPrat%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DD.%26aulast%3DBuil%26aufirst%3DM.%2BA.%26aulast%3DCrepso%26aufirst%3DM.%2BI.%26aulast%3DCasals%26aufirst%3DG.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DTort%26aufirst%3DL.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DMonle%25C3%25B3n%26aufirst%3DJ.%2BM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DDom%25C3%25A9nech%26aufirst%3DT.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DAnt%25C3%25B3n%26aufirst%3DF.%26aulast%3DHuerta%26aufirst%3DJ.%2BM.%26aulast%3DEspinosa%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez%26aufirst%3DM.%26aulast%3DSentellas%26aufirst%3DS.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DM.%26aulast%3DAlbert%25C3%25AD%26aufirst%3DJ.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DC%25C3%25A1rdenas%26aufirst%3DA.%26aulast%3DBeleta%26aufirst%3DJ.%26aulast%3DRyder%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Novel%2520Quaternary%2520Ammonium%2520Derivatives%2520of%2520%25283R%2529-Quinuclidinol%2520Esters%2520as%2520Potent%2520and%2520Long-Acting%2520Muscarinic%2520Antagonists%2520with%2520Potential%2520for%2520Minimal%2520Systemic%2520Exposure%2520after%2520Inhaled%2520Administration%253A%2520Identification%2520of%2520%25283R%2529-3-%257B%255BHydroxy%2528di-2-thienyl%2529acetyl%255Doxy%257D-1-%25283-phenoxypropyl%2529-1-azoniabicyclo%255B2.2.2%255Doctane%2520Bromide%2520%2528Aclidinium%2520Bromide%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5076%26epage%3D5092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Cazzola, M.</span><span> </span><span class="NLM_article-title">Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=482-490&author=M.+Cazzola&title=Aclidinium+bromide%2C+a+novel+long-acting+muscarinic+M3+antagonist+for+the+treatment+of+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DAclidinium%2520bromide%252C%2520a%2520novel%2520long-acting%2520muscarinic%2520M3%2520antagonist%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D10%26spage%3D482%26epage%3D490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Haeberlin, B.; Stowasser, F.; Wirth, W.; Baumberger, A.; Abel, S.; Kaerger, S.; Kieckbusch, T.</span><span> </span><span class="NLM_article-title">Compositions of glycopyrronium salt for inhalation</span>. PCT Int. Appl. Publ. WO 2008000482,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=B.+Haeberlin&author=F.+Stowasser&author=W.+Wirth&author=A.+Baumberger&author=S.+Abel&author=S.+Kaerger&author=T.+Kieckbusch&title=Compositions+of+glycopyrronium+salt+for+inhalation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHaeberlin%26aufirst%3DB.%26atitle%3DCompositions%2520of%2520glycopyrronium%2520salt%2520for%2520inhalation%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Denton, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span> </span><span class="NLM_article-title">A Modified Bouveault Reaction for the Preparation of α,α-Dimethylamines from Amides</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1999&pages=55-56&author=S.+M.+Dentonauthor=A.+Wood&title=A+Modified+Bouveault+Reaction+for+the+Preparation+of+%CE%B1%2C%CE%B1-Dimethylamines+from+Amides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDenton%26aufirst%3DS.%2BM.%26aulast%3DWood%26aufirst%3DA.%26atitle%3DA%2520Modified%2520Bouveault%2520Reaction%2520for%2520the%2520Preparation%2520of%2520%25CE%25B1%252C%25CE%25B1-Dimethylamines%2520from%2520Amides%26jtitle%3DSynlett%26date%3D1999%26volume%3D1%26spage%3D55%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Boehringer, M.; Hunziker, D.; Kuehne, H.; Loeffler, B. M.; Sarabu, R.; Wessel, H. P.</span><span> </span><span class="NLM_article-title"><i>N</i>-substituted Pyrrolidine Derivatives as Dipeptidyl Peptidase IV Inhibitors</span>. PCT Int. Appl. Publ. WO 2003037327,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+Boehringer&author=D.+Hunziker&author=H.+Kuehne&author=B.+M.+Loeffler&author=R.+Sarabu&author=H.+P.+Wessel&title=N-substituted+Pyrrolidine+Derivatives+as+Dipeptidyl+Peptidase+IV+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoehringer%26aufirst%3DM.%26atitle%3DN-substituted%2520Pyrrolidine%2520Derivatives%2520as%2520Dipeptidyl%2520Peptidase%2520IV%2520Inhibitors%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Espino, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehn, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du Bois, J.</span><span> </span><span class="NLM_article-title">Synthesis of 1,3-Difunctionalized Amine Derivatives through Selective C–H Bond Oxidation</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">6935</span><span class="NLM_x">–</span> <span class="NLM_lpage">6936</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja011033x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2001&pages=6935-6936&author=C.+G.+Espinoauthor=P.+M.+Wehnauthor=J.+Chowauthor=J.+Du+Bois&title=Synthesis+of+1%2C3-Difunctionalized+Amine+Derivatives+through+Selective+C%E2%80%93H+Bond+Oxidation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fja011033x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja011033x%26sid%3Dliteratum%253Aachs%26aulast%3DEspino%26aufirst%3DC.%2BG.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DChow%26aufirst%3DJ.%26aulast%3DDu%2BBois%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%25201%252C3-Difunctionalized%2520Amine%2520Derivatives%2520through%2520Selective%2520C%25E2%2580%2593H%2520Bond%2520Oxidation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2001%26volume%3D123%26spage%3D6935%26epage%3D6936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Bower, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Švenda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charmant, J. P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szeto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, T.</span><span> </span><span class="NLM_article-title">Cyclic Sulfamidates as Vehicles for the Synthesis of Substituted Lactams</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">4727</span><span class="NLM_x">–</span> <span class="NLM_lpage">4730</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol048036%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=4727-4730&author=J.+F.+Bowerauthor=J.+%C5%A0vendaauthor=A.+J.+Williamsauthor=J.+P.+H.+Charmantauthor=R.+M.+Lawrenceauthor=P.+Szetoauthor=T.+Gallagher&title=Cyclic+Sulfamidates+as+Vehicles+for+the+Synthesis+of+Substituted+Lactams"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fol048036%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol048036%252B%26sid%3Dliteratum%253Aachs%26aulast%3DBower%26aufirst%3DJ.%2BF.%26aulast%3D%25C5%25A0venda%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DCharmant%26aufirst%3DJ.%2BP.%2BH.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DSzeto%26aufirst%3DP.%26aulast%3DGallagher%26aufirst%3DT.%26atitle%3DCyclic%2520Sulfamidates%2520as%2520Vehicles%2520for%2520the%2520Synthesis%2520of%2520Substituted%2520Lactams%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D4727%26epage%3D4730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Glossop, P. A.; Mantell, S. J.; Strang, R. S.; Watson, C. A. L.; Wood, A.</span><span> </span><span class="NLM_article-title">Carboxamide derivatives as muscarinic receptor antagonists</span>. PCT Int. Appl. Publ. WO 2007034325,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+A.+Glossop&author=S.+J.+Mantell&author=R.+S.+Strang&author=C.+A.+L.+Watson&author=A.+Wood&title=Carboxamide+derivatives+as+muscarinic+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26atitle%3DCarboxamide%2520derivatives%2520as%2520muscarinic%2520receptor%2520antagonists%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gantner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, M.</span><span> </span><span class="NLM_article-title">Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1124%2Fjpet.109.152470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=19478135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFCltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=660-668&author=P.+Casarosaauthor=T.+Bouyssouauthor=S.+Germeyerauthor=A.+Schnappauthor=F.+Gantnerauthor=M.+Pieper&title=Preclinical+Evaluation+of+Long-Acting+Muscarinic+Antagonists%3A+Comparison+of+Tiotropium+and+Investigational+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs</span></div><div class="casAuthors">Casarosa, Paola; Bouyssou, Thierry; Germeyer, Sabine; Schnapp, Andreas; Gantner, Florian; Pieper, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">660-668</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation caused by persistent inflammatory processes in the airways.  An increased cholinergic tone mediates different pathophysiol. features of COPD, such as bronchoconstriction and mucus hypersecretion, mostly through activation of the human muscarinic M3 receptor (hM3) subtype.  Tiotropium bromide (Spiriva) is a well established muscarinic antagonist in the pharmacol. management of COPD with a once-daily posol.  The rationale behind the sustained bronchodilation obtained with tiotropium consists in its slow dissocn. from hM3 receptors.  In this study, we performed a comprehensive preclin. comparison of tiotropium with other long-acting muscarinic antagonists (LAMAs) currently in clin. development, namely aclidinium bromide and glycopyrrolate.  The different muscarinic antagonists were characterized for their (1) affinity toward the different human muscarinic receptor subtypes expressed in Chinese hamster ovary cells and kinetics of receptor dissocn., (2) potency in inhibiting the agonist-induced activation of muscarinic receptors through measurement of second messengers, and (3) efficacy and duration of bronchoprotection, as tested in a model of acetylcholine-induced bronchoconstriction in anesthetized dogs over a period of 24 h.  All of the tested LAMAs showed high affinity and potency toward the hM3 receptor (tiotropium, pA2 = 10.4; aclidinium, pA2 = 9.6; and glycopyrrolate, pA2 = 9.7).  However, dissocn. half-lives of the LA-MAs from the hM3 receptor differed significantly (tiotropium, t1/2=27 h; aclidinium, t1/2=10.7 h; and glycopyrrolate, t1/2=6.1 h).  In line with their kinetic properties at the hM3, the tested LAMAs provided different levels of bronchoprotection in the in vivo setting 24 h after administration (tiotropium = 35%, aclidinium = 21%, and glycopyrrolate = 0% at 24 h) when applied at equieffective doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorQCmscRp-17Vg90H21EOLACvtfcHk0lgpDxMsjWvjpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFCltrk%253D&md5=060333cce96f1491b192e4bdbe4bfec5</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152470%26sid%3Dliteratum%253Aachs%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DGermeyer%26aufirst%3DS.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DGantner%26aufirst%3DF.%26aulast%3DPieper%26aufirst%3DM.%26atitle%3DPreclinical%2520Evaluation%2520of%2520Long-Acting%2520Muscarinic%2520Antagonists%253A%2520Comparison%2520of%2520Tiotropium%2520and%2520Investigational%2520Drugs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D660%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreño, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viñals, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doménech, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcasona, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gras, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortijo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llenas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span> </span><span class="NLM_article-title">Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">331</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1124%2Fjpet.109.151639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=19710368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=740-751&author=A.+Gavald%C3%A0author=M.+Miralpeixauthor=I.+Ramosauthor=R.+Otalauthor=C.+Carre%C3%B1oauthor=M.+Vi%C3%B1alsauthor=T.+Dom%C3%A9nechauthor=C.+Carcasonaauthor=B.+Reyesauthor=D.+Vilellaauthor=J.+Grasauthor=J.+Cortijoauthor=E.+Morcilloauthor=J.+Llenasauthor=H.+Ryderauthor=J.+Beleta&title=Characterization+of+Aclidinium+Bromide%2C+a+Novel+Inhaled+Muscarinic+Antagonist%2C+with+Long+Duration+of+Action+and+a+Favorable+Pharmacological+Profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile</span></div><div class="casAuthors">Gavalda, Amadeu; Miralpeix, Montserrat; Ramos, Israel; Otal, Raquel; Carreno, Cristina; Vinals, Marisa; Domenech, Teresa; Carcasona, Carla; Reyes, Blanca; Vilella, Dolors; Gras, Jordi; Cortijo, Julio; Morcillo, Esteban; Llenas, Jesus; Ryder, Hamish; Beleta, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">740-751</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease.  Aclidinium showed subnanomolar affinity for the five human muscarinic receptors (M1-M5).  [3H]Aclidinium dissocd. slightly faster from M2 and M3 receptors than [3H]tiotropium but much more slowly than [3H]ipratropium.  Its assocn. rate for the M3 receptor was similar to [3H]ipratropium and 2.6 times faster than [3H]tiotropium.  Residence half-life of [3H]aclidinium at the M2 receptor was shorter than at the M3 receptor, demonstrating kinetic selectivity for the M3 receptor.  In isolated guinea pig trachea, aclidinium showed comparable potency to ipratropium and tiotropium, faster onset of action than tiotropium, and duration of action similar to tiotropium and significantly longer than ipratropium.  Nebulized aclidinium inhibited bronchoconstriction induced by acetylcholine in guinea pigs in a concn.-dependent manner with an onset of action faster than tiotropium.  Duration of action of aclidinium (t1/2 = 29 h) was much longer than ipratropium (8 h) but shorter than tiotropium (64 h).  In dogs, aclidinium induced a smaller and more transient increase in heart rate than tiotropium at comparable supratherapeutic doses.  Therefore, under these conditions, aclidinium showed a greater therapeutic index than tiotropium (4.2 vs. 1.6).  These results indicate that aclidinium is a potent muscarinic antagonist with a fast onset of action, a long duration of effect, and a favorable cardiovascular safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZpskcHCQILLVg90H21EOLACvtfcHk0lghD-sdqoZBpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7rF&md5=c66b0d729cd5c6dcba6e3a80e0c5f468</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.151639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.151639%26sid%3Dliteratum%253Aachs%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DOtal%26aufirst%3DR.%26aulast%3DCarre%25C3%25B1o%26aufirst%3DC.%26aulast%3DVi%25C3%25B1als%26aufirst%3DM.%26aulast%3DDom%25C3%25A9nech%26aufirst%3DT.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DReyes%26aufirst%3DB.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DGras%26aufirst%3DJ.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DMorcillo%26aufirst%3DE.%26aulast%3DLlenas%26aufirst%3DJ.%26aulast%3DRyder%26aufirst%3DH.%26aulast%3DBeleta%26aufirst%3DJ.%26atitle%3DCharacterization%2520of%2520Aclidinium%2520Bromide%252C%2520a%2520Novel%2520Inhaled%2520Muscarinic%2520Antagonist%252C%2520with%2520Long%2520Duration%2520of%2520Action%2520and%2520a%2520Favorable%2520Pharmacological%2520Profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D740%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_contrib-group">Cross, P. E.; Mackenzie, A. R.</span><span> </span><span class="NLM_article-title">Preparation of pyrrolidine derivatives as muscarinic receptor antagonists</span>. Eur. Pat. Appl. Publ. EP388054,<span class="NLM_x"> </span><span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=P.+E.+Cross&author=A.+R.+Mackenzie&title=Preparation+of+pyrrolidine+derivatives+as+muscarinic+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DP.%2BE.%26atitle%3DPreparation%2520of%2520pyrrolidine%2520derivatives%2520as%2520muscarinic%2520receptor%2520antagonists%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_contrib-group">Alabaster, V. A.</span><span> </span><span class="NLM_article-title">Discovery and development of selective M<sub>3</sub> antagonists for clinical use</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1060</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1997&pages=1053-1060&author=V.+A.+Alabaster&title=Discovery+and+development+of+selective+M3+antagonists+for+clinical+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlabaster%26aufirst%3DV.%2BA.%26atitle%3DDiscovery%2520and%2520development%2520of%2520selective%2520M3%2520antagonists%2520for%2520clinical%2520use%26jtitle%3DLife%2520Sci.%26date%3D1997%26volume%3D60%26spage%3D1053%26epage%3D1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberstein, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funck-Brentano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lineberry, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woosley, R. L.</span><span> </span><span class="NLM_article-title">The Role of Genetically Determined Polymorphic Drug Metabolism in the Beta-Blockade Produced by Propafenone</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">1764</span><span class="NLM_x">–</span> <span class="NLM_lpage">1768</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1056%2FNEJM199006213222502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=1971708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADyaK3cXls1Gisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=1990&pages=1764-1768&author=J.+T.+Leeauthor=H.+K.+Kroemerauthor=D.+J.+Silbersteinauthor=C.+Funck-Brentanoauthor=M.+D.+Lineberryauthor=A.+J.+Woodauthor=D.+M.+Rodenauthor=R.+L.+Woosley&title=The+Role+of+Genetically+Determined+Polymorphic+Drug+Metabolism+in+the+Beta-Blockade+Produced+by+Propafenone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone</span></div><div class="casAuthors">Lee, John T.; Kroemer, Heyo K.; Silberstein, David J.; Funck-Brentano, Christian; Lineberry, Mark D.; Wood, Alastair J. J.; Roden, Dan M.; Woosley, Raymond L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1764-8</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">Propranolol and the sodium-channel-blocking antiarrhythmic agent propafenone share structural features.  Although propafenone's β-blocking actions are readily demonstrable in vitro, clin. significant β-blockade occurs inconsistently in vivo.  The present study tested the hypothesis that genetically detd. variations in the biotransformation of propafenone to its 5-hydroxy metabolite account for variations in the drug's β-blocking action.  β-Blockade was assessed by measuring the redn. in tachycardia produced by boluses of isoproterenol and treadmill exercise in 14 normal subjects during treatment with placebo and with 150, 225, and 300 mg of propafenone every eight hours for five days each.  Nine subjects (with the extensive-metabolizer phenotype) metabolized most of the propafenone to 5-hydroxypropafenone, and five (with the poor-metabolizer phenotype) did not produce this metabolite.  At the lower dosages, β-blockade was present in both groups but was significantly greater in the subjects with poor metab., in whom deficient 5-hydroxylation was assocd. with higher plasma propafenone levels.  At the highest dose, a similar degree of β-blockade was obsd. in the two groups.  Propafenone also had a higher affinity for β2 receptors in vitro than either of its major metabolites.  Thus, the degree of β-blockade during propafenone therapy reflects genetically detd. variations in the metab. of the parent drug, which is necessary for β-blockade, and this action of propafenone is considerably enhanced in patients with deficient 5-hydroxylation of propafenone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXPKwdNHn3PLVg90H21EOLACvtfcHk0ljk3tGODED67A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls1Gisb4%253D&md5=e7ae74b71a0a4c6137c6f5c9ea54a05e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJM199006213222502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199006213222502%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DKroemer%26aufirst%3DH.%2BK.%26aulast%3DSilberstein%26aufirst%3DD.%2BJ.%26aulast%3DFunck-Brentano%26aufirst%3DC.%26aulast%3DLineberry%26aufirst%3DM.%2BD.%26aulast%3DWood%26aufirst%3DA.%2BJ.%26aulast%3DRoden%26aufirst%3DD.%2BM.%26aulast%3DWoosley%26aufirst%3DR.%2BL.%26atitle%3DThe%2520Role%2520of%2520Genetically%2520Determined%2520Polymorphic%2520Drug%2520Metabolism%2520in%2520the%2520Beta-Blockade%2520Produced%2520by%2520Propafenone%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D1990%26volume%3D322%26spage%3D1764%26epage%3D1768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Williams, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goosen, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterkin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koup, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, S. E.</span><span> </span><span class="NLM_article-title">Drug-Drug Interactions for UDP-Glucuronosyltransferase Substrates: A Pharmacokinetic Explanation for Typically Observed Low Exposure (AUC<sub>I</sub>/AUC) Ratios</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1201</span><span class="NLM_x">–</span> <span class="NLM_lpage">1208</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=1201-1208&author=J.+A.+Williamsauthor=R.+Hylandauthor=B.+C.+Jonesauthor=D.+A.+Smithauthor=S.+Hurstauthor=T.+C.+Goosenauthor=V.+Peterkinauthor=J.+R.+Koupauthor=S.+E.+Ball&title=Drug-Drug+Interactions+for+UDP-Glucuronosyltransferase+Substrates%3A+A+Pharmacokinetic+Explanation+for+Typically+Observed+Low+Exposure+%28AUCI%2FAUC%29+Ratios"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26aulast%3DHyland%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DHurst%26aufirst%3DS.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DPeterkin%26aufirst%3DV.%26aulast%3DKoup%26aufirst%3DJ.%2BR.%26aulast%3DBall%26aufirst%3DS.%2BE.%26atitle%3DDrug-Drug%2520Interactions%2520for%2520UDP-Glucuronosyltransferase%2520Substrates%253A%2520A%2520Pharmacokinetic%2520Explanation%2520for%2520Typically%2520Observed%2520Low%2520Exposure%2520%2528AUCI%252FAUC%2529%2520Ratios%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D1201%26epage%3D1208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F. J.</span><span> </span><span class="NLM_article-title">Inhalation by Design: Novel Ultra-Long-Acting β<sub>2</sub>-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">–</span> <span class="NLM_lpage">6652</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&author=P.+A.+Glossopauthor=C.+A.+L.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+J.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+Design%3A+Novel+Ultra-Long-Acting+%CE%B22-Adrenoreceptor+Agonists+for+Inhaled+Once-Daily+Treatment+of+Asthma+and+Chronic+Obstructive+Pulmonary+Disease+That+Utilize+a+Sulfonamide+Agonist+Headgroup"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%2BL.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%2BJ.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520Design%253A%2520Novel%2520Ultra-Long-Acting%2520%25CE%25B22-Adrenoreceptor%2520Agonists%2520for%2520Inhaled%2520Once-Daily%2520Treatment%2520of%2520Asthma%2520and%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%2520That%2520Utilize%2520a%2520Sulfonamide%2520Agonist%2520Headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6640%26epage%3D6652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Boase, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miners, J. O.</span><span> </span><span class="NLM_article-title">In vitro-in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1046%2Fj.1365-2125.2002.01669.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=12445028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD38Xps1Olsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=493-503&author=S.+Boaseauthor=J.+O.+Miners&title=In+vitro-in+vivo+correlations+for+drugs+eliminated+by+glucuronidation%3A+Investigations+with+the+model+substrate+zidovudine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine</span></div><div class="casAuthors">Boase, Sam; Miners, John O.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">493-503</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Aims: To investigate the effects of incubation conditions on the kinetic consts. for zidovudine (AZT) glucuronidation by human liver microsomes, and whether microsomal intrinsic clearance (CLint) derived for the various conditions predicted hepatic AZT clearance by glucuronidation (CLH) in vivo.  Methods: The effects of incubation constituents, particularly buffer type (phosphate, Tris) and activators (Brij 58, alamethacin, UDP-N-acetylglucosamine (UDP-NAcG)), on the kinetics of AZT glucuronidation by human liver microsomes was investigated.  AZT glucuronide (AZTG) formation by microsomal incubations was quantified by HPLC.  Microsomal CLint values detd. for the various exptl. conditions were extrapolated to a whole organ CLint and these data were used to calc. in vivo CLH using the well-stirred, parallel tube and dispersion models.  Results: Mean CLint values for Brij 58 activated microsomes in both phosphate (3.66 μL/min/mg, 95% CI 1.92, 5.39) and Tris (3.79 μL/min/mg, 95% CI 2.87, 4.71) buffers were higher than the resp. values for native microsomes (1.04, 95% CI 0.53, 1.56 and 1.37 μL/min/mg, 95% CI 1.00, 1.73).  Extrapolation of the microsomal data to a whole organ CLint and substitution of these values in the expressions for the well-stirred, parallel tube and dispersion models underestimated the known in vivo blood AZT clearance by glucuronidation by 6.5- to 23-fold (3.61-1.271 L/h vs. 82 L/h).  There was no significant difference in the CLH predicted by each of the models for each set of conditions.  A wide range of incubation constituents and conditions were subsequently investigated to assess their effects on AZTG formation, including alamethacin, UDP-NAcG, MgCl2, D-saccharic acid 1,4-lactone, ATP, GTP, and buffer pH and ionic strength.  Of these, only decreasing the phosphate buffer concn. from 0.1 M to 0.02 M for Brij 58 activated microsomes substantially increased the rate of AZTG formation, but the extrapolated CLH detd. for this condition still underestimated known AZT glucuronidation clearance by more than 4-fold.  AZT was shown not to bind nonspecifically to microsomes.  Anal. of published data for other glucuronidated drugs confirmed a trend for microsomal CLint to underestimate in vivo CLH.  Conclusions: AZT glucuronidation kinetics by human liver microsomes are markedly dependent on incubation conditions, and there is a need for interlab. standardization.  Extrapolation of in vitro CLint underestimates in vivo hepatic clearance of drugs eliminated by glucuronidation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_JXaVf0cYx7Vg90H21EOLACvtfcHk0liX9gNs_DQaDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xps1Olsbw%253D&md5=64886479df5cc0cff932c62195669f18</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.2002.01669.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.2002.01669.x%26sid%3Dliteratum%253Aachs%26aulast%3DBoase%26aufirst%3DS.%26aulast%3DMiners%26aufirst%3DJ.%2BO.%26atitle%3DIn%2520vitro-in%2520vivo%2520correlations%2520for%2520drugs%2520eliminated%2520by%2520glucuronidation%253A%2520Investigations%2520with%2520the%2520model%2520substrate%2520zidovudine%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2002%26volume%3D54%26spage%3D493%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Magdalou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournel-Gigleux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouzzine, M.</span><span> </span><span class="NLM_article-title">Insights on membrane topology and structure/function of UDP-glucuronosyltransferases</span> <span class="citation_source-journal">Drug Metab. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.3109%2F03602530903209270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=19807219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=159-166&author=J.+Magdalouauthor=S.+Fournel-Gigleuxauthor=M.+Ouzzine&title=Insights+on+membrane+topology+and+structure%2Ffunction+of+UDP-glucuronosyltransferases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Insights on membrane topology and structure/function of UDP-glucuronosyltransferases</span></div><div class="casAuthors">Magdalou, Jacques; Fournel-Gigleux, Sylvie; Ouzzine, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">159-166</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The main characteristic of uridine diphosphate (UDP)-glucuronosyltransferases is their potency to glucuronidate a large array of structurally unrelated substances with various nucleophilic groups.  The activity of these enzymes strongly depends on their tight assocn. to the membrane of the endoplasmic reticulum.  In light of recent data, this review is focused on the membrane-assembly process, which is a prerequisite for activity, and on the amino acids that govern substrate recognition and catalysis at the active site.  The major implication of the highly variable N-terminal domain of UDP-glucuronosyltransferases in the substrate specificity of these enzymes is highlighted.  In the absence of crystal data of the N-terminal domain, multidisciplinary approaches of genetic-/protein-engineering techniques, homol. modeling with glycosyltransferases, and quant. structure-activity relationships allowed us to point out crucial amino acids.  On the basis of these results, possible reaction mechanisms for the glucuronidation of xenobiotics, involving histidine and aspartic acid residues, have been built and are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ1jNLDZdQPrVg90H21EOLACvtfcHk0li9EBhZYw2hzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFantw%253D%253D&md5=28cae4aa50f41e218d4dd85940389c2a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3109%2F03602530903209270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602530903209270%26sid%3Dliteratum%253Aachs%26aulast%3DMagdalou%26aufirst%3DJ.%26aulast%3DFournel-Gigleux%26aufirst%3DS.%26aulast%3DOuzzine%26aufirst%3DM.%26atitle%3DInsights%2520on%2520membrane%2520topology%2520and%2520structure%252Ffunction%2520of%2520UDP-glucuronosyltransferases%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2010%26volume%3D42%26spage%3D159%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nature Rev. Drug Discov.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0liIQnrZ0MPwbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNature%2520Rev.%2520Drug%2520Discov.%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speck, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traunecker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammer, R.</span><span> </span><span class="NLM_article-title">Ba 679 BR, A novel long-acting anticholinergic bronchodilator</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1993&pages=537-544&author=B.+Disseauthor=R.+Reichlauthor=G.+Speckauthor=W.+Trauneckerauthor=K.+L.+Romingerauthor=R.+Hammer&title=Ba+679+BR%2C+A+novel+long-acting+anticholinergic+bronchodilator"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DReichl%26aufirst%3DR.%26aulast%3DSpeck%26aufirst%3DG.%26aulast%3DTraunecker%26aufirst%3DW.%26aulast%3DRominger%26aufirst%3DK.%2BL.%26aulast%3DHammer%26aufirst%3DR.%26atitle%3DBa%2520679%2520BR%252C%2520A%2520novel%2520long-acting%2520anticholinergic%2520bronchodilator%26jtitle%3DLife%2520Sci.%26date%3D1993%26volume%3D52%26spage%3D537%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Nials, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumner, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, R. A.</span><span> </span><span class="NLM_article-title">Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">515</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1111%2Fj.1476-5381.1993.tb12833.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=8095419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADyaK3sXisVOgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=1993&pages=507-515&author=A.+T.+Nialsauthor=M.+J.+Sumnerauthor=M.+Johnsonauthor=R.+A.+Coleman&title=Investigations+into+factors+determining+the+duration+of+action+of+the+beta+2-adrenoceptor+agonist%2C+salmeterol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations into factors determining the duration of action of the β2-adrenoceptor agonist, salmeterol</span></div><div class="casAuthors">Nials, Anthony T.; Sumner, Michael J.; Johnson, Malcolm; Coleman, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">507-15</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">This study has explored the mechanism underlying the long duration of action of the β2-adrenoceptor agonist, salmeterol.  Salmeterol, salbutamol and isoprenaline caused a concn.-related inhibition of elec.-induced contractile responses of the guinea-pig superfused trachea prepn.  The effects of both isoprenaline and salbutamol were rapid in onset and rapidly reversed upon removal of the agonist.  In contrast, the effects of salmeterol were slower in onset and could not be reversed by superfusion of the tissue with agonist-free Krebs soln. even for periods of up to 10 h.  The effects of salmeterol were, however, readily reversed by a no. of β-adrenoceptor blocking drugs, as was the effect of a continuous infusion of isoprenaline.  Upon removal of the antagonist, however, the effects of salmeterol and of the isoprenaline infusion were reasserted at a rate which was inversely related to the lipophilicity of the β-adrenoceptor blocking drugs.  Salmeterol inhibited the binding of [125I]-(-)-iodopindolol (100 pM) to rat lung membranes (pIC50. 7.1), with isoprenaline (pIC50 6.2) and salbutamol (pIC50 5.1) having lower potencies.  The inhibition of binding by salmeterol was apparently non-competitive, whereas that produced by salbutamol and isoprenaline was competitive in nature.  Isoprenaline and salbutamol rapidly dissocd. from their binding sites, whereas in marked contrast, the binding of salmeterol showed no dissocn. for periods of up to 1 h.  These data are consistent with a mechanism in which salmeterol binds adjacent to the active site of the β2-adrenoceptor, such that the drug cannot be washed out of the tissue, yet can interact with and activate the receptor.  This latter property is susceptible to antagonism by β-adrenoceptor blocking drugs but is reasserted when the antagonists are removed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmU1VWz9S-iLVg90H21EOLACvtfcHk0li2IHGBCpEjpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVOgsLg%253D&md5=2ac85caa0d32c826dc8eda06dbebb182</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1993.tb12833.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1993.tb12833.x%26sid%3Dliteratum%253Aachs%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DSumner%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DR.%2BA.%26atitle%3DInvestigations%2520into%2520factors%2520determining%2520the%2520duration%2520of%2520action%2520of%2520the%2520beta%25202-adrenoceptor%2520agonist%252C%2520salmeterol%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1993%26volume%3D108%26spage%3D507%26epage%3D515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Motulsky, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahan, L. C.</span><span> </span><span class="NLM_article-title">The Kinetics of Competitive Radioligand Binding Predicted by the Law of Mass Action</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=6708928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=1-9&author=H.+J.+Motulskyauthor=L.+C.+Mahan&title=The+Kinetics+of+Competitive+Radioligand+Binding+Predicted+by+the+Law+of+Mass+Action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The kinetics of competitive radioligand binding predicted by the law of mass action</span></div><div class="casAuthors">Motulsky H J; Mahan L C</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Although equilibrium competitive radioligand binding studies are often used to characterize hormone and neurotransmitter receptors, the kinetics of such experiments have not been extensively explored.  The interactions of the radioligand and competitor with the receptors can be described by two differential equations which can be solved to yield a single equation describing the binding of the radioligand as a function of time.  This equation has several applications: First, it can be used to simulate competitive binding reactions under defined conditions.  Second, fitting experimental data to this equation allows one to determine the association and dissociation rate constants of the competing ligand, parameters that cannot be derived from equilibrium experiments.  Furthermore, this method can be used to determine the KI of the competing drug from data acquired before equilibrium is reached.  Third, mathematical analysis of the binding equation allowed us to answer two specific questions regarding the kinetics of competitive radioligand binding: how long such an incubation takes to equilibrate, and how the IC50 varies over time.  The answers to these questions depended, to a large extent, on the relative values of the dissociation rate constants of the radioligand and competitor, which can be determined as noted above.  When the competitor dissociates from the receptors more rapidly than the radioligand, the IC50 first decreases and then increases, but never has a value less than the KI.  At low radioligand concentrations, equilibrium is reached in the same amount of time required of the radioligand to dissociate completely from the receptors as determined in an "off-rate experiment." At higher concentrations of radioligand this time is halved.  When the competitor dissociates from the receptor more slowly than does the radioligand, then the time required to equilibrate depends only on the dissociation rate constant of the competitor, and the IC50 decreases over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCXDwvoK7MbN1QT_1O5WBYfW6udTcc2eZBS-8nfKdzQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D&md5=f0c09a16d7f8947fe0d72c256e2e4914</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMotulsky%26aufirst%3DH.%2BJ.%26aulast%3DMahan%26aufirst%3DL.%2BC.%26atitle%3DThe%2520Kinetics%2520of%2520Competitive%2520Radioligand%2520Binding%2520Predicted%2520by%2520the%2520Law%2520of%2520Mass%2520Action%26jtitle%3DMol.%2520Pharmacol.%26date%3D1984%26volume%3D25%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Wright, K.; Davies, T.; Clarke, N.; Yeadon, M.; Perros-Huguet, C.</span><span> </span><span class="NLM_article-title">PF-00610355 – an inhaled β<sub>2</sub>-adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction</span>.  <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">S53</span>), Abstract P2060.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=19324957" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&issue=S53&author=K.+Wright&author=T.+Davies&author=N.+Clarke&author=M.+Yeadon&author=C.+Perros-Huguet&title=PF-00610355+%E2%80%93+an+inhaled+%CE%B22-adrenoceptor+agonist+with+superior+potency+and+duration+of+action+%28DoA%29+to+salmeterol+in+the+conscious+dog+model+of+bronchoconstriction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DK.%26atitle%3DPF-00610355%2520%25E2%2580%2593%2520an%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%2520with%2520superior%2520potency%2520and%2520duration%2520of%2520action%2520%2528DoA%2529%2520to%2520salmeterol%2520in%2520the%2520conscious%2520dog%2520model%2520of%2520bronchoconstriction%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D34%26issue%3DS53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Taburet, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmit, B.</span><span> </span><span class="NLM_article-title">Pharmacokinetic Optimization of Asthma Treatment</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">396</span><span class="NLM_x">–</span> <span class="NLM_lpage">418</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.2165%2F00003088-199426050-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=7914480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADyaK2cXls1ekt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1994&pages=396-418&author=A.+M.+Taburetauthor=B.+Schmit&title=Pharmacokinetic+Optimization+of+Asthma+Treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic optimization of asthma treatment</span></div><div class="casAuthors">Taburet, Anne-Marie; Schmit, Benedicte</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">396-418</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">A review with > ∼ 140 refs.  Asthma is generally managed with bronchodilator therapy and/or anti-inflammatory drugs.  Guidelines now advocate selection of drugs and pharmaceutical formulations (long-acting vs. short-acting, inhaled vs. systemic) on the basis of disease severity.  Theophylline has a narrow therapeutic margin.  Clearance is highly variable and plasma concns. should be monitored to avoid the occurrence of plasma concn.-related adverse effects.  The rate of absorption of theophylline differs depending on the sustained-release formulation administered.  Some products do not provide sufficient plasma drug concns. for therapeutic efficacy over a 12-h period, particularly in patients with high clearance rates (e.g. children and patients who smoke).  Administration of drugs via inhalation offers several advantages over systemic routes of administration (e.g. adverse effects are decreased).  Inhalation is now advocated as first-line therapy.  Aerosol medications available for the treatment of asthma are β2-agonists (including the newer long-acting agents such as salmeterol), corticosteroids, anticholinergic drugs, sodium cromoglycate (cromolyn sodium) and nedocromil.  To reach the airways, aerosolized particles should be 1 to 5 μm in diam.  Particles of the size can be produced by nebulizer for continuous administration or by metered-dose inhaler and drug powder inhaler for unit dose medication.  For efficient use of the metered-dose inhaler, slow inhalation and actuation must be coordinated.  However, efficacy and convenience can be improved when spacer devices are used.  Furthermore, spacer devices lessen the oropharyngeal adverse effects of inhaled corticosteroids.  Dry powder inhalers are more easily used by children and elderly patients than metered-dose inhalers.  Regardless of the device used, a max. of 10% of the inhaled dose reaches the airways.  The rest of the dose is swallowed and absorbed through the gastrointestinal tract.  Most inhaled drugs have low oral bioavailability, either because of a high first-pass metab. (β2-agonists and glucocorticoids) or because of lack of absorption (sodium cromoglycate).  Sulfation of β2-agonists occurs in the wall of the gastrointestinal tract and extensive metab. of inhaled corticosteroids occurs in the liver.  Low bioavailability of the swallowed fraction contributes to reduced adverse effects.  The pharmacokinetic properties of an inhaled drug are of interest.  The fraction of the dose absorbed through the lung has the same disposition characteristics as an i.v. dose, and the swallowed fraction has the same disposition as an orally administered dose.  However, for many drugs, pharmacokinetic data after inhalation are limited and cannot be used as a criteria for selection of therapy.  Whatever the device used to deliver the aerosolized drug, patients should be instructed on how to use the inhaler device so that max. benefit may be obtained from their inhaled therapy.  Although inhalation therapy is the first-line treatment for asthma, aerosol delivery to the airways and convenience of the devices could be improved, without increasing the cost of therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7-NQ7w9Y1OrVg90H21EOLACvtfcHk0liPU1Jl1qphkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXls1ekt7s%253D&md5=eda2e7e33db25968587dabea1927d4fa</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2165%2F00003088-199426050-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199426050-00006%26sid%3Dliteratum%253Aachs%26aulast%3DTaburet%26aufirst%3DA.%2BM.%26aulast%3DSchmit%26aufirst%3DB.%26atitle%3DPharmacokinetic%2520Optimization%2520of%2520Asthma%2520Treatment%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1994%26volume%3D26%26spage%3D396%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Glossop, P. A.; James, K.</span><span> </span><span class="NLM_article-title">The hydrochloride salt of 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide and its use as a medicament</span>. PCT Int. Appl. Publ. WO 2008135819,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+A.+Glossop&author=K.+James&title=The+hydrochloride+salt+of+5-%283-%283-hydroxyphenoxy%29azetidin-1-yl%29-5-methyl-2%2C2-diphenylhexanamide+and+its+use+as+a+medicament"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26atitle%3DThe%2520hydrochloride%2520salt%2520of%25205-%25283-%25283-hydroxyphenoxy%2529azetidin-1-yl%2529-5-methyl-2%252C2-diphenylhexanamide%2520and%2520its%2520use%2520as%2520a%2520medicament%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Sladen, L.; Wright, K.; Adcock, J.; Chaffe, P.; Clarke, N.; Yeadon, M.; Perros-Huguet, C.</span><span> </span><span class="NLM_article-title">Effects of intra tracheal PF-00610355, an inhaled β<sub>2</sub>-adrenoceptor agonist, in anaesthetised animals</span>.  <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">S53</span>), Abstract P2020.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&issue=S53&author=L.+Sladen&author=K.+Wright&author=J.+Adcock&author=P.+Chaffe&author=N.+Clarke&author=M.+Yeadon&author=C.+Perros-Huguet&title=Effects+of+intra+tracheal+PF-00610355%2C+an+inhaled+%CE%B22-adrenoceptor+agonist%2C+in+anaesthetised+animals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSladen%26aufirst%3DL.%26atitle%3DEffects%2520of%2520intra%2520tracheal%2520PF-00610355%252C%2520an%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%252C%2520in%2520anaesthetised%2520animals%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D34%26issue%3DS53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Watson, J.; Strawbridge, M.; Brown, R.; Campany, K.; Coghlan, M.; Trevethick, M.</span><span> </span><span class="NLM_article-title">Offset rates of tiotropium and ipratropium at human recombinant muscarinic M<sub>1</sub>-M<sub>5</sub> receptors using a dilution-offset methodology</span>.  <span class="citation_source-journal">Fundam. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">S2</span>),  <span class="NLM_fpage">78</span>, Abstract P102.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=78&issue=S2&author=J.+Watson&author=M.+Strawbridge&author=R.+Brown&author=K.+Campany&author=M.+Coghlan&author=M.+Trevethick&title=Offset+rates+of+tiotropium+and+ipratropium+at+human+recombinant+muscarinic+M1-M5+receptors+using+a+dilution-offset+methodology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DJ.%26atitle%3DOffset%2520rates%2520of%2520tiotropium%2520and%2520ipratropium%2520at%2520human%2520recombinant%2520muscarinic%2520M1-M5%2520receptors%2520using%2520a%2520dilution-offset%2520methodology%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D22%26issue%3DS2%26spage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Banholzer, R.; Bauer, R.; Reichl, R.</span><span> </span><span class="NLM_article-title">Preparation of anticholinergic scopine, (nor)tropine, and granatoline esters of thienylcarboxylic acids and their quaternary salts</span>. Eur. Pat. Appl. Publ. EP 418716,<span class="NLM_x"> </span><span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=R.+Banholzer&author=R.+Bauer&author=R.+Reichl&title=Preparation+of+anticholinergic+scopine%2C+%28nor%29tropine%2C+and+granatoline+esters+of+thienylcarboxylic+acids+and+their+quaternary+salts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBanholzer%26aufirst%3DR.%26atitle%3DPreparation%2520of%2520anticholinergic%2520scopine%252C%2520%2528nor%2529tropine%252C%2520and%2520granatoline%2520esters%2520of%2520thienylcarboxylic%2520acids%2520and%2520their%2520quaternary%2520salts%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19a','cit19b'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 24 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Sanjeev Kumar, Jesse P. Waldo, Firoz A. Jaipuri, Agnieszka Marcinowicz, Clarissa Van Allen, James Adams, Tanay Kesharwani, Xiaoxia Zhang, Richard Metz, Angela J. Oh, Seth F. Harris, <span class="NLM_string-name hlFld-ContribAuthor">Mario R. Mautino</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6705-6733. <a href="https://doi.org/10.1021/acs.jmedchem.9b00662" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00662</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00662%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BClinical%252BCandidate%252B%2525281R%25252C4r%252529-4-%252528%252528R%252529-2-%252528%252528S%252529-6-Fluoro-5H-imidazo%25255B5%25252C1-a%25255Disoindol-5-yl%252529-1-hydroxyethyl%252529cyclohexan-1-ol%252B%252528Navoximod%252529%25252C%252Ba%252BPotent%252Band%252BSelective%252BInhibitor%252Bof%252BIndoleamine%252B2%25252C3-Dioxygenase%252B1%26aulast%3DKumar%26aufirst%3DSanjeev%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D24042019%26date%3D02072019%26date%3D18062019%26volume%3D62%26issue%3D14%26spage%3D6705%26epage%3D6733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mark Bell, David Foley, Claire Naylor, Gavin Wood, Colin Robinson, Jennifer Riley, Ola Epemolu, Lucy Ellis, Paul Scullion, Yoko Shishikura, Maria Osuna-Cabello, Liam Ferguson, Erika Pinto, Daniel Fletcher, Elad Katz, W. H. Irwin McLean, Paul Wyatt, Kevin D Read, <span class="NLM_string-name hlFld-ContribAuthor">Andrew Woodland</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Soft-Drug Topical Tool Modulators of Sphingosine-1-phosphate Receptor 1 (S1PR1). </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 341-347. <a href="https://doi.org/10.1021/acsmedchemlett.8b00616" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00616</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00616%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BSoft-Drug%252BTopical%252BTool%252BModulators%252Bof%252BSphingosine-1-phosphate%252BReceptor%252B1%252B%252528S1PR1%252529%26aulast%3DBell%26aufirst%3DMark%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D07122018%26date%3D14022019%26date%3D19022019%26date%3D14022019%26volume%3D10%26issue%3D3%26spage%3D341%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gang Wu, Shaowei Liu, Ting Wang, Zhongke Jiang, Kai Lv, Yucheng Wang, <span class="NLM_string-name hlFld-ContribAuthor">Chenghang Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Total Synthesis of Originally Proposed and Revised Structure of Hetiamacin A. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (12)
                                     , 3566-3569. <a href="https://doi.org/10.1021/acs.orglett.8b01350" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b01350</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b01350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b01350%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DTotal%252BSynthesis%252Bof%252BOriginally%252BProposed%252Band%252BRevised%252BStructure%252Bof%252BHetiamacin%252BA%26aulast%3DWu%26aufirst%3DGang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D28042018%26date%3D25052018%26volume%3D20%26issue%3D12%26spage%3D3566%26epage%3D3569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2166-2210. <a href="https://doi.org/10.1021/acs.jmedchem.7b00315" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00315%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNatural-Products-Inspired%252BUse%252Bof%252Bthe%252Bgem-Dimethyl%252BGroup%252Bin%252BMedicinal%252BChemistry%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D27022017%26date%3D08092017%26date%3D29082017%26volume%3D61%26issue%3D6%26spage%3D2166%26epage%3D2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard S. Roberts, Sara Sevilla, Manel Ferrer, Joan Taltavull, Begoña Hernández, Victor Segarra, Jordi Gràcia, Martin D. Lehner, Amadeu Gavaldà, Miriam Andrés, Judit Cabedo, Dolors Vilella, Peter Eichhorn, Elena Calama, Carla Carcasona, <span class="NLM_string-name hlFld-ContribAuthor">Montserrat Miralpeix</span>. </span><span class="cited-content_cbyCitation_article-title">4-Amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure–Activity Relationships. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2472-2489. <a href="https://doi.org/10.1021/acs.jmedchem.7b01751" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01751</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01751%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-Amino-7%25252C8-dihydro-1%25252C6-naphthyridin-5%2525286H%252529-ones%252Bas%252BInhaled%252BPhosphodiesterase%252BType%252B4%252B%252528PDE4%252529%252BInhibitors%25253A%252BStructural%252BBiology%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%26aulast%3DRoberts%26aufirst%3DRichard%2BS.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D01122017%26date%3D13032018%26date%3D05032018%26volume%3D61%26issue%3D6%26spage%3D2472%26epage%3D2489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter J.  Tonge</span>  . </span><span class="cited-content_cbyCitation_article-title">Drug–Target Kinetics in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     , 29-39. <a href="https://doi.org/10.1021/acschemneuro.7b00185" title="DOI URL">https://doi.org/10.1021/acschemneuro.7b00185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.7b00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.7b00185%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DDrug%2525E2%252580%252593Target%252BKinetics%252Bin%252BDrug%252BDiscovery%26aulast%3DTonge%26aufirst%3DPeter%2BJ.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D20052017%26date%3D22062017%26date%3D14072017%26date%3D17012018%26date%3D22062017%26volume%3D9%26issue%3D1%26spage%3D29%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Bortolato</span>, <span class="hlFld-ContribAuthor ">Francesca  Deflorian</span>, <span class="hlFld-ContribAuthor ">Dahlia R.  Weiss</span>, and <span class="hlFld-ContribAuthor ">Jonathan S.  Mason</span>  . </span><span class="cited-content_cbyCitation_article-title">Decoding the Role of Water Dynamics in Ligand–Protein Unbinding: CRF1R as a Test Case. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (9)
                                     , 1857-1866. <a href="https://doi.org/10.1021/acs.jcim.5b00440" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00440</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00440%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDecoding%252Bthe%252BRole%252Bof%252BWater%252BDynamics%252Bin%252BLigand%2525E2%252580%252593Protein%252BUnbinding%25253A%252BCRF1R%252Bas%252Ba%252BTest%252BCase%26aulast%3DBortolato%26aufirst%3DAndrea%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D13072015%26date%3D10092015%26date%3D28092015%26date%3D03092015%26volume%3D55%26issue%3D9%26spage%3D1857%26epage%3D1866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paolo  Montuschi</span> and <span class="hlFld-ContribAuthor ">Giovanni  Ciabattoni</span>  . </span><span class="cited-content_cbyCitation_article-title">Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (10)
                                     , 4131-4164. <a href="https://doi.org/10.1021/jm5013227" title="DOI URL">https://doi.org/10.1021/jm5013227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5013227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5013227%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBronchodilating%252BDrugs%252Bfor%252BChronic%252BObstructive%252BPulmonary%252BDisease%25253A%252BCurrent%252BStatus%252Band%252BFuture%252BTrends%26aulast%3DMontuschi%26aufirst%3DPaolo%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D28082014%26date%3D09022015%26date%3D28052015%26date%3D14012015%26volume%3D58%26issue%3D10%26spage%3D4131%26epage%3D4164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christofer S.  Tautermann</span>, <span class="hlFld-ContribAuthor ">Tobias  Kiechle</span>, <span class="hlFld-ContribAuthor ">Daniel  Seeliger</span>, <span class="hlFld-ContribAuthor ">Sonja  Diehl</span>, <span class="hlFld-ContribAuthor ">Eva  Wex</span>, <span class="hlFld-ContribAuthor ">Rolf  Banholzer</span>, <span class="hlFld-ContribAuthor ">Florian  Gantner</span>, <span class="hlFld-ContribAuthor ">Michael P.  Pieper</span>, and <span class="hlFld-ContribAuthor ">Paola  Casarosa</span>  . </span><span class="cited-content_cbyCitation_article-title">Molecular Basis for the Long Duration of Action and Kinetic Selectivity of Tiotropium for the Muscarinic M3 Receptor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (21)
                                     , 8746-8756. <a href="https://doi.org/10.1021/jm401219y" title="DOI URL">https://doi.org/10.1021/jm401219y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401219y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401219y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMolecular%252BBasis%252Bfor%252Bthe%252BLong%252BDuration%252Bof%252BAction%252Band%252BKinetic%252BSelectivity%252Bof%252BTiotropium%252Bfor%252Bthe%252BMuscarinic%252BM3%252BReceptor%26aulast%3DTautermann%26aufirst%3DChristofer%2BS.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D06082013%26date%3D25102013%26date%3D14112013%26date%3D02102013%26volume%3D56%26issue%3D21%26spage%3D8746%26epage%3D8756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barry R.  Dillon</span>, <span class="hlFld-ContribAuthor ">Dannielle F.  Roberts</span>, <span class="hlFld-ContribAuthor ">David A.  Entwistle</span>, <span class="hlFld-ContribAuthor ">Paul A.  Glossop</span>, <span class="hlFld-ContribAuthor ">Craig J.  Knight</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Laity</span>, <span class="hlFld-ContribAuthor ">Kim  James</span>, <span class="hlFld-ContribAuthor ">Celine F.  Praquin</span>, <span class="hlFld-ContribAuthor ">Ross S.  Strang</span>, and <span class="hlFld-ContribAuthor ">Christine A. L.  Watson</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of a Scaleable Synthesis of a Geminal Dimethyl Tertiary Amine as an Inhaled Muscarinic Antagonist for the Treatment of COPD. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2012,</strong> <em>16 </em>
                                    (2)
                                     , 195-203. <a href="https://doi.org/10.1021/op200233r" title="DOI URL">https://doi.org/10.1021/op200233r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/op200233r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fop200233r%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BScaleable%252BSynthesis%252Bof%252Ba%252BGeminal%252BDimethyl%252BTertiary%252BAmine%252Bas%252Ban%252BInhaled%252BMuscarinic%252BAntagonist%252Bfor%252Bthe%252BTreatment%252Bof%252BCOPD%26aulast%3DDillon%26aufirst%3DBarry%2BR.%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D25082011%26date%3D26012012%26date%3D17022012%26date%3D06012012%26volume%3D16%26issue%3D2%26spage%3D195%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kuanglei  Wang</span>, <span class="hlFld-ContribAuthor ">Hongxi  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongqian  Zhao</span>, <span class="hlFld-ContribAuthor ">Kun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongshou  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Application of carbamyl in structural optimization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103757. <a href="https://doi.org/10.1016/j.bioorg.2020.103757" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103757%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DApplication%252Bof%252Bcarbamyl%252Bin%252Bstructural%252Boptimization%26aulast%3DWang%26aufirst%3DKuanglei%26date%3D2020%26volume%3D98%26spage%3D103757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Toshio  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Fumiaki  Takahashi</span>. </span><span class="cited-content_cbyCitation_article-title">Eldecalcitol and Osteoporosis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 695-707. <a href="https://doi.org/10.1016/B978-0-12-809963-6.00093-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-809963-6.00093-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809963-6.00093-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809963-6.00093-6%26sid%3Dliteratum%253Aachs%26atitle%3DEldecalcitol%252Band%252BOsteoporosis%26aulast%3DMatsumoto%26aufirst%3DToshio%26date%3D2018%26spage%3D695%26epage%3D707%26pub%3DElsevier%26atitle%3DVitamin%252BD%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J. Richard  Morphy</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies to Prevent Compound Attrition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 215-228. <a href="https://doi.org/10.1002/9781118819586.ch8" title="DOI URL">https://doi.org/10.1002/9781118819586.ch8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118819586.ch8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118819586.ch8%26sid%3Dliteratum%253Aachs%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bto%252BPrevent%252BCompound%252BAttrition%26aulast%3DMorphy%26aufirst%3DJ.%2BRichard%26date%3D2015%26date%3D2015%26spage%3D215%26epage%3D228%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DAttrition%252Bin%252Bthe%252BPharmaceutical%252BIndustry%26aulast%3DAlex%26aufirst%3DAlexander%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Schoop</span>, <span class="hlFld-ContribAuthor ">Fabian  Dey</span>. </span><span class="cited-content_cbyCitation_article-title">On-rate based optimization of structure–kinetic relationship – surfing the kinetic map. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today: Technologies</span><span> <strong>2015,</strong> <em>17 </em>, 9-15. <a href="https://doi.org/10.1016/j.ddtec.2015.08.003" title="DOI URL">https://doi.org/10.1016/j.ddtec.2015.08.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ddtec.2015.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ddtec.2015.08.003%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technologies%26atitle%3DOn-rate%252Bbased%252Boptimization%252Bof%252Bstructure%2525E2%252580%252593kinetic%252Brelationship%252B%2525E2%252580%252593%252Bsurfing%252Bthe%252Bkinetic%252Bmap%26aulast%3DSchoop%26aufirst%3DAndreas%26date%3D2015%26volume%3D17%26spage%3D9%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Felix  Schiele</span>, <span class="hlFld-ContribAuthor ">Pelin  Ayaz</span>, <span class="hlFld-ContribAuthor ">Anke  Müller-Fahrnow</span>. </span><span class="cited-content_cbyCitation_article-title">The Use of Structural Information to Understand Binding Kinetics. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 237-256. <a href="https://doi.org/10.1002/9783527673025.ch12" title="DOI URL">https://doi.org/10.1002/9783527673025.ch12</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527673025.ch12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527673025.ch12%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BUse%252Bof%252BStructural%252BInformation%252Bto%252BUnderstand%252BBinding%252BKinetics%26aulast%3DSchiele%26aufirst%3DFelix%26date%3D2015%26date%3D2015%26spage%3D237%26epage%3D256%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DThermodynamics%252Band%252BKinetics%252Bof%252BDrug%252BBinding%26aulast%3DKeser%25C3%25BC%26aufirst%3DGy%25C3%25B6rgy%2BM.%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacobus P.D.  van Veldhoven</span>, <span class="hlFld-ContribAuthor ">Rongfang  Liu</span>, <span class="hlFld-ContribAuthor ">Stephanie A.  Thee</span>, <span class="hlFld-ContribAuthor ">Yessica  Wouters</span>, <span class="hlFld-ContribAuthor ">Sanne J.M.  Verhoork</span>, <span class="hlFld-ContribAuthor ">Christiaan  Mooiman</span>, <span class="hlFld-ContribAuthor ">Julien  Louvel</span>, <span class="hlFld-ContribAuthor ">Adriaan P.  IJzerman</span>. </span><span class="cited-content_cbyCitation_article-title">Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (14)
                                     , 4013-4025. <a href="https://doi.org/10.1016/j.bmc.2015.02.018" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.02.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.02.018%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAffinity%252Band%252Bkinetics%252Bstudy%252Bof%252Banthranilic%252Bacids%252Bas%252BHCA2%252Breceptor%252Bagonists%26aulast%3Dvan%2BVeldhoven%26aufirst%3DJacobus%2BP.D.%26date%3D2015%26volume%3D23%26issue%3D14%26spage%3D4013%26epage%3D4025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin P.  Cusack</span>, <span class="hlFld-ContribAuthor ">Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Michael Z.  Hoemann</span>, <span class="hlFld-ContribAuthor ">Jasmina  Marjanovic</span>, <span class="hlFld-ContribAuthor ">Roland G.  Heym</span>, <span class="hlFld-ContribAuthor ">Anil  Vasudevan</span>. </span><span class="cited-content_cbyCitation_article-title">Design strategies to address kinetics of drug binding and residence time. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (10)
                                     , 2019-2027. <a href="https://doi.org/10.1016/j.bmcl.2015.02.027" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.02.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.02.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Bstrategies%252Bto%252Baddress%252Bkinetics%252Bof%252Bdrug%252Bbinding%252Band%252Bresidence%252Btime%26aulast%3DCusack%26aufirst%3DKevin%2BP.%26date%3D2015%26volume%3D25%26issue%3D10%26spage%3D2019%26epage%3D2027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan Antonio  Alonso</span>, <span class="hlFld-ContribAuthor ">Miriam  Andrés</span>, <span class="hlFld-ContribAuthor ">Mónica  Bravo</span>, <span class="hlFld-ContribAuthor ">Maria Antonia  Buil</span>, <span class="hlFld-ContribAuthor ">Marta  Calbet</span>, <span class="hlFld-ContribAuthor ">Jordi  Castro</span>, <span class="hlFld-ContribAuthor ">Paul R.  Eastwood</span>, <span class="hlFld-ContribAuthor ">Cristina  Esteve</span>, <span class="hlFld-ContribAuthor ">Manel  Ferrer</span>, <span class="hlFld-ContribAuthor ">Pilar  Forns</span>, <span class="hlFld-ContribAuthor ">Elena  Gómez</span>, <span class="hlFld-ContribAuthor ">Jacob  González</span>, <span class="hlFld-ContribAuthor ">Estrella  Lozoya</span>, <span class="hlFld-ContribAuthor ">Marta  Mir</span>, <span class="hlFld-ContribAuthor ">Imma  Moreno</span>, <span class="hlFld-ContribAuthor ">Silvia  Petit</span>, <span class="hlFld-ContribAuthor ">Richard S.  Roberts</span>, <span class="hlFld-ContribAuthor ">Sara  Sevilla</span>, <span class="hlFld-ContribAuthor ">Bernat  Vidal</span>, <span class="hlFld-ContribAuthor ">Laura  Vidal</span>, <span class="hlFld-ContribAuthor ">Pere  Vilaseca</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–activity relationships (SAR) and structure–kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists III: The role of a hydrogen-bond acceptor in long receptor residence times. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (21)
                                     , 5127-5133. <a href="https://doi.org/10.1016/j.bmcl.2014.08.028" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.08.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.08.028%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure%2525E2%252580%252593activity%252Brelationships%252B%252528SAR%252529%252Band%252Bstructure%2525E2%252580%252593kinetic%252Brelationships%252B%252528SKR%252529%252Bof%252Bbicyclic%252Bheteroaromatic%252Bacetic%252Bacids%252Bas%252Bpotent%252BCRTh2%252Bantagonists%252BIII%25253A%252BThe%252Brole%252Bof%252Ba%252Bhydrogen-bond%252Bacceptor%252Bin%252Blong%252Breceptor%252Bresidence%252Btimes%26aulast%3DAlonso%26aufirst%3DJuan%2BAntonio%26date%3D2014%26volume%3D24%26issue%3D21%26spage%3D5127%26epage%3D5133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong  Guo</span>, <span class="hlFld-ContribAuthor ">Julia M.  Hillger</span>, <span class="hlFld-ContribAuthor ">Adriaan P.  IJzerman</span>, <span class="hlFld-ContribAuthor ">Laura H.  Heitman</span>. </span><span class="cited-content_cbyCitation_article-title">Drug-Target Residence Time-A Case for G Protein-Coupled Receptors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2014,</strong> <em>34 </em>
                                    (4)
                                     , 856-892. <a href="https://doi.org/10.1002/med.21307" title="DOI URL">https://doi.org/10.1002/med.21307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21307%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DDrug-Target%252BResidence%252BTime-A%252BCase%252Bfor%252BG%252BProtein-Coupled%252BReceptors%26aulast%3DGuo%26aufirst%3DDong%26date%3D2014%26date%3D2014%26volume%3D34%26issue%3D4%26spage%3D856%26epage%3D892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoshiyuki  Ono</span>. </span><span class="cited-content_cbyCitation_article-title">Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Steroid Biochemistry and Molecular Biology</span><span> <strong>2014,</strong> <em>139 </em>, 88-97. <a href="https://doi.org/10.1016/j.jsbmb.2013.10.007" title="DOI URL">https://doi.org/10.1016/j.jsbmb.2013.10.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jsbmb.2013.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jsbmb.2013.10.007%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Steroid%2520Biochemistry%2520and%2520Molecular%2520Biology%26atitle%3DMultifunctional%252Band%252Bpotent%252Broles%252Bof%252Bthe%252B3-hydroxypropoxy%252Bgroup%252Bprovide%252Beldecalcitol%252527s%252Bbenefit%252Bin%252Bosteoporosis%252Btreatment%26aulast%3DOno%26aufirst%3DYoshiyuki%26date%3D2014%26volume%3D139%26spage%3D88%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benito  Alcaide</span>, <span class="hlFld-ContribAuthor ">Pedro  Almendros</span>, <span class="hlFld-ContribAuthor ">Cristina  Aragoncillo</span>, <span class="hlFld-ContribAuthor ">Gonzalo  Gómez-Campillos</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Functionalized Azetidines through Chemoselective Zinc-Catalyzed Reduction of β-Lactams with Silanes. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2013,</strong> <em>355 </em>
                                    (10)
                                     , 2089-2094. <a href="https://doi.org/10.1002/adsc.201300320" title="DOI URL">https://doi.org/10.1002/adsc.201300320</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201300320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201300320%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DSynthesis%252Bof%252BFunctionalized%252BAzetidines%252Bthrough%252BChemoselective%252BZinc-Catalyzed%252BReduction%252Bof%252B%2525CE%2525B2-Lactams%252Bwith%252BSilanes%26aulast%3DAlcaide%26aufirst%3DBenito%26date%3D2013%26date%3D2013%26volume%3D355%26issue%3D10%26spage%3D2089%26epage%3D2094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasuhiro  Takano</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Mitsuhashi</span>, <span class="hlFld-ContribAuthor ">Seiichi  Ishizuka</span>, <span class="hlFld-ContribAuthor ">Katsushi  Takahashi</span>, <span class="hlFld-ContribAuthor ">Manabu  Chokki</span>, <span class="hlFld-ContribAuthor ">Kazuya  Takenouchi</span>, <span class="hlFld-ContribAuthor ">Qingzhi  Gao</span>, <span class="hlFld-ContribAuthor ">Hiroko  Tanaka</span>, <span class="hlFld-ContribAuthor ">Atsushi  Hazato</span>, <span class="hlFld-ContribAuthor ">Masayasu  Tabe</span>, <span class="hlFld-ContribAuthor ">Minoru  Furuya</span>, <span class="hlFld-ContribAuthor ">Kenji  Manabe</span>, <span class="hlFld-ContribAuthor ">Koichi  Ueno</span>. </span><span class="cited-content_cbyCitation_article-title">TEI-A00114: A new vitamin D3 analogue that inhibits neutrophil recruitment in an acute lung injury hamster model while showing reduced hypercalcemic activity. </span><span class="cited-content_cbyCitation_journal-name">Steroids</span><span> <strong>2012,</strong> <em>77 </em>
                                    (14)
                                     , 1535-1542. <a href="https://doi.org/10.1016/j.steroids.2012.09.008" title="DOI URL">https://doi.org/10.1016/j.steroids.2012.09.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.steroids.2012.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.steroids.2012.09.008%26sid%3Dliteratum%253Aachs%26jtitle%3DSteroids%26atitle%3DTEI-A00114%25253A%252BA%252Bnew%252Bvitamin%252BD3%252Banalogue%252Bthat%252Binhibits%252Bneutrophil%252Brecruitment%252Bin%252Ban%252Bacute%252Blung%252Binjury%252Bhamster%252Bmodel%252Bwhile%252Bshowing%252Breduced%252Bhypercalcemic%252Bactivity%26aulast%3DTakano%26aufirst%3DYasuhiro%26date%3D2012%26volume%3D77%26issue%3D14%26spage%3D1535%26epage%3D1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sabina A  Antoniu</span>. </span><span class="cited-content_cbyCitation_article-title">Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2012,</strong> <em>21 </em>
                                    (11)
                                     , 1607-1618. <a href="https://doi.org/10.1517/13543784.2012.712112" title="DOI URL">https://doi.org/10.1517/13543784.2012.712112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543784.2012.712112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543784.2012.712112%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DDiscontinued%252Bdrugs%252B2011%25253A%252Bpulmonary%25252C%252Ballergy%25252C%252Bgastrointestinal%252Band%252Barthritis%26aulast%3DAntoniu%26aufirst%3DSabina%2BA%26date%3D2012%26date%3D2012%26volume%3D21%26issue%3D11%26spage%3D1607%26epage%3D1618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benito  Alcaide</span>, <span class="hlFld-ContribAuthor ">Pedro  Almendros</span>. </span><span class="cited-content_cbyCitation_article-title">Four-Membered Ring Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 115-137. <a href="https://doi.org/10.1016/B978-0-08-096807-0.00004-X" title="DOI URL">https://doi.org/10.1016/B978-0-08-096807-0.00004-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-096807-0.00004-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-096807-0.00004-X%26sid%3Dliteratum%253Aachs%26atitle%3DFour-Membered%252BRing%252BSystems%26aulast%3DAlcaide%26aufirst%3DBenito%26date%3D2012%26spage%3D115%26epage%3D137%26pub%3DElsevier%26date%3D2012%26volume%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0015.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0016.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrrolidine <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <sup><i>t</i></sup>Butyl acrylate, KOH, MeOH, <sup><i>t</i></sup>BuOH, 50 °C, 5 h, 90%; (b) 4 M HCl in 1,4-dioxane, RT, 18 h, 77%; (c) (i) CDI, THF, RT, 18 h; (ii) NaBH<sub>4</sub>, RT, 18 h, 40%; (d) Dess–Martin periodinane, CH<sub>2</sub>Cl<sub>2</sub>, RT, 3 h, 90%; (e) (<i>S</i>)-3-phenoxypyrrolidine, Na(OAc)<sub>3</sub>BH, AcOH, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, RT, 5 h, 47%; (f) KOH, 3-methyl-3-pentanol, reflux, 18 h, 62%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrrolidines (<i>R</i>)- and (<i>S</i>)-<b>9</b> and (<i>S</i>)-<b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (<i>S</i>)-3-phenoxypyrrolidine or (<i>R</i>)-3-phenoxypyrrolidine or (<i>S</i>)-3-(3-methoxyphenoxy)pyrrolidine, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, RT, 18 h, 41–100%; (b) TiCl<sub>4</sub>, THF, −10 °C, 0.5 h; MeMgBr, −5 °C–RT, 18 h, 54%, or ZrCl<sub>4</sub>, THF, −20 °C, 1 h; MeMgCl, −10 °C, 2 h, 59–78%; (c) KOH, 3-methyl-3-pentanol, reflux, 18 h, 62–96%; (d) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 0.5 h, 60%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Pyrrolidines (<i>R</i>)-<b>11</b>, (<i>S</i>)-<b>15</b>, (<i>S</i>)-<b>16</b>, (<i>S</i>)-<b>19</b>, and (<i>R</i>)-<b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (<i>R</i>)-3-benzyloxypyrrolidine, CDI, THF, RT, 18 h, 83%, or (<i>S</i>)-3-benzyloxypyrrolidine, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, RT, 18 h, 70%; (b) (i) ZrCl<sub>4</sub>, THF, −20 °C, 1 h; MeMgCl, −10 °C, 2 h, 76% (ii) KOH, 3-methyl-3-pentanol, reflux, 24 h, 78–89%; (c) FeCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, RT, 3 h, 60%, or 20% Pd(OH)<sub>2</sub>/C, 1 M HCl, EtOH, H<sub>2</sub>, 50 psi, 50 °C, 28 h, 90%; (d) ArOH, PPh<sub>3</sub>, DIAD, THF, 0 °C–RT, 2–22 h, 75–7%; (e) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, RT, 18 h, 46–68%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Azetidine <b>25</b> and Piperidine <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>2</b>, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, Et<sub>3</sub>N, DMF, RT, 18 h, 75–95%; (b) (i) ZrCl<sub>4</sub>, THF, −20 °C, 1 h; (ii) MeMgCl, −10 °C, 2 h, 38–41%; (c) KOH, 3-methyl-3-pentanol, reflux, 18 h, 88–93%.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Piperidine <b>32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaH, 3-bromobenzyl bromide, THF, 0 °C–RT, 18 h, 61%; (b) 4 M HCl in 1,4-dioxane, RT, 2.5 h, 98%; (c) <b>2</b>, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, Et<sub>3</sub>N, DMF, RT, 18 h, 95%; (d) (i) ZrCl<sub>4</sub>, THF, −20 °C, 1 h; (ii) MeMgCl, −10 °C, 2 h, 33%; (e) KOH, 3-methyl-3-pentanol, reflux, 18 h, 99%; (f) 20% Pd(OH)<sub>2</sub>/C, 1 M HCl, EtOH, H<sub>2</sub>, 50 psi, 50 °C, 18 h, 95%; (g) resorcinol, PPh<sub>3</sub>, DIAD, THF, 0 °C–RT, 12 h, 14%.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Azetidine <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) oxalyl chloride, DMF, CH<sub>2</sub>Cl<sub>2</sub>, 2 h; (ii) 3-(methanesulfonyl)azetidine, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C, 1 h, 97%; (b) (i) 2-(benzyloxy)phenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 18 h, 77%; (ii) ZrCl<sub>4</sub>, THF, −35 °C, 1 h; (iii) MeMgCl, −20 °C, 1 h, 10%; (c) (i) KOH, 3-methyl-3-pentanol, reflux, 20 h, 55%; (ii) NH<sub>4</sub>HCO<sub>2</sub>, 20% Pd(OH)<sub>2</sub>/C, EtOH, reflux, 4 h, 100%.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Azetidines <b>47</b>–<b>53</b> and <b>55</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) diphenylacetonitrile, KO<sup>t</sup>Bu, THF, RT, 4 h; (ii) 4 M HCl in dioxane, 50 °C, 2 h, 87%; (b) epichlorohydrin, EtOH, 70 °C, 18 h, 79%; (c) MsCl, pyridine, −15–5 °C, 3 h, 100%; (d) ArOH, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 18 h, 68–90%; (e) KOH, 3-methyl-3-pentanol, reflux, 18 h, 72–96%; (f) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 2 h, 25–100%, or 4 M HCl in dioxane, 60 °C, 0.5 h, 61%; (g) 1-allyloxy-3-bromomethylbenzene, NaH, DMF, 0 °C, 1 h, 54%; (h) 4 M HCl in dioxane, 85 °C, 0.5 h, 70%.</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Azetidine <b>64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) HCOOH, 0 °C, 0.5 h; (ii) 2-cyclopentyl ethanol, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, < 7 °C, 2 h, 95%; (b) rhodium acetate dimer, magnesium oxide, iodobenzene diacetate, CH<sub>2</sub>Cl<sub>2</sub>, 18 h, 75%; (c) di-<i>tert</i>-butyl dicarbonate, Et<sub>3</sub>N, 4-dimethylaminopyridine, CH<sub>2</sub>Cl<sub>2</sub>, 3 h, 46%; (d) (i) diphenylacetonitrile, KO<sup>t</sup>Bu, DMF, 18 h; (ii) 4 M HCl in dioxane, 40 °C, 2 h, 67%; (e) epichlorohydrin, MeOH, 60 °C, 48 h, 52%; (f) MsCl, pyridine, −15 °C, 2 h, 59%; (g) 3-methoxyphenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 18 h, 73%; (h) KOH, 3-methyl-3-pentanol, reflux, 20 h, 48%; (i) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 2 h, 53%.</p></p></figure><figure data-id="fig1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0018.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Lung resistance data in anaesthetized guinea pigs for (<i>R</i>)- and (<i>S</i>)-<b>11</b>, <b>47</b>, <b>52</b>, and tiotropium bromide, following cumulative intratracheal administration at hourly intervals, as solutions in micelle vehicle. ACh (iv) challenge was administered hourly (prior to the next escalating dose of compound) and the maximum increase in lung resistance recorded over a 5 min period. Data are expressed as a percentage of the pretreatment ACh (iv) control response (100%).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0019.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Lung resistance data in conscious dogs for <b>47</b>, ipratropium bromide, and tiotropium bromide, following intratracheal administration of a single dose, as a solution in micelle vehicle. MCh (it.) challenge was administered at 0.5 h, 1 h, and subsequently 2 h intervals, for up to 32 h, to measure the maximum increase in lung resistance, expressed as a percentage of the pretreatment MCh (it.) control response (100%).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0020.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Heart rate data in conscious dogs for <b>47</b>, ipratropium bromide and tiotropium bromide following intratracheal administration of a single dose, as a solution in micelle vehicle. MCh (it.) challenge was administered at 0.5 h, 1 h and subsequently 2 h intervals, for up to 32 h, to measure CV parameters relative to the pretreatment MCh (it.) control response measured in that animal at the start of the study. Data are presented as heart rate, in beats-per-minute (bpm).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0021.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Phase I spirometry data in healthy human volunteers for <b>47</b>, following inhalation of dry-powder formulations. Data are expressed as the mean change in FEV<sub>1</sub> from baseline, by treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/medium/jm-2011-00884j_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0017.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-19/jm200884j/production/images/large/jm-2011-00884j_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200884j&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88335" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88335" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Rabe, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurd, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzueto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Roisin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Weel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zielinski, J.</span><span> </span><span class="NLM_article-title">Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">176</span><span class="NLM_x">, </span> <span class="NLM_fpage">532</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1164%2Frccm.200703-456SO" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=17507545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A280%3ADC%252BD2sritlGhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2007&pages=532-555&author=K.+F.+Rabeauthor=S.+Hurdauthor=A.+Anzuetoauthor=P.+J.+Barnesauthor=S.+A.+Buistauthor=P.+Calverleyauthor=Y.+Fukuchiauthor=C.+Jenkinsauthor=R.+Rodriguez-Roisinauthor=C.+van+Weelauthor=J.+Zielinski&title=Global+Strategy+for+the+Diagnosis%2C+Management%2C+and+Prevention+of+Chronic+Obstructive+Pulmonary+Disease%3A+GOLD+Executive+Summary"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</span></div><div class="casAuthors">Rabe Klaus F; Hurd Suzanne; Anzueto Antonio; Barnes Peter J; Buist Sonia A; Calverley Peter; Fukuchi Yoshinosuke; Jenkins Christine; Rodriguez-Roisin Roberto; van Weel Chris; Zielinski Jan</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">532-55</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) remains a major public health problem.  It is the fourth leading cause of chronic morbidity and mortality in the United States, and is projected to rank fifth in 2020 in burden of disease worldwide, according to a study published by the World Bank/World Health Organization.  Yet, COPD remains relatively unknown or ignored by the public as well as public health and government officials.  In 1998, in an effort to bring more attention to COPD, its management, and its prevention, a committed group of scientists encouraged the U.S.  National Heart, Lung, and Blood Institute and the World Health Organization to form the Global Initiative for Chronic Obstructive Lung Disease (GOLD).  Among the important objectives of GOLD are to increase awareness of COPD and to help the millions of people who suffer from this disease and die prematurely of it or its complications.  The first step in the GOLD program was to prepare a consensus report, Global Strategy for the Diagnosis, Management, and Prevention of COPD, published in 2001.  The present, newly revised document follows the same format as the original consensus report, but has been updated to reflect the many publications on COPD that have appeared.  GOLD national leaders, a network of international experts, have initiated investigations of the causes and prevalence of COPD in their countries, and developed innovative approaches for the dissemination and implementation of COPD management guidelines.  We appreciate the enormous amount of work the GOLD national leaders have done on behalf of their patients with COPD.  Despite the achievements in the 5 years since the GOLD report was originally published, considerable additional work is ahead of us if we are to control this major public health problem.  The GOLD initiative will continue to bring COPD to the attention of governments, public health officials, health care workers, and the general public, but a concerted effort by all involved in health care will be necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQt87qJVGIYXLYtC3U5jeOifW6udTcc2eZPVPDwfAfcS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sritlGhsA%253D%253D&md5=19028a83e5ad7543912586212f1f8693</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1164%2Frccm.200703-456SO&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200703-456SO%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26aulast%3DHurd%26aufirst%3DS.%26aulast%3DAnzueto%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DBuist%26aufirst%3DS.%2BA.%26aulast%3DCalverley%26aufirst%3DP.%26aulast%3DFukuchi%26aufirst%3DY.%26aulast%3DJenkins%26aufirst%3DC.%26aulast%3DRodriguez-Roisin%26aufirst%3DR.%26aulast%3Dvan%2BWeel%26aufirst%3DC.%26aulast%3DZielinski%26aufirst%3DJ.%26atitle%3DGlobal%2520Strategy%2520for%2520the%2520Diagnosis%252C%2520Management%252C%2520and%2520Prevention%2520of%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%253A%2520GOLD%2520Executive%2520Summary%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2007%26volume%3D176%26spage%3D532%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hansel, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Tiotropium bromide: A novel once-daily anticholinergic bronchodilator for the treatment of COPD</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">585</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1358%2Fdot.2002.38.9.696535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD38XosFKhtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2002&pages=585-600&author=T.+T.+Hanselauthor=P.+J.+Barnes&title=Tiotropium+bromide%3A+A+novel+once-daily+anticholinergic+bronchodilator+for+the+treatment+of+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD</span></div><div class="casAuthors">Hansel, Trevor T.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">585-600</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">0025-7656</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">Tiotropium bromide (Spiriva, BA679BR, Boehringer Ingelheim) is a novel inhaled, long-acting anti-cholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).  Like ipratropium bromide, tiotropium bromide is a quaternary ammonium deriv. that binds to muscarinic receptors.  However, although tiotropium binds with high affinity to muscarinic receptors of M1-, M2- and M3-subtypes, it dissocs. very slowly from M1- and M3-receptors but more rapidly from M2-receptors, thereby giving it a unique kinetic selectivity.  To date, the short-acting anticholinergic agents ipratropium and oxitropium bromide have been extensively employed as bronchodilator therapy for patients with COPD.  Indeed, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy emphasizes the role of bronchodilators in symptomatic management of all stages of COPD.  It is encouraging that tiotropium given once daily from a dry powder inhaler at 18 μg has been shown to cause greater improvement in lung function and redn. in symptoms than ipratropium bromide given four times daily.  Furthermore, clin. studies over a 1-yr period have demonstrated that tiotropium has impressive and maintained effects on lung function, symptoms and health-related quality of life, and may also reduce exacerbations.  In a recent large scale comparative study over 6 mo, tiotropium has been shown to cause superior bronchodilation and symptomatic improvement when compared to twice daily salmeterol in COPD.  The only significant reported adverse event is dry mouth, which is found in approx. 10%-15% of subjects, but this is reversible and rarely causes discontinuation of therapy.  Based on these promising features, it is likely that tiotropium used alone or in combination with other bronchodilators will emerge as first-line maintenance treatment for patients with airway obstruction due to COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp36GmvIgkIbVg90H21EOLACvtfcHk0lii30fot0RACg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XosFKhtbc%253D&md5=e5fead30196f449a4f2cb714b8b24a35</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1358%2Fdot.2002.38.9.696535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2002.38.9.696535%26sid%3Dliteratum%253Aachs%26aulast%3DHansel%26aufirst%3DT.%2BT.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DTiotropium%2520bromide%253A%2520A%2520novel%2520once-daily%2520anticholinergic%2520bronchodilator%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DDrugs%2520Today%26date%3D2002%26volume%3D38%26spage%3D585%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Gross, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skorodin, M. S.</span><span> </span><span class="NLM_article-title">Role of the Parasympathetic System in Airway Obstruction Due to Emphysema</span> <span class="citation_source-journal">N. Eng. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1056%2FNEJM198408163110701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=6749189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A280%3ADyaL2c3ntVGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=1984&pages=421-425&author=N.+J.+Grossauthor=M.+S.+Skorodin&title=Role+of+the+Parasympathetic+System+in+Airway+Obstruction+Due+to+Emphysema"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the parasympathetic system in airway obstruction due to emphysema</span></div><div class="casAuthors">Gross N J; Skorodin M S</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">421-5</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">To study the relative contributions of parasympathetic and sympathetic mechanisms in airway obstruction in patients with emphysema, we gave supramaximal doses of anticholinergic and adrenergic agents in sequence and in combination.  Serial doses of one agent were administered to achieve a plateau of bronchodilatation; after that the other agent was administered.  The plateau achieved with the anticholinergic agent (atropine methonitrate) was significantly higher than that achieved with the adrenergic agent (salbutamol).  When the adrenergic agent was given first, additional bronchodilatation was achieved with subsequent use of the anticholinergic agent.  When the anticholinergic agent was given first, no additional bronchodilatation was achieved with subsequent administration of the adrenergic agent.  When both agents were given simultaneously, the degree of bronchodilatation was virtually identical to that obtained with the anticholinergic agent alone.  Tests sensitive to small-airway and large-airway function and lung volumes gave essentially the same results.  Thus, all achievable bronchodilatation was obtained with the anticholinergic agent alone.  These results suggest that the two classes of agents produce bronchodilatation through a common cholinergic pathway in emphysema, and support the concept that parasympathetic activity is the dominant reversible component of airway obstruction in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbD4U-qyRieu3MPKNEWB5RfW6udTcc2eZnQKGtsx5m57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c3ntVGgtQ%253D%253D&md5=8db96527324d9d91a101a7a639e69804</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJM198408163110701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198408163110701%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DN.%2BJ.%26aulast%3DSkorodin%26aufirst%3DM.%2BS.%26atitle%3DRole%2520of%2520the%2520Parasympathetic%2520System%2520in%2520Airway%2520Obstruction%2520Due%2520to%2520Emphysema%26jtitle%3DN.%2520Eng.%2520J.%2520Med.%26date%3D1984%26volume%3D311%26spage%3D421%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Coulson, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fryer, A. D.</span><span> </span><span class="NLM_article-title">Muscarinic acetylcholine receptors and airway diseases</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1016%2FS0163-7258%2803%2900004-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=12667888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12nsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2003&pages=59-69&author=F.+R.+Coulsonauthor=A.+D.+Fryer&title=Muscarinic+acetylcholine+receptors+and+airway+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Muscarinic acetylcholine receptors and airway diseases</span></div><div class="casAuthors">Coulson, Fiona R.; Fryer, Allison D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-69</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  Parasympathetic nerves provide the dominant autonomic innervation of the airways.  Release of acetylcholine from parasympathetic nerves activates postjunctional muscarinic receptors present on airway smooth muscle, submucosal glands, and blood vessels to cause bronchoconstriction, mucus secretion, and vasodilatation, resp.  Acetylcholine also feeds back onto prejunctional muscarinic receptors to enhance or inhibit further acetylcholine release.  In asthma and chronic obstructive pulmonary disease, bronchoconstriction and mucus secretion is increased and the airways are hyperresponsive to contractile agents.  These changes are due to increased parasympathetic nerve activity.  The no. and function of postjunctional muscarinic receptors in the airways are unchanged in animal models of asthma.  Rather, it is the supply of acetylcholine to the postjunctional cells (smooth muscle and submucosal gland) that is increased.  The increase in acetylcholine release occurs because prejunctional, inhibitory M2 muscarinic receptors on the parasympathetic nerves are dysfunctional.  M2 muscarinic receptor dysfunction and subsequent airway hyperreactivity were demonstrated to occur in animals in response to a variety of triggers, including antigen challenge, virus infection, ozone exposure, and vitamin A deficiency.  In humans, there is evidence that loss of M2 muscarinic receptor function is related to asthma.  The mechanisms by which neuronal M2 muscarinic receptor function is lost and its relevance to human airway disease are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK8xZ3prJjm7Vg90H21EOLACvtfcHk0ljPoB6Nzkpo2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12nsbc%253D&md5=c63bed82af7061b6d8d095314660e691</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900004-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900004-4%26sid%3Dliteratum%253Aachs%26aulast%3DCoulson%26aufirst%3DF.%2BR.%26aulast%3DFryer%26aufirst%3DA.%2BD.%26atitle%3DMuscarinic%2520acetylcholine%2520receptors%2520and%2520airway%2520diseases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D98%26spage%3D59%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Joos, G. F.</span><span> </span><span class="NLM_article-title">Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Expert. Opin. Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">264</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=257-264&author=G.+F.+Joos&title=Potential+for+long-acting+muscarinic+antagonists+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJoos%26aufirst%3DG.%2BF.%26atitle%3DPotential%2520for%2520long-acting%2520muscarinic%2520antagonists%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DExpert.%2520Opin.%2520Investig.%2520Drugs%26date%3D2010%26volume%3D19%26spage%3D257%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Lainé, D. I.</span><span> </span><span class="NLM_article-title">Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1586%2Fecp.09.48" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=22111532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyiur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=43-53&author=D.+I.+Lain%C3%A9&title=Long-acting+muscarinic+antagonists+for+the+treatment+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Laine, Dramane I.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Muscarinic acetylcholine receptor antagonists, particularly of the M3 subtype, are useful therapeutics as bronchodilators in chronic obstructive pulmonary disease (COPD).  The first long-acting muscarinic antagonist, tiotropium bromide (Spiriva), was launched in 2002 and has since become established as the gold-std. muscarinic antagonist for the treatment of COPD.  This review will survey the preclin. profiles of tiotropium and nine inhaled development candidates as well as literature reports of other preclin. compds. specifically designed as inhaled antimuscarinic agents for the treatment of COPD.  The design strategies employed lay behind three common principles: high potency and slow reversibility at the M3 receptor and low systemic exposure.  In addn. to their effectiveness as bronchodilators, the differentiation of these agents in the clinic may be linked to their potential to be utilized in combination with other therapeutics.  In the long term, the emerging knowledge around the role of muscarinic antagonists in the inflammation and remodeling of the airways may also help in discriminating them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKrhaXj61Tm7Vg90H21EOLACvtfcHk0ljPoB6Nzkpo2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyiur7O&md5=690cd53b03e85b28a97edeff1941abca</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1586%2Fecp.09.48&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.09.48%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26atitle%3DLong-acting%2520muscarinic%2520antagonists%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2010%26volume%3D3%26spage%3D43%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Cazzola, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matera, M. G.</span><span> </span><span class="NLM_article-title">Emerging inhaled bronchodilators: an update</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">757</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1183%2F09031936.00013109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=19720811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Whsb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=757-769&author=M.+Cazzolaauthor=M.+G.+Matera&title=Emerging+inhaled+bronchodilators%3A+an+update"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging inhaled bronchodilators an update</span></div><div class="casAuthors">Cazzola, M.; Matera, M. G.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">757-769</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Bronchodilators remain central to the symptomatic management of chronic obstructive pulmonary disease and asthma, and, for this reason and also because the patent protection of many bronchodilators has expired, several companies have reinitiated research into the field.  The only limits set for the development of a long-lasting bronchodilator with a new product profile are medical needs and marketing opportunities.  The incorporation of once-daily dose administration is an important strategy for improving adherence and is a regimen preferred by most patients.  A variety of β2-agonists and antimuscarinic agents with longer half-lives and inhalers contg. a combination of several classes of long-acting bronchodilator are currently under development.  The present article reviews all of the most important compds. under development, describing what has been done and discussing their genuine advantage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Ttk1mXA947Vg90H21EOLACvtfcHk0lhk-zc_xb8x8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Whsb7L&md5=0f5ddd276c714d15974318b51a8a5be5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1183%2F09031936.00013109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00013109%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26atitle%3DEmerging%2520inhaled%2520bronchodilators%253A%2520an%2520update%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D34%26spage%3D757%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolzoni, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battipaglia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenacchi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cacciani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaniboni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scudellaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razzetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span> </span><span class="NLM_article-title">Bronchodilator Activity of (3<i>R</i>)-3-[[[(3-Fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane Bromide (CHF5407), a Potent, Long-Acting, and Selective Muscarinic M<sub>3</sub> Receptor Antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">–</span> <span class="NLM_lpage">635</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1124%2Fjpet.110.170035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=20805306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=622-635&author=G.+Villettiauthor=F.+Pastoreauthor=M.+Bergamaschiauthor=F.+Bassaniauthor=P.+T.+Bolzoniauthor=L.+Battipagliaauthor=G.+Amariauthor=A.+Rizziauthor=M.+Delcanaleauthor=R.+Voltaauthor=V.+Cenacchiauthor=F.+Caccianiauthor=M.+Zaniboniauthor=F.+Bertiauthor=G.+Rossoniauthor=S.+Harrisonauthor=P.+Petrilloauthor=E.+Santoroauthor=R.+Scudellaroauthor=F.+Manniniauthor=P.+A.+Geppettiauthor=R.+Razzettiauthor=R.+Patacchiniauthor=M.+Civelli&title=Bronchodilator+Activity+of+%283R%29-3-%5B%5B%5B%283-Fluorophenyl%29%5B%283%2C4%2C5-trifluorophenyl%29methyl%5Damino%5Dcarbonyl%5Doxy%5D-1-%5B2-oxo-2-%282-thienyl%29ethyl%5D-1-azoniabicyclo%5B2.2.2%5Doctane+Bromide+%28CHF5407%29%2C+a+Potent%2C+Long-Acting%2C+and+Selective+Muscarinic+M3+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist</span></div><div class="casAuthors">Villetti, G.; Pastore, F.; Bergamaschi, M.; Bassani, F.; Bolzoni, P. T.; Battipaglia, L.; Amari, G.; Rizzi, A.; Delcanale, M.; Volta, R.; Cenacchi, V.; Cacciani, F.; Zaniboni, M.; Berti, F.; Rossoni, G.; Harrison, S.; Petrillo, P.; Santoro, E.; Scudellaro, R.; Mannini, F.; Geppetti, P. A.; Razzetti, R.; Patacchini, R.; Civelli, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">622-635</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The novel quaternary ammonium salt (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407) showed subnanomolar affinities for human muscarinic M1 (hM1), M2 (hM2), and M3 (hM3) receptors and dissocd. very slowly from hM3 receptors (t1/2 = 166 min) with a large part of the receptorial complex (54%) remaining undissociated at 32 h from radioligand washout.  In contrast, [3H]CHF5407 dissocd. quickly from hM2 receptors (t1/2 = 31 min), whereas [3H]tiotropium dissocd. slowly from both hM3 (t1/2 = 163 min) and hM2 receptor (t1/2 = 297 min).  In the guinea pig isolated trachea and human isolated bronchus, CHF5407 produced a potent (pIC50 = 9.0-9.6) and long-lasting (up to 24 h) inhibition of M3 receptor-mediated contractile responses to carbachol.  In the guinea pig elec. driven left atrium, the M2 receptor-mediated inhibitory response to carbachol was recovered more quickly in CHF5407-pretreated than in tiotropium-pretreated prepns.  CHF5407, administered intratracheally to anesthetized guinea pigs, potently inhibited acetylcholine (Ach)-induced bronchoconstriction with an ED50 value of 0.15 nmol/kg.  The effect was sustained over a period of 24 h, with a residual 57% inhibition 48 h after antagonist administration at 1 nmol/kg.  In conscious guinea pigs, inhaled CHF5407 inhibited Ach-induced bronchoconstriction for at least 24 h as did tiotropium at similar dosages.  Cardiovascular parameters in anesthetized guinea pigs were not significantly changed by CHF5407, up to 100 nmol/kg i.v. and up to 1000 nmol/kg i.t.  In conclusion, CHF5407 shows a prolonged antibronchospastic activity both in vitro and in vivo, caused by a very slow dissocn. from M3 receptors.  In contrast, CHF5407 is markedly short-acting at M2 receptors, a behavior not shared by tiotropium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnCU6YfyC1MLVg90H21EOLACvtfcHk0lhk-zc_xb8x8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrnJ&md5=54ae71e74a98081c6c574a5f7dd0faad</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.170035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.170035%26sid%3Dliteratum%253Aachs%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DBattipaglia%26aufirst%3DL.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DCacciani%26aufirst%3DF.%26aulast%3DZaniboni%26aufirst%3DM.%26aulast%3DBerti%26aufirst%3DF.%26aulast%3DRossoni%26aufirst%3DG.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DPetrillo%26aufirst%3DP.%26aulast%3DSantoro%26aufirst%3DE.%26aulast%3DScudellaro%26aufirst%3DR.%26aulast%3DMannini%26aufirst%3DF.%26aulast%3DGeppetti%26aufirst%3DP.%2BA.%26aulast%3DRazzetti%26aufirst%3DR.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DCivelli%26aufirst%3DM.%26atitle%3DBronchodilator%2520Activity%2520of%2520%25283R%2529-3-%255B%255B%255B%25283-Fluorophenyl%2529%255B%25283%252C4%252C5-trifluorophenyl%2529methyl%255Damino%255Dcarbonyl%255Doxy%255D-1-%255B2-oxo-2-%25282-thienyl%2529ethyl%255D-1-azoniabicyclo%255B2.2.2%255Doctane%2520Bromide%2520%2528CHF5407%2529%252C%2520a%2520Potent%252C%2520Long-Acting%252C%2520and%2520Selective%2520Muscarinic%2520M3%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D622%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_contrib-group">Wan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmonte, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M.</span><span> </span><span class="NLM_article-title">Discovery of (3-<i>endo</i>)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4560</span><span class="NLM_x">–</span> <span class="NLM_lpage">4562</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4560-4562&author=Z.+Wanauthor=D.+I.+Laineauthor=H.+Yanauthor=C.+Zhuauthor=K.+L.+Widdowsonauthor=P.+T.+Buckleyauthor=M.+Burmanauthor=J.+J.+Foleyauthor=H.+M.+Sarauauthor=D.+B.+Schmidtauthor=E.+F.+Webbauthor=K.+E.+Belmonteauthor=M.+Palovich&title=Discovery+of+%283-endo%29-3-%282-cyano-2%2C2-diphenylethyl%29-8%2C8-dimethyl-8-azoniabicyclo%5B3.2.1%5Doctane+bromide+as+an+efficacious+inhaled+muscarinic+acetylcholine+receptor+antagonist+for+the+treatment+of+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DZ.%26aulast%3DLaine%26aufirst%3DD.%2BI.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DBuckley%26aufirst%3DP.%2BT.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DSchmidt%26aufirst%3DD.%2BB.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DBelmonte%26aufirst%3DK.%2BE.%26aulast%3DPalovich%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520%25283-endo%2529-3-%25282-cyano-2%252C2-diphenylethyl%2529-8%252C8-dimethyl-8-azoniabicyclo%255B3.2.1%255Doctane%2520bromide%2520as%2520an%2520efficacious%2520inhaled%2520muscarinic%2520acetylcholine%2520receptor%2520antagonist%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4560%26epage%3D4562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_contrib-group">Lainé, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neipp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmonte, K.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Structure–Activity Relationship of Tropane Muscarinic Acetylcholine Receptor Antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5241</span><span class="NLM_x">–</span> <span class="NLM_lpage">5252</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900736e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5241-5252&author=D.+I.+Lain%C3%A9author=Z.+Wanauthor=H.+Yanauthor=C.+Zhuauthor=H.+Xieauthor=W.+Fuauthor=J.+Busch-Petersenauthor=C.+Neippauthor=R.+Davisauthor=K.+L.+Widdowsonauthor=F.+E.+Blaneyauthor=J.+Foleyauthor=A.+M.+Baconauthor=E.+F.+Webbauthor=M.+A.+Luttmannauthor=M.+Burmanauthor=H.+M.+Sarauauthor=M.+Salmonauthor=M.+R.+Palovichauthor=K.+Belmonte&title=Design%2C+Synthesis%2C+and+Structure%E2%80%93Activity+Relationship+of+Tropane+Muscarinic+Acetylcholine+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm900736e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900736e%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26aulast%3DWan%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26aulast%3DNeipp%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26aulast%3DFoley%26aufirst%3DJ.%26aulast%3DBacon%26aufirst%3DA.%2BM.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DBelmonte%26aufirst%3DK.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Structure%25E2%2580%2593Activity%2520Relationship%2520of%2520Tropane%2520Muscarinic%2520Acetylcholine%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5241%26epage%3D5252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Prat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buil, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crepso, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casals, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tort, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monleón, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doménech, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antón, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huerta, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sentellas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">González, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertí, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segarra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cárdenas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, H.</span><span> </span><span class="NLM_article-title">Discovery of Novel Quaternary Ammonium Derivatives of (3<i>R</i>)-Quinuclidinol Esters as Potent and Long-Acting Muscarinic Antagonists with Potential for Minimal Systemic Exposure after Inhaled Administration: Identification of (3<i>R</i>)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane Bromide (Aclidinium Bromide)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5076</span><span class="NLM_x">–</span> <span class="NLM_lpage">5092</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900132z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5076-5092&author=M.+Pratauthor=D.+Fern%C3%A1ndezauthor=M.+A.+Builauthor=M.+I.+Crepsoauthor=G.+Casalsauthor=M.+Ferrerauthor=L.+Tortauthor=J.+Castroauthor=J.+M.+Monle%C3%B3nauthor=A.+Gavald%C3%A0author=M.+Miralpeixauthor=I.+Ramosauthor=T.+Dom%C3%A9nechauthor=D.+Vilellaauthor=F.+Ant%C3%B3nauthor=J.+M.+Huertaauthor=S.+Espinosaauthor=M.+L%C3%B3pezauthor=S.+Sentellasauthor=M.+Gonz%C3%A1lezauthor=J.+Albert%C3%ADauthor=V.+Segarraauthor=A.+C%C3%A1rdenasauthor=J.+Beletaauthor=H.+Ryder&title=Discovery+of+Novel+Quaternary+Ammonium+Derivatives+of+%283R%29-Quinuclidinol+Esters+as+Potent+and+Long-Acting+Muscarinic+Antagonists+with+Potential+for+Minimal+Systemic+Exposure+after+Inhaled+Administration%3A+Identification+of+%283R%29-3-%7B%5BHydroxy%28di-2-thienyl%29acetyl%5Doxy%7D-1-%283-phenoxypropyl%29-1-azoniabicyclo%5B2.2.2%5Doctane+Bromide+%28Aclidinium+Bromide%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm900132z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900132z%26sid%3Dliteratum%253Aachs%26aulast%3DPrat%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DD.%26aulast%3DBuil%26aufirst%3DM.%2BA.%26aulast%3DCrepso%26aufirst%3DM.%2BI.%26aulast%3DCasals%26aufirst%3DG.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DTort%26aufirst%3DL.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DMonle%25C3%25B3n%26aufirst%3DJ.%2BM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DDom%25C3%25A9nech%26aufirst%3DT.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DAnt%25C3%25B3n%26aufirst%3DF.%26aulast%3DHuerta%26aufirst%3DJ.%2BM.%26aulast%3DEspinosa%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez%26aufirst%3DM.%26aulast%3DSentellas%26aufirst%3DS.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DM.%26aulast%3DAlbert%25C3%25AD%26aufirst%3DJ.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DC%25C3%25A1rdenas%26aufirst%3DA.%26aulast%3DBeleta%26aufirst%3DJ.%26aulast%3DRyder%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Novel%2520Quaternary%2520Ammonium%2520Derivatives%2520of%2520%25283R%2529-Quinuclidinol%2520Esters%2520as%2520Potent%2520and%2520Long-Acting%2520Muscarinic%2520Antagonists%2520with%2520Potential%2520for%2520Minimal%2520Systemic%2520Exposure%2520after%2520Inhaled%2520Administration%253A%2520Identification%2520of%2520%25283R%2529-3-%257B%255BHydroxy%2528di-2-thienyl%2529acetyl%255Doxy%257D-1-%25283-phenoxypropyl%2529-1-azoniabicyclo%255B2.2.2%255Doctane%2520Bromide%2520%2528Aclidinium%2520Bromide%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5076%26epage%3D5092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Cazzola, M.</span><span> </span><span class="NLM_article-title">Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=482-490&author=M.+Cazzola&title=Aclidinium+bromide%2C+a+novel+long-acting+muscarinic+M3+antagonist+for+the+treatment+of+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DAclidinium%2520bromide%252C%2520a%2520novel%2520long-acting%2520muscarinic%2520M3%2520antagonist%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D10%26spage%3D482%26epage%3D490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Haeberlin, B.; Stowasser, F.; Wirth, W.; Baumberger, A.; Abel, S.; Kaerger, S.; Kieckbusch, T.</span><span> </span><span class="NLM_article-title">Compositions of glycopyrronium salt for inhalation</span>. PCT Int. Appl. Publ. WO 2008000482,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=B.+Haeberlin&author=F.+Stowasser&author=W.+Wirth&author=A.+Baumberger&author=S.+Abel&author=S.+Kaerger&author=T.+Kieckbusch&title=Compositions+of+glycopyrronium+salt+for+inhalation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHaeberlin%26aufirst%3DB.%26atitle%3DCompositions%2520of%2520glycopyrronium%2520salt%2520for%2520inhalation%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Denton, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span> </span><span class="NLM_article-title">A Modified Bouveault Reaction for the Preparation of α,α-Dimethylamines from Amides</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1999&pages=55-56&author=S.+M.+Dentonauthor=A.+Wood&title=A+Modified+Bouveault+Reaction+for+the+Preparation+of+%CE%B1%2C%CE%B1-Dimethylamines+from+Amides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDenton%26aufirst%3DS.%2BM.%26aulast%3DWood%26aufirst%3DA.%26atitle%3DA%2520Modified%2520Bouveault%2520Reaction%2520for%2520the%2520Preparation%2520of%2520%25CE%25B1%252C%25CE%25B1-Dimethylamines%2520from%2520Amides%26jtitle%3DSynlett%26date%3D1999%26volume%3D1%26spage%3D55%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Boehringer, M.; Hunziker, D.; Kuehne, H.; Loeffler, B. M.; Sarabu, R.; Wessel, H. P.</span><span> </span><span class="NLM_article-title"><i>N</i>-substituted Pyrrolidine Derivatives as Dipeptidyl Peptidase IV Inhibitors</span>. PCT Int. Appl. Publ. WO 2003037327,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+Boehringer&author=D.+Hunziker&author=H.+Kuehne&author=B.+M.+Loeffler&author=R.+Sarabu&author=H.+P.+Wessel&title=N-substituted+Pyrrolidine+Derivatives+as+Dipeptidyl+Peptidase+IV+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoehringer%26aufirst%3DM.%26atitle%3DN-substituted%2520Pyrrolidine%2520Derivatives%2520as%2520Dipeptidyl%2520Peptidase%2520IV%2520Inhibitors%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Espino, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehn, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du Bois, J.</span><span> </span><span class="NLM_article-title">Synthesis of 1,3-Difunctionalized Amine Derivatives through Selective C–H Bond Oxidation</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">6935</span><span class="NLM_x">–</span> <span class="NLM_lpage">6936</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja011033x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2001&pages=6935-6936&author=C.+G.+Espinoauthor=P.+M.+Wehnauthor=J.+Chowauthor=J.+Du+Bois&title=Synthesis+of+1%2C3-Difunctionalized+Amine+Derivatives+through+Selective+C%E2%80%93H+Bond+Oxidation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fja011033x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja011033x%26sid%3Dliteratum%253Aachs%26aulast%3DEspino%26aufirst%3DC.%2BG.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DChow%26aufirst%3DJ.%26aulast%3DDu%2BBois%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%25201%252C3-Difunctionalized%2520Amine%2520Derivatives%2520through%2520Selective%2520C%25E2%2580%2593H%2520Bond%2520Oxidation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2001%26volume%3D123%26spage%3D6935%26epage%3D6936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Bower, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Švenda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charmant, J. P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szeto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, T.</span><span> </span><span class="NLM_article-title">Cyclic Sulfamidates as Vehicles for the Synthesis of Substituted Lactams</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">4727</span><span class="NLM_x">–</span> <span class="NLM_lpage">4730</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol048036%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=4727-4730&author=J.+F.+Bowerauthor=J.+%C5%A0vendaauthor=A.+J.+Williamsauthor=J.+P.+H.+Charmantauthor=R.+M.+Lawrenceauthor=P.+Szetoauthor=T.+Gallagher&title=Cyclic+Sulfamidates+as+Vehicles+for+the+Synthesis+of+Substituted+Lactams"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fol048036%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol048036%252B%26sid%3Dliteratum%253Aachs%26aulast%3DBower%26aufirst%3DJ.%2BF.%26aulast%3D%25C5%25A0venda%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DCharmant%26aufirst%3DJ.%2BP.%2BH.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DSzeto%26aufirst%3DP.%26aulast%3DGallagher%26aufirst%3DT.%26atitle%3DCyclic%2520Sulfamidates%2520as%2520Vehicles%2520for%2520the%2520Synthesis%2520of%2520Substituted%2520Lactams%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D4727%26epage%3D4730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Glossop, P. A.; Mantell, S. J.; Strang, R. S.; Watson, C. A. L.; Wood, A.</span><span> </span><span class="NLM_article-title">Carboxamide derivatives as muscarinic receptor antagonists</span>. PCT Int. Appl. Publ. WO 2007034325,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+A.+Glossop&author=S.+J.+Mantell&author=R.+S.+Strang&author=C.+A.+L.+Watson&author=A.+Wood&title=Carboxamide+derivatives+as+muscarinic+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26atitle%3DCarboxamide%2520derivatives%2520as%2520muscarinic%2520receptor%2520antagonists%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gantner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, M.</span><span> </span><span class="NLM_article-title">Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1124%2Fjpet.109.152470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=19478135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFCltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=660-668&author=P.+Casarosaauthor=T.+Bouyssouauthor=S.+Germeyerauthor=A.+Schnappauthor=F.+Gantnerauthor=M.+Pieper&title=Preclinical+Evaluation+of+Long-Acting+Muscarinic+Antagonists%3A+Comparison+of+Tiotropium+and+Investigational+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs</span></div><div class="casAuthors">Casarosa, Paola; Bouyssou, Thierry; Germeyer, Sabine; Schnapp, Andreas; Gantner, Florian; Pieper, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">660-668</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation caused by persistent inflammatory processes in the airways.  An increased cholinergic tone mediates different pathophysiol. features of COPD, such as bronchoconstriction and mucus hypersecretion, mostly through activation of the human muscarinic M3 receptor (hM3) subtype.  Tiotropium bromide (Spiriva) is a well established muscarinic antagonist in the pharmacol. management of COPD with a once-daily posol.  The rationale behind the sustained bronchodilation obtained with tiotropium consists in its slow dissocn. from hM3 receptors.  In this study, we performed a comprehensive preclin. comparison of tiotropium with other long-acting muscarinic antagonists (LAMAs) currently in clin. development, namely aclidinium bromide and glycopyrrolate.  The different muscarinic antagonists were characterized for their (1) affinity toward the different human muscarinic receptor subtypes expressed in Chinese hamster ovary cells and kinetics of receptor dissocn., (2) potency in inhibiting the agonist-induced activation of muscarinic receptors through measurement of second messengers, and (3) efficacy and duration of bronchoprotection, as tested in a model of acetylcholine-induced bronchoconstriction in anesthetized dogs over a period of 24 h.  All of the tested LAMAs showed high affinity and potency toward the hM3 receptor (tiotropium, pA2 = 10.4; aclidinium, pA2 = 9.6; and glycopyrrolate, pA2 = 9.7).  However, dissocn. half-lives of the LA-MAs from the hM3 receptor differed significantly (tiotropium, t1/2=27 h; aclidinium, t1/2=10.7 h; and glycopyrrolate, t1/2=6.1 h).  In line with their kinetic properties at the hM3, the tested LAMAs provided different levels of bronchoprotection in the in vivo setting 24 h after administration (tiotropium = 35%, aclidinium = 21%, and glycopyrrolate = 0% at 24 h) when applied at equieffective doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorQCmscRp-17Vg90H21EOLACvtfcHk0lhBzcLBwS9AAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFCltrk%253D&md5=060333cce96f1491b192e4bdbe4bfec5</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152470%26sid%3Dliteratum%253Aachs%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DGermeyer%26aufirst%3DS.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DGantner%26aufirst%3DF.%26aulast%3DPieper%26aufirst%3DM.%26atitle%3DPreclinical%2520Evaluation%2520of%2520Long-Acting%2520Muscarinic%2520Antagonists%253A%2520Comparison%2520of%2520Tiotropium%2520and%2520Investigational%2520Drugs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D660%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreño, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viñals, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doménech, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcasona, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gras, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortijo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llenas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span> </span><span class="NLM_article-title">Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">331</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1124%2Fjpet.109.151639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=19710368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=740-751&author=A.+Gavald%C3%A0author=M.+Miralpeixauthor=I.+Ramosauthor=R.+Otalauthor=C.+Carre%C3%B1oauthor=M.+Vi%C3%B1alsauthor=T.+Dom%C3%A9nechauthor=C.+Carcasonaauthor=B.+Reyesauthor=D.+Vilellaauthor=J.+Grasauthor=J.+Cortijoauthor=E.+Morcilloauthor=J.+Llenasauthor=H.+Ryderauthor=J.+Beleta&title=Characterization+of+Aclidinium+Bromide%2C+a+Novel+Inhaled+Muscarinic+Antagonist%2C+with+Long+Duration+of+Action+and+a+Favorable+Pharmacological+Profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile</span></div><div class="casAuthors">Gavalda, Amadeu; Miralpeix, Montserrat; Ramos, Israel; Otal, Raquel; Carreno, Cristina; Vinals, Marisa; Domenech, Teresa; Carcasona, Carla; Reyes, Blanca; Vilella, Dolors; Gras, Jordi; Cortijo, Julio; Morcillo, Esteban; Llenas, Jesus; Ryder, Hamish; Beleta, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">740-751</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease.  Aclidinium showed subnanomolar affinity for the five human muscarinic receptors (M1-M5).  [3H]Aclidinium dissocd. slightly faster from M2 and M3 receptors than [3H]tiotropium but much more slowly than [3H]ipratropium.  Its assocn. rate for the M3 receptor was similar to [3H]ipratropium and 2.6 times faster than [3H]tiotropium.  Residence half-life of [3H]aclidinium at the M2 receptor was shorter than at the M3 receptor, demonstrating kinetic selectivity for the M3 receptor.  In isolated guinea pig trachea, aclidinium showed comparable potency to ipratropium and tiotropium, faster onset of action than tiotropium, and duration of action similar to tiotropium and significantly longer than ipratropium.  Nebulized aclidinium inhibited bronchoconstriction induced by acetylcholine in guinea pigs in a concn.-dependent manner with an onset of action faster than tiotropium.  Duration of action of aclidinium (t1/2 = 29 h) was much longer than ipratropium (8 h) but shorter than tiotropium (64 h).  In dogs, aclidinium induced a smaller and more transient increase in heart rate than tiotropium at comparable supratherapeutic doses.  Therefore, under these conditions, aclidinium showed a greater therapeutic index than tiotropium (4.2 vs. 1.6).  These results indicate that aclidinium is a potent muscarinic antagonist with a fast onset of action, a long duration of effect, and a favorable cardiovascular safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZpskcHCQILLVg90H21EOLACvtfcHk0liX5YTogXR0uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7rF&md5=c66b0d729cd5c6dcba6e3a80e0c5f468</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.151639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.151639%26sid%3Dliteratum%253Aachs%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DOtal%26aufirst%3DR.%26aulast%3DCarre%25C3%25B1o%26aufirst%3DC.%26aulast%3DVi%25C3%25B1als%26aufirst%3DM.%26aulast%3DDom%25C3%25A9nech%26aufirst%3DT.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DReyes%26aufirst%3DB.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DGras%26aufirst%3DJ.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DMorcillo%26aufirst%3DE.%26aulast%3DLlenas%26aufirst%3DJ.%26aulast%3DRyder%26aufirst%3DH.%26aulast%3DBeleta%26aufirst%3DJ.%26atitle%3DCharacterization%2520of%2520Aclidinium%2520Bromide%252C%2520a%2520Novel%2520Inhaled%2520Muscarinic%2520Antagonist%252C%2520with%2520Long%2520Duration%2520of%2520Action%2520and%2520a%2520Favorable%2520Pharmacological%2520Profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D740%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_contrib-group">Cross, P. E.; Mackenzie, A. R.</span><span> </span><span class="NLM_article-title">Preparation of pyrrolidine derivatives as muscarinic receptor antagonists</span>. Eur. Pat. Appl. Publ. EP388054,<span class="NLM_x"> </span><span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=P.+E.+Cross&author=A.+R.+Mackenzie&title=Preparation+of+pyrrolidine+derivatives+as+muscarinic+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DP.%2BE.%26atitle%3DPreparation%2520of%2520pyrrolidine%2520derivatives%2520as%2520muscarinic%2520receptor%2520antagonists%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_contrib-group">Alabaster, V. A.</span><span> </span><span class="NLM_article-title">Discovery and development of selective M<sub>3</sub> antagonists for clinical use</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1060</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1997&pages=1053-1060&author=V.+A.+Alabaster&title=Discovery+and+development+of+selective+M3+antagonists+for+clinical+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlabaster%26aufirst%3DV.%2BA.%26atitle%3DDiscovery%2520and%2520development%2520of%2520selective%2520M3%2520antagonists%2520for%2520clinical%2520use%26jtitle%3DLife%2520Sci.%26date%3D1997%26volume%3D60%26spage%3D1053%26epage%3D1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberstein, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funck-Brentano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lineberry, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woosley, R. L.</span><span> </span><span class="NLM_article-title">The Role of Genetically Determined Polymorphic Drug Metabolism in the Beta-Blockade Produced by Propafenone</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">1764</span><span class="NLM_x">–</span> <span class="NLM_lpage">1768</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1056%2FNEJM199006213222502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=1971708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADyaK3cXls1Gisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=1990&pages=1764-1768&author=J.+T.+Leeauthor=H.+K.+Kroemerauthor=D.+J.+Silbersteinauthor=C.+Funck-Brentanoauthor=M.+D.+Lineberryauthor=A.+J.+Woodauthor=D.+M.+Rodenauthor=R.+L.+Woosley&title=The+Role+of+Genetically+Determined+Polymorphic+Drug+Metabolism+in+the+Beta-Blockade+Produced+by+Propafenone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone</span></div><div class="casAuthors">Lee, John T.; Kroemer, Heyo K.; Silberstein, David J.; Funck-Brentano, Christian; Lineberry, Mark D.; Wood, Alastair J. J.; Roden, Dan M.; Woosley, Raymond L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1764-8</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">Propranolol and the sodium-channel-blocking antiarrhythmic agent propafenone share structural features.  Although propafenone's β-blocking actions are readily demonstrable in vitro, clin. significant β-blockade occurs inconsistently in vivo.  The present study tested the hypothesis that genetically detd. variations in the biotransformation of propafenone to its 5-hydroxy metabolite account for variations in the drug's β-blocking action.  β-Blockade was assessed by measuring the redn. in tachycardia produced by boluses of isoproterenol and treadmill exercise in 14 normal subjects during treatment with placebo and with 150, 225, and 300 mg of propafenone every eight hours for five days each.  Nine subjects (with the extensive-metabolizer phenotype) metabolized most of the propafenone to 5-hydroxypropafenone, and five (with the poor-metabolizer phenotype) did not produce this metabolite.  At the lower dosages, β-blockade was present in both groups but was significantly greater in the subjects with poor metab., in whom deficient 5-hydroxylation was assocd. with higher plasma propafenone levels.  At the highest dose, a similar degree of β-blockade was obsd. in the two groups.  Propafenone also had a higher affinity for β2 receptors in vitro than either of its major metabolites.  Thus, the degree of β-blockade during propafenone therapy reflects genetically detd. variations in the metab. of the parent drug, which is necessary for β-blockade, and this action of propafenone is considerably enhanced in patients with deficient 5-hydroxylation of propafenone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXPKwdNHn3PLVg90H21EOLACvtfcHk0lhoJg9k4QKrDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls1Gisb4%253D&md5=e7ae74b71a0a4c6137c6f5c9ea54a05e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJM199006213222502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199006213222502%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DKroemer%26aufirst%3DH.%2BK.%26aulast%3DSilberstein%26aufirst%3DD.%2BJ.%26aulast%3DFunck-Brentano%26aufirst%3DC.%26aulast%3DLineberry%26aufirst%3DM.%2BD.%26aulast%3DWood%26aufirst%3DA.%2BJ.%26aulast%3DRoden%26aufirst%3DD.%2BM.%26aulast%3DWoosley%26aufirst%3DR.%2BL.%26atitle%3DThe%2520Role%2520of%2520Genetically%2520Determined%2520Polymorphic%2520Drug%2520Metabolism%2520in%2520the%2520Beta-Blockade%2520Produced%2520by%2520Propafenone%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D1990%26volume%3D322%26spage%3D1764%26epage%3D1768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Williams, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goosen, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterkin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koup, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, S. E.</span><span> </span><span class="NLM_article-title">Drug-Drug Interactions for UDP-Glucuronosyltransferase Substrates: A Pharmacokinetic Explanation for Typically Observed Low Exposure (AUC<sub>I</sub>/AUC) Ratios</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1201</span><span class="NLM_x">–</span> <span class="NLM_lpage">1208</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=1201-1208&author=J.+A.+Williamsauthor=R.+Hylandauthor=B.+C.+Jonesauthor=D.+A.+Smithauthor=S.+Hurstauthor=T.+C.+Goosenauthor=V.+Peterkinauthor=J.+R.+Koupauthor=S.+E.+Ball&title=Drug-Drug+Interactions+for+UDP-Glucuronosyltransferase+Substrates%3A+A+Pharmacokinetic+Explanation+for+Typically+Observed+Low+Exposure+%28AUCI%2FAUC%29+Ratios"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26aulast%3DHyland%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DHurst%26aufirst%3DS.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DPeterkin%26aufirst%3DV.%26aulast%3DKoup%26aufirst%3DJ.%2BR.%26aulast%3DBall%26aufirst%3DS.%2BE.%26atitle%3DDrug-Drug%2520Interactions%2520for%2520UDP-Glucuronosyltransferase%2520Substrates%253A%2520A%2520Pharmacokinetic%2520Explanation%2520for%2520Typically%2520Observed%2520Low%2520Exposure%2520%2528AUCI%252FAUC%2529%2520Ratios%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D1201%26epage%3D1208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F. J.</span><span> </span><span class="NLM_article-title">Inhalation by Design: Novel Ultra-Long-Acting β<sub>2</sub>-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">–</span> <span class="NLM_lpage">6652</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&author=P.+A.+Glossopauthor=C.+A.+L.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+J.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+Design%3A+Novel+Ultra-Long-Acting+%CE%B22-Adrenoreceptor+Agonists+for+Inhaled+Once-Daily+Treatment+of+Asthma+and+Chronic+Obstructive+Pulmonary+Disease+That+Utilize+a+Sulfonamide+Agonist+Headgroup"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%2BL.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%2BJ.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520Design%253A%2520Novel%2520Ultra-Long-Acting%2520%25CE%25B22-Adrenoreceptor%2520Agonists%2520for%2520Inhaled%2520Once-Daily%2520Treatment%2520of%2520Asthma%2520and%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%2520That%2520Utilize%2520a%2520Sulfonamide%2520Agonist%2520Headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6640%26epage%3D6652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Boase, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miners, J. O.</span><span> </span><span class="NLM_article-title">In vitro-in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1046%2Fj.1365-2125.2002.01669.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=12445028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD38Xps1Olsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=493-503&author=S.+Boaseauthor=J.+O.+Miners&title=In+vitro-in+vivo+correlations+for+drugs+eliminated+by+glucuronidation%3A+Investigations+with+the+model+substrate+zidovudine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine</span></div><div class="casAuthors">Boase, Sam; Miners, John O.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">493-503</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Aims: To investigate the effects of incubation conditions on the kinetic consts. for zidovudine (AZT) glucuronidation by human liver microsomes, and whether microsomal intrinsic clearance (CLint) derived for the various conditions predicted hepatic AZT clearance by glucuronidation (CLH) in vivo.  Methods: The effects of incubation constituents, particularly buffer type (phosphate, Tris) and activators (Brij 58, alamethacin, UDP-N-acetylglucosamine (UDP-NAcG)), on the kinetics of AZT glucuronidation by human liver microsomes was investigated.  AZT glucuronide (AZTG) formation by microsomal incubations was quantified by HPLC.  Microsomal CLint values detd. for the various exptl. conditions were extrapolated to a whole organ CLint and these data were used to calc. in vivo CLH using the well-stirred, parallel tube and dispersion models.  Results: Mean CLint values for Brij 58 activated microsomes in both phosphate (3.66 μL/min/mg, 95% CI 1.92, 5.39) and Tris (3.79 μL/min/mg, 95% CI 2.87, 4.71) buffers were higher than the resp. values for native microsomes (1.04, 95% CI 0.53, 1.56 and 1.37 μL/min/mg, 95% CI 1.00, 1.73).  Extrapolation of the microsomal data to a whole organ CLint and substitution of these values in the expressions for the well-stirred, parallel tube and dispersion models underestimated the known in vivo blood AZT clearance by glucuronidation by 6.5- to 23-fold (3.61-1.271 L/h vs. 82 L/h).  There was no significant difference in the CLH predicted by each of the models for each set of conditions.  A wide range of incubation constituents and conditions were subsequently investigated to assess their effects on AZTG formation, including alamethacin, UDP-NAcG, MgCl2, D-saccharic acid 1,4-lactone, ATP, GTP, and buffer pH and ionic strength.  Of these, only decreasing the phosphate buffer concn. from 0.1 M to 0.02 M for Brij 58 activated microsomes substantially increased the rate of AZTG formation, but the extrapolated CLH detd. for this condition still underestimated known AZT glucuronidation clearance by more than 4-fold.  AZT was shown not to bind nonspecifically to microsomes.  Anal. of published data for other glucuronidated drugs confirmed a trend for microsomal CLint to underestimate in vivo CLH.  Conclusions: AZT glucuronidation kinetics by human liver microsomes are markedly dependent on incubation conditions, and there is a need for interlab. standardization.  Extrapolation of in vitro CLint underestimates in vivo hepatic clearance of drugs eliminated by glucuronidation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_JXaVf0cYx7Vg90H21EOLACvtfcHk0lg1dMCY_-Dd5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xps1Olsbw%253D&md5=64886479df5cc0cff932c62195669f18</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.2002.01669.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.2002.01669.x%26sid%3Dliteratum%253Aachs%26aulast%3DBoase%26aufirst%3DS.%26aulast%3DMiners%26aufirst%3DJ.%2BO.%26atitle%3DIn%2520vitro-in%2520vivo%2520correlations%2520for%2520drugs%2520eliminated%2520by%2520glucuronidation%253A%2520Investigations%2520with%2520the%2520model%2520substrate%2520zidovudine%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2002%26volume%3D54%26spage%3D493%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Magdalou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournel-Gigleux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouzzine, M.</span><span> </span><span class="NLM_article-title">Insights on membrane topology and structure/function of UDP-glucuronosyltransferases</span> <span class="citation_source-journal">Drug Metab. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.3109%2F03602530903209270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=19807219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=159-166&author=J.+Magdalouauthor=S.+Fournel-Gigleuxauthor=M.+Ouzzine&title=Insights+on+membrane+topology+and+structure%2Ffunction+of+UDP-glucuronosyltransferases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Insights on membrane topology and structure/function of UDP-glucuronosyltransferases</span></div><div class="casAuthors">Magdalou, Jacques; Fournel-Gigleux, Sylvie; Ouzzine, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">159-166</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The main characteristic of uridine diphosphate (UDP)-glucuronosyltransferases is their potency to glucuronidate a large array of structurally unrelated substances with various nucleophilic groups.  The activity of these enzymes strongly depends on their tight assocn. to the membrane of the endoplasmic reticulum.  In light of recent data, this review is focused on the membrane-assembly process, which is a prerequisite for activity, and on the amino acids that govern substrate recognition and catalysis at the active site.  The major implication of the highly variable N-terminal domain of UDP-glucuronosyltransferases in the substrate specificity of these enzymes is highlighted.  In the absence of crystal data of the N-terminal domain, multidisciplinary approaches of genetic-/protein-engineering techniques, homol. modeling with glycosyltransferases, and quant. structure-activity relationships allowed us to point out crucial amino acids.  On the basis of these results, possible reaction mechanisms for the glucuronidation of xenobiotics, involving histidine and aspartic acid residues, have been built and are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ1jNLDZdQPrVg90H21EOLACvtfcHk0lgMILEfJQzsrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFantw%253D%253D&md5=28cae4aa50f41e218d4dd85940389c2a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3109%2F03602530903209270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602530903209270%26sid%3Dliteratum%253Aachs%26aulast%3DMagdalou%26aufirst%3DJ.%26aulast%3DFournel-Gigleux%26aufirst%3DS.%26aulast%3DOuzzine%26aufirst%3DM.%26atitle%3DInsights%2520on%2520membrane%2520topology%2520and%2520structure%252Ffunction%2520of%2520UDP-glucuronosyltransferases%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2010%26volume%3D42%26spage%3D159%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nature Rev. Drug Discov.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lgMILEfJQzsrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNature%2520Rev.%2520Drug%2520Discov.%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speck, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traunecker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammer, R.</span><span> </span><span class="NLM_article-title">Ba 679 BR, A novel long-acting anticholinergic bronchodilator</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1993&pages=537-544&author=B.+Disseauthor=R.+Reichlauthor=G.+Speckauthor=W.+Trauneckerauthor=K.+L.+Romingerauthor=R.+Hammer&title=Ba+679+BR%2C+A+novel+long-acting+anticholinergic+bronchodilator"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DReichl%26aufirst%3DR.%26aulast%3DSpeck%26aufirst%3DG.%26aulast%3DTraunecker%26aufirst%3DW.%26aulast%3DRominger%26aufirst%3DK.%2BL.%26aulast%3DHammer%26aufirst%3DR.%26atitle%3DBa%2520679%2520BR%252C%2520A%2520novel%2520long-acting%2520anticholinergic%2520bronchodilator%26jtitle%3DLife%2520Sci.%26date%3D1993%26volume%3D52%26spage%3D537%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Nials, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumner, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, R. A.</span><span> </span><span class="NLM_article-title">Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">515</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.1111%2Fj.1476-5381.1993.tb12833.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=8095419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADyaK3sXisVOgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=1993&pages=507-515&author=A.+T.+Nialsauthor=M.+J.+Sumnerauthor=M.+Johnsonauthor=R.+A.+Coleman&title=Investigations+into+factors+determining+the+duration+of+action+of+the+beta+2-adrenoceptor+agonist%2C+salmeterol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations into factors determining the duration of action of the β2-adrenoceptor agonist, salmeterol</span></div><div class="casAuthors">Nials, Anthony T.; Sumner, Michael J.; Johnson, Malcolm; Coleman, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">507-15</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">This study has explored the mechanism underlying the long duration of action of the β2-adrenoceptor agonist, salmeterol.  Salmeterol, salbutamol and isoprenaline caused a concn.-related inhibition of elec.-induced contractile responses of the guinea-pig superfused trachea prepn.  The effects of both isoprenaline and salbutamol were rapid in onset and rapidly reversed upon removal of the agonist.  In contrast, the effects of salmeterol were slower in onset and could not be reversed by superfusion of the tissue with agonist-free Krebs soln. even for periods of up to 10 h.  The effects of salmeterol were, however, readily reversed by a no. of β-adrenoceptor blocking drugs, as was the effect of a continuous infusion of isoprenaline.  Upon removal of the antagonist, however, the effects of salmeterol and of the isoprenaline infusion were reasserted at a rate which was inversely related to the lipophilicity of the β-adrenoceptor blocking drugs.  Salmeterol inhibited the binding of [125I]-(-)-iodopindolol (100 pM) to rat lung membranes (pIC50. 7.1), with isoprenaline (pIC50 6.2) and salbutamol (pIC50 5.1) having lower potencies.  The inhibition of binding by salmeterol was apparently non-competitive, whereas that produced by salbutamol and isoprenaline was competitive in nature.  Isoprenaline and salbutamol rapidly dissocd. from their binding sites, whereas in marked contrast, the binding of salmeterol showed no dissocn. for periods of up to 1 h.  These data are consistent with a mechanism in which salmeterol binds adjacent to the active site of the β2-adrenoceptor, such that the drug cannot be washed out of the tissue, yet can interact with and activate the receptor.  This latter property is susceptible to antagonism by β-adrenoceptor blocking drugs but is reasserted when the antagonists are removed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmU1VWz9S-iLVg90H21EOLACvtfcHk0li5ECkiK2WemA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVOgsLg%253D&md5=2ac85caa0d32c826dc8eda06dbebb182</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1993.tb12833.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1993.tb12833.x%26sid%3Dliteratum%253Aachs%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DSumner%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DR.%2BA.%26atitle%3DInvestigations%2520into%2520factors%2520determining%2520the%2520duration%2520of%2520action%2520of%2520the%2520beta%25202-adrenoceptor%2520agonist%252C%2520salmeterol%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1993%26volume%3D108%26spage%3D507%26epage%3D515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Motulsky, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahan, L. C.</span><span> </span><span class="NLM_article-title">The Kinetics of Competitive Radioligand Binding Predicted by the Law of Mass Action</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=6708928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=1-9&author=H.+J.+Motulskyauthor=L.+C.+Mahan&title=The+Kinetics+of+Competitive+Radioligand+Binding+Predicted+by+the+Law+of+Mass+Action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The kinetics of competitive radioligand binding predicted by the law of mass action</span></div><div class="casAuthors">Motulsky H J; Mahan L C</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Although equilibrium competitive radioligand binding studies are often used to characterize hormone and neurotransmitter receptors, the kinetics of such experiments have not been extensively explored.  The interactions of the radioligand and competitor with the receptors can be described by two differential equations which can be solved to yield a single equation describing the binding of the radioligand as a function of time.  This equation has several applications: First, it can be used to simulate competitive binding reactions under defined conditions.  Second, fitting experimental data to this equation allows one to determine the association and dissociation rate constants of the competing ligand, parameters that cannot be derived from equilibrium experiments.  Furthermore, this method can be used to determine the KI of the competing drug from data acquired before equilibrium is reached.  Third, mathematical analysis of the binding equation allowed us to answer two specific questions regarding the kinetics of competitive radioligand binding: how long such an incubation takes to equilibrate, and how the IC50 varies over time.  The answers to these questions depended, to a large extent, on the relative values of the dissociation rate constants of the radioligand and competitor, which can be determined as noted above.  When the competitor dissociates from the receptors more rapidly than the radioligand, the IC50 first decreases and then increases, but never has a value less than the KI.  At low radioligand concentrations, equilibrium is reached in the same amount of time required of the radioligand to dissociate completely from the receptors as determined in an "off-rate experiment." At higher concentrations of radioligand this time is halved.  When the competitor dissociates from the receptor more slowly than does the radioligand, then the time required to equilibrate depends only on the dissociation rate constant of the competitor, and the IC50 decreases over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCXDwvoK7MbN1QT_1O5WBYfW6udTcc2eZWjSbUjP2uaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D&md5=f0c09a16d7f8947fe0d72c256e2e4914</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMotulsky%26aufirst%3DH.%2BJ.%26aulast%3DMahan%26aufirst%3DL.%2BC.%26atitle%3DThe%2520Kinetics%2520of%2520Competitive%2520Radioligand%2520Binding%2520Predicted%2520by%2520the%2520Law%2520of%2520Mass%2520Action%26jtitle%3DMol.%2520Pharmacol.%26date%3D1984%26volume%3D25%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Wright, K.; Davies, T.; Clarke, N.; Yeadon, M.; Perros-Huguet, C.</span><span> </span><span class="NLM_article-title">PF-00610355 – an inhaled β<sub>2</sub>-adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction</span>.  <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">S53</span>), Abstract P2060.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=19324957" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&issue=S53&author=K.+Wright&author=T.+Davies&author=N.+Clarke&author=M.+Yeadon&author=C.+Perros-Huguet&title=PF-00610355+%E2%80%93+an+inhaled+%CE%B22-adrenoceptor+agonist+with+superior+potency+and+duration+of+action+%28DoA%29+to+salmeterol+in+the+conscious+dog+model+of+bronchoconstriction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DK.%26atitle%3DPF-00610355%2520%25E2%2580%2593%2520an%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%2520with%2520superior%2520potency%2520and%2520duration%2520of%2520action%2520%2528DoA%2529%2520to%2520salmeterol%2520in%2520the%2520conscious%2520dog%2520model%2520of%2520bronchoconstriction%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D34%26issue%3DS53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Taburet, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmit, B.</span><span> </span><span class="NLM_article-title">Pharmacokinetic Optimization of Asthma Treatment</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">396</span><span class="NLM_x">–</span> <span class="NLM_lpage">418</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm200884j&amp;key=10.2165%2F00003088-199426050-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm200884j&amp;key=7914480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm200884j&amp;key=1%3ACAS%3A528%3ADyaK2cXls1ekt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1994&pages=396-418&author=A.+M.+Taburetauthor=B.+Schmit&title=Pharmacokinetic+Optimization+of+Asthma+Treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic optimization of asthma treatment</span></div><div class="casAuthors">Taburet, Anne-Marie; Schmit, Benedicte</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">396-418</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">A review with > ∼ 140 refs.  Asthma is generally managed with bronchodilator therapy and/or anti-inflammatory drugs.  Guidelines now advocate selection of drugs and pharmaceutical formulations (long-acting vs. short-acting, inhaled vs. systemic) on the basis of disease severity.  Theophylline has a narrow therapeutic margin.  Clearance is highly variable and plasma concns. should be monitored to avoid the occurrence of plasma concn.-related adverse effects.  The rate of absorption of theophylline differs depending on the sustained-release formulation administered.  Some products do not provide sufficient plasma drug concns. for therapeutic efficacy over a 12-h period, particularly in patients with high clearance rates (e.g. children and patients who smoke).  Administration of drugs via inhalation offers several advantages over systemic routes of administration (e.g. adverse effects are decreased).  Inhalation is now advocated as first-line therapy.  Aerosol medications available for the treatment of asthma are β2-agonists (including the newer long-acting agents such as salmeterol), corticosteroids, anticholinergic drugs, sodium cromoglycate (cromolyn sodium) and nedocromil.  To reach the airways, aerosolized particles should be 1 to 5 μm in diam.  Particles of the size can be produced by nebulizer for continuous administration or by metered-dose inhaler and drug powder inhaler for unit dose medication.  For efficient use of the metered-dose inhaler, slow inhalation and actuation must be coordinated.  However, efficacy and convenience can be improved when spacer devices are used.  Furthermore, spacer devices lessen the oropharyngeal adverse effects of inhaled corticosteroids.  Dry powder inhalers are more easily used by children and elderly patients than metered-dose inhalers.  Regardless of the device used, a max. of 10% of the inhaled dose reaches the airways.  The rest of the dose is swallowed and absorbed through the gastrointestinal tract.  Most inhaled drugs have low oral bioavailability, either because of a high first-pass metab. (β2-agonists and glucocorticoids) or because of lack of absorption (sodium cromoglycate).  Sulfation of β2-agonists occurs in the wall of the gastrointestinal tract and extensive metab. of inhaled corticosteroids occurs in the liver.  Low bioavailability of the swallowed fraction contributes to reduced adverse effects.  The pharmacokinetic properties of an inhaled drug are of interest.  The fraction of the dose absorbed through the lung has the same disposition characteristics as an i.v. dose, and the swallowed fraction has the same disposition as an orally administered dose.  However, for many drugs, pharmacokinetic data after inhalation are limited and cannot be used as a criteria for selection of therapy.  Whatever the device used to deliver the aerosolized drug, patients should be instructed on how to use the inhaler device so that max. benefit may be obtained from their inhaled therapy.  Although inhalation therapy is the first-line treatment for asthma, aerosol delivery to the airways and convenience of the devices could be improved, without increasing the cost of therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7-NQ7w9Y1OrVg90H21EOLACvtfcHk0lhqsVkcSxPyQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXls1ekt7s%253D&md5=eda2e7e33db25968587dabea1927d4fa</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2165%2F00003088-199426050-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199426050-00006%26sid%3Dliteratum%253Aachs%26aulast%3DTaburet%26aufirst%3DA.%2BM.%26aulast%3DSchmit%26aufirst%3DB.%26atitle%3DPharmacokinetic%2520Optimization%2520of%2520Asthma%2520Treatment%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1994%26volume%3D26%26spage%3D396%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Glossop, P. A.; James, K.</span><span> </span><span class="NLM_article-title">The hydrochloride salt of 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide and its use as a medicament</span>. PCT Int. Appl. Publ. WO 2008135819,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+A.+Glossop&author=K.+James&title=The+hydrochloride+salt+of+5-%283-%283-hydroxyphenoxy%29azetidin-1-yl%29-5-methyl-2%2C2-diphenylhexanamide+and+its+use+as+a+medicament"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26atitle%3DThe%2520hydrochloride%2520salt%2520of%25205-%25283-%25283-hydroxyphenoxy%2529azetidin-1-yl%2529-5-methyl-2%252C2-diphenylhexanamide%2520and%2520its%2520use%2520as%2520a%2520medicament%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Sladen, L.; Wright, K.; Adcock, J.; Chaffe, P.; Clarke, N.; Yeadon, M.; Perros-Huguet, C.</span><span> </span><span class="NLM_article-title">Effects of intra tracheal PF-00610355, an inhaled β<sub>2</sub>-adrenoceptor agonist, in anaesthetised animals</span>.  <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">S53</span>), Abstract P2020.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&issue=S53&author=L.+Sladen&author=K.+Wright&author=J.+Adcock&author=P.+Chaffe&author=N.+Clarke&author=M.+Yeadon&author=C.+Perros-Huguet&title=Effects+of+intra+tracheal+PF-00610355%2C+an+inhaled+%CE%B22-adrenoceptor+agonist%2C+in+anaesthetised+animals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSladen%26aufirst%3DL.%26atitle%3DEffects%2520of%2520intra%2520tracheal%2520PF-00610355%252C%2520an%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%252C%2520in%2520anaesthetised%2520animals%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D34%26issue%3DS53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Watson, J.; Strawbridge, M.; Brown, R.; Campany, K.; Coghlan, M.; Trevethick, M.</span><span> </span><span class="NLM_article-title">Offset rates of tiotropium and ipratropium at human recombinant muscarinic M<sub>1</sub>-M<sub>5</sub> receptors using a dilution-offset methodology</span>.  <span class="citation_source-journal">Fundam. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">S2</span>),  <span class="NLM_fpage">78</span>, Abstract P102.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=78&issue=S2&author=J.+Watson&author=M.+Strawbridge&author=R.+Brown&author=K.+Campany&author=M.+Coghlan&author=M.+Trevethick&title=Offset+rates+of+tiotropium+and+ipratropium+at+human+recombinant+muscarinic+M1-M5+receptors+using+a+dilution-offset+methodology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DJ.%26atitle%3DOffset%2520rates%2520of%2520tiotropium%2520and%2520ipratropium%2520at%2520human%2520recombinant%2520muscarinic%2520M1-M5%2520receptors%2520using%2520a%2520dilution-offset%2520methodology%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D22%26issue%3DS2%26spage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Banholzer, R.; Bauer, R.; Reichl, R.</span><span> </span><span class="NLM_article-title">Preparation of anticholinergic scopine, (nor)tropine, and granatoline esters of thienylcarboxylic acids and their quaternary salts</span>. Eur. Pat. Appl. Publ. EP 418716,<span class="NLM_x"> </span><span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=R.+Banholzer&author=R.+Bauer&author=R.+Reichl&title=Preparation+of+anticholinergic+scopine%2C+%28nor%29tropine%2C+and+granatoline+esters+of+thienylcarboxylic+acids+and+their+quaternary+salts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBanholzer%26aufirst%3DR.%26atitle%3DPreparation%2520of%2520anticholinergic%2520scopine%252C%2520%2528nor%2529tropine%252C%2520and%2520granatoline%2520esters%2520of%2520thienylcarboxylic%2520acids%2520and%2520their%2520quaternary%2520salts%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-5"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i38"><a href="/doi/suppl/10.1021/jm200884j">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_72117"></div></div></div></div></div><hr /></hr><p class="last">Biology experimental section for the in vitro human bronchus assay, in vivo anaesthetized guinea pig model, and in vivo rabbit lung Aδ-fiber cough model; chemistry experimental details and analytical data for intermediates <b>1</b>–<b>3</b>, (<i>R</i>)- and (<i>S</i>)-<b>5</b>, (<i>S</i>)-<b>6</b>, (<i>R</i>)- and (<i>S</i>)-<b>7</b>, (<i>S</i>)-<b>8</b>, (<i>R</i>)- and (<i>S</i>)-<b>10</b>, (<i>R</i>)- and (<i>S</i>)-<b>12</b>–<b>14</b>, (<i>S</i>)-<b>17</b>, (<i>R</i>)-<b>18</b>, <b>23</b>, <b>24</b>, <b>28</b>–<b>31</b>, <b>33</b>, <b>34</b>, <b>41</b>–<b>46</b>, <b>54</b>, <b>56</b>–<b>63</b>, and test compounds <b>4</b>, (<i>R</i>)- and (<i>S</i>)-<b>9</b>, (<i>R</i>)- and (<i>S</i>)-<b>11</b>, (<i>S</i>)-<b>15</b>, (<i>S</i>)-<b>16</b>, (<i>S</i>)-<b>19</b>, (<i>R</i>)-<b>20</b>, <b>25</b>, <b>26</b>, <b>32</b>, <b>35</b>, <b>48</b>–<b>53</b>, <b>55</b>, <b>64</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm200884j/suppl_file/jm200884j_si_001.pdf">jm200884j_si_001.pdf (327.78 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm200884j&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm200884j%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-19%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm200884j" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679960c9eff63d48","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
